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Summary 
 
During the biogenesis of messenger RNA, RNA polymerase II (RNAP II, Pol II) associates  
with numerous proteins and multiprotein complexes. These factors regulate the correct 
progression of the transcription cycle, which can be divided into three major phases: 
initiation, elongation and termination. This thesis describes the characterization of two 
important factors involved in two different phases of the transcription cycle in a highly 
interdisciplinary approach. Spt6 is an essential, modular protein involved in transcription 
elongation. It was characterized as a histone chaperone that binds to histones and 
assembles nucleosomes onto DNA after the passage of Pol II. In addition, it is linked to 
processes like splicing, mRNA processing and export, and histone modification. This 
functional versatility makes it a central player in the elongation process. The first part of this 
work shows the high resolution structure of the C-terminal SH2 domain of Spt6. The domain 
was shown previously to interact with the C-terminal domain (CTD) of Pol II, phosphorylated 
at Ser2 residues. Thus it links Spt6 functions directly to the transcription machinery. The 
domain has an unconventional binding specifity in contrast to the numerous SH2 domains 
involved in cellular signaling pathways. It binds phosphoserine instead of phosphotyrosine. In 
addition, it is the only SH2 domain encoded in the yeast genome, opposing a multitude of 
these domains in the genomes of higher eukaryotes. The X-ray structure gives insight into 
the peculiarities of this domain, with implications on its substrate specificity and molecular 
evolution. In this light, a model for the interaction with the CTD, as well as a deep analysis of 
the evolutionary relationship to other SH2 domains is presented. Microarray gene expression 
analysis shows the impact of a deletion of the SH2 domain on the transcription of the yeast 
genome. A genome wide localization map of Spt6, obtained by ChIP-on-chip experiments, is 
presented and compared to the localization of Pol II.  
The nuclear exoribonuclease complex Rat1/Rai1 plays a role in transcription termination. 
Two models explain the events at the end of a protein coding gene. The so-called „torpedo 
model“ states that Rat1/Rai1 processively degrades 3’ nascent RNA that is still attached to 
elongating Pol II after the mRNA product is cleaved by cleavage/polyadenylation factors. 
Upon contact with Pol II, Rat1/Rai1 is thought to disrupt the elongation complex and 
terminate transcription. There is however also data supporting the "allosteric model" that 
predicts the recruitment of a termination factor or the dissociation of an anti-termination 
factor. The second part of this thesis describes the establishment of a highly defined 
biochemical assay to test the "torpedo model" in vitro. A protocol for the expression and 
purification of the recombinant and active exonuclease complex and an additional interacting 
protein, Rtt103, was established. In combination with an improved in vitro elongation assay it 
is shown that Rat1 is not the dedicated termination factor that is predicted by the torpedo 
model. 
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1  General introduction 1 
1  General introduction 
?
1.1 Structure of RNA polymerase II and the elongation complex 
?
In eukaryotic cells,  the transcription of all protein-coding genes, as well as small nucleolar 
and small nuclear RNA (snoRNA and snRNA, respectively) is carried out by RNA 
polymerase II (Pol II) in the nucleoplasm.  
Polymerase II consists of a 10 subunit core and a peripheral heterodimer of the subunits 
Rpb4 and Rpb7 . The crystal structures of core Pol II revealed, that the two largest subunits, 
Rpb1 and Rpb2, are on opposite sides of a positively charged cleft that bears the active site 
(Cramer et al, 2000). Together with the bridge helix, which spans the cleft, the active site 
lines a pore in the floor of the cleft. The smaller subunits are placed around the “jaw-like” 
structure of Rpb1 and Rpb2. Indeed, these two subunits work like a jaw, as the Rpb1 side of 
the cleft forms a mobile clamp, which was trapped in two different open states in the free 
core structures (Cramer et al, 2001a). In the structure of a core complex that included DNA 
and RNA the clamp was closed (Gnatt et al, 2001; Kettenberger et al, 2004b). This mobile 
clamp is connected to the body of the polymerase by five switch regions that are variable in 
conformation. The Rpb2 side of the cleft consists of the lobe and protrusion domains and 
Rpb2 also forms a protein wall that blocks the end of the cleft. Additional crystal structures at 
a resolution around 4 Å revealed the position of the two missing subunits, Rpb4 and Rpb7, 
which can dissociate from the yeast enzyme (Edwards et al, 1991). The heterodimer binds 
like a wedge between the clamp and the linker of the long C-terminal domain (CTD, see 1.2) 
of Pol II (Armache et al, 2003; Armache et al, 2005b; Bushnell & Kornberg, 2003). In the 
crystal structures of the 12 subunit Pol II, the clamp was always in a closed conformation. A 
complete atomic model of Pol II could be refined, when the crystal structure of free Rpb4/7 
together with an improved resolution of the complete Pol II was available (Armache et al, 
2005b). 
The interactions of Pol II with its substrate was revealed in structural studies of Pol II-nucleic 
acid complexes. The point of DNA entry into the polymerase cleft was shown by EM 
(Poglitsch et al, 1999). The first crystal structure of the core Pol II transcribing a tailed 
template DNA revealed downstream DNA entering the cleft and a 8 to 9 base pair DNA-RNA 
hybrid in the active center (Gnatt et al, 2001). In addition, comparison with the structure of 
the core polymerase (Cramer et al, 2001a) suggested protein surface elements for functional 
roles. With the use of syntethic nucleic acid scaffols containing mismatch transcription 
bubbles, the location of the downstream DNA duplex with RNA annealed to the central 
mismatched bubble region could be detected, as well as a part of the upstream region  
(Fig. 1, Kettenberger et al., 2004b). 
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Figure 1: Structure of complete 12-subunit RNA polymerase II elongation complex (Kettenberger et al, 
2004a). 
Two views of a ribbon model of the protein subunits and nucleic acids, side view (left) and top view (right). The 
polymerase subunits Rpb1–Rpb12 are colored according to the key between the views. Template DNA, 
nontemplate DNA, and product RNA are shown in blue, cyan, and red, respectively. Phosphorous atoms are 
indicated as spheres and extrapolated B-form downstream DNA is colored in light pink. Eight zinc ions and the 
active site magnesium ion are depicted as cyan spheres and a magenta sphere, respectively. Secondary 
structure assignments for pol II are according to (Cramer et al, 2001b) and (Armache et al, 2005a). This figure is 
adapted from Kettenberger et al, (2004a). 
 
The 3’ end of the RNA is centered at the active site of Pol II that contains two magnesium 
ions which are needed for the catalysis of nucleotide incorporation (Steitz, 1998). One metal 
ion is permanently bound inside the Pol II active site (Cramer et al, 2001a), the second metal 
is binding the tri-phosphate moiety of the incoming NTP (Westover et al, 2004). Nucleotide 
insertion involves the trigger loop, a mobile part of the active center (Kettenberger et al, 
2003; Vassylyev et al, 2002), that folds upon binding of the new NTP (Kettenberger et al, 
2003; Vassylyev et al, 2002; Wang et al, 2006). Crystal structures including the NTP 
substrate suggested how Pol II selects the correct NTP for incorporation (Kettenberger et al, 
2004b; Wang et al, 2006; Westover et al, 2004). The NTP was trapped in two slightly 
different but overlapping conformations, termed the insertion site (active) and the preinsertion 
site (inactive). In both states the NTP forms Watson-Crick interactions with a base in the 
DNA template.  
In one model, the NTP to be incorporated first binds to an open active center conformation in 
the preinsertion site, where the two magnesium ions are not close enough for catalysis. 
Folding of the trigger loop then closes the active center, delivers the NTP to the insertion site 
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and enables catalysis (Kettenberger et al, 2004b; Vassylyev et al, 2007b).  An alternative 
model for nucleotide addition involves binding of the NTP to a putative entry site in the pore, 
in which the nucleotide base is oriented away from the DNA template. Rotation of the NTP 
around its bound metal ion brings it into the insertion site (Westover et al, 2004).  
The bridge helix, that spans the cleft of Pol II, is also involved in the nucleotide addition 
cycle. Straight and bent conformations of this highly conserved helix were observed in 
different crystal structures of different polymerases (Cramer et al, 2001a; Vassylyev et al, 
2002; Zhang et al, 1999) and this movement in concert with movement of the trigger loop 
apparently directs nucleotide addition to the growing RNA-chain and translocation of Pol II 
relative to the template RNA (Brueckner & Cramer, 2008; Tuske et al, 2005).  
 
1.2 The C-terminal domain (CTD) of Pol II subunit Rpb1 
 
The CTD is a unique feature of the largest subunit of Pol II, Rpb1. It consists of multiple 
heptapeptide repeats of the consensus sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (Y1-S2-
P3-T4-S5-P6-S7).  The length of the CTD increases with organismic complexity, for example 
26 repeats in yeast and 52 in human cells. Yeast needs at least eight repeats for viability 
(Nonet et al, 1987; West & Corden, 1995). The heptads are not uniformly distributed over the 
length of the CTD, which can be divided into 3 regions: a short N-terminal linker that attaches 
it to the body of the polymerase (Cramer et al, 2001a), a region of continuously repeated 
consensus heptads and a rather diverse part at the C-terminus where the repeats diverge 
from the consensus sequence (Chapman et al, 2008). The CTD serves as a platform for the 
integration of nuclear events by binding proteins that are involved in mRNA biogenesis and 
other transcription-coupled reactions. These interactions are timed and allocated to certain 
phases of the transcription cycle by the dynamic phosphorylation and dephosphorylation of 
the heptapeptide residues (Orphanides & Reinberg, 2002). Potential phosphorylation sites in 
the consensus sequence are Tyr1, Ser2, Thr4, Ser5, Ser7. Phosphorylation of Ser2 and Ser5 
predominates the regulative events that are described so far (Corden et al, 1985; Dahmus, 
1996; Zhang & Corden, 1991). This phosphorylation pattern is established and maintained by 
the concerted action of CTD kinases and phosphatases (Meinhart et al, 2005). Ser5-
phosphorylation occurs proximal to the promoter during initiation and early elongation, which 
is essential for the recruitment of capping enzymes (Cho et al, 1997; Komarnitsky et al, 2000; 
McCracken et al, 1997; Schroeder et al, 2000). Following transcription towards the 3’ end, 
Ser5-phosphorylation decreases, whereas Ser2-phosphorylation increases, with an 
intermittent overlap of both phosphorylations (Ser5-Ser2) (Cho et al, 2001; Schroeder et al, 
2000). This leads to the recruitment of mRNA processing, polyadenylation and termination 
factors (Ahn et al, 2004; McCracken et al, 1997; Proudfoot et al, 2002). Both modifications 
are independently essential for cell viability (West & Corden, 1995). Recently, it was shown 
1  General introduction 4 
that phosphorylation of Ser7 is involved in the expression of snRNA genes (Chapman et al, 
2007; Egloff et al, 2007), which further increases the complexity of CTD-directed regulation. 
A further layer of complexity is introduced by the combination of the specific 
phosphorylations combined with cis-/trans-interconversions of peptide bonds N-terminal of 
prolines in the heptad repeats, which are regulated by peptidyl-prolyl isomerases (Hani et al, 
1999; Lu et al, 1999). Considering only  Ser2 and Ser5 phosphorylation, this gives a total of 
16 different CTD states. This defines the “CTD code” which specifies the position of Pol II 
within the transcription cycle (Buratowski, 2003). 
Due to its flexibility, the CTD cannot be seen in Pol II structures (Armache et al, 2003; 
Cramer et al, 2001a), but it is not entirely unstructured. Studies by NMR and circular 
dichroism showed an overall structural plasticity with residual structure and the propensity to 
form ?-turns (Meinhart et al, 2005). A leap forward in gaining information about CTD-
structure were crystal-structures of CTD-binding domains in conjunction with synthetic CTD 
peptides. The structure of the WW domain of Pin1, a CTD-specific Peptidylprolyl-cis/trans-
isomerase, binding to a single heptad repeat with phosphate moieties on Ser2 and Ser5 
shows the CTD binding as an extended coil with both phosphoserine-proline peptide bonds 
in the trans configuration (Verdecia et al, 2000). A different conformation was seen in the 
structure of guanylyltransferase Cgt1 with Ser5-phosphorylated repeats. There, an extended 
surface of Cgt1 binds the repeats by anchoring both ends by electrostatic interactions with 
Ser5-P. Additional van der Waals contacts between Cgt1 and CTD residues contribute to the 
binding (Fabrega et al, 2003). The first structure of a protein binding a Ser2-phosphorylated 
CTD-peptide was the CID-domain (CTD-interacting domain) of Pcf11, which is involved in 
pre-mRNA 3'-end processing and transcription termination (Amrani et al, 1997). There, a 
Ser2P-Pro3-Thr4-Ser5 is recognized not directly via the phosphate moiety. The four central 
amino-acids form a ?-turn, whereas the flanking residues are in a extended conformation. 
The phospho-group points away from the domain-surface but seems to stabilize the ?-turn by 
a hydrogen-bond (Meinhart & Cramer, 2004). The NMR structure of the histone H3 
methyltransferase Set2 SRI-domain shows a novel CTD-binding fold, a left handed three-
helix bundle. The interaction with two heptapeptide repeats of a Ser2-/Ser5-phosphorylated 
peptide was shown by NMR titration experiments and biacore binding studies, and revealed 
the binding of both tyrosine residues by the SRI-domain (Li et al, 2005; Vojnic et al, 2006). 
Taken together, the interactions of the CTD with the various factors that assemble on it are 
structurally diverse and best characterized by an “induced fit” mechanism.  
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1.3 The mRNA transcription cycle 
?
Unlike bacterial RNA polymerases, where a single subunit called the ?-factor is sufficient to 
assist the polymerase to start transcription, the situation in eukaryotic organisms is much 
more complex. Pol II is guided by numerous factors to start transcription at the promoters of 
genes and every subsequent step is highly regulated by a large arsenal of different proteins 
and regulative nucleic acid sequences. This interplay of factors can be described as the 
transcription cycle, which can be divided into the three major stages of initiation, elongation 
and termination. A further subdivision of these stages is shown in Fig. 2.  
 
 
 
 
Figure 2: The mRNA transcription cycle 
Main phases of the transcription cycle are colored orange, important events of regulation are coloured in yellow. 
The circle in the middle depicts the occurrence of the events in relation to the gene. GTFs = general transcription 
factors; ORF = open reading frame. 
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Numerous factors regulate the initiation of gene transcription. The general transcription 
factors (GTFs) guide Pol II to the promoter and open the DNA duplex. The large multi-
subunit complex Mediator is essential for basal and activated transcription and transmits 
signals from regulatory factors to Pol II (Hahn, 2004; Lee & Young, 2000). Factors that 
interact with chromatin (ATP-dependent chromatin remodeling enzymes, histone acetylases, 
histone methylases) have to regulate the structure of chromatin in promoter regions to 
facilitate access of the transcription machinery to DNA to initiate transcription. Likewise the 
CTD seems to play a role in the formation of a stable initiation complex and its transformation 
into a elongation competent form (Lux et al, 2005). During promoter clearance, the pre-
initiation complex is partially disassembled. A subset of GTFs remains at the promoter, 
leaving behind a scaffold-complex (Fig. 2) for the facilitated reinitiation of transcription of the 
same gene (Hahn, 2004). 
Shortly after initiation in the early elongation phase, the elongation complex is not yet stably 
formed and Pol II tends to release RNA, resulting in the appearance of short RNA products 
(abortive initiation). This is accompanied by the tendency of Pol II to slip laterally on the 
template (Pal & Luse, 2002). This tendency diminishes when the RNA is synthesized to a 
length of 8-9 nt and becomes undetectable when the RNA is ?23 nt long. This comes 
together with an increased stability of the transcription complex (Kireeva et al, 2000; Pal & 
Luse, 2003). Starting early elongation, the transcription complex enters a checkpoint to 
ensure proper capping of the 5’ end of freshly generated RNA. A major player in this 
checkpoint regulation is the heterodimeric factor Spt4/Spt5 (DSIF in human cells) that binds 
to Pol II shortly after initiation (Wada et al, 1998). Subsequently, this complex recruits the 
negative elongation factor (NELF), that traps the transcription machinery at promoter 
proximal sites (Yamaguchi et al, 1999) (see also section 3.1.2). During this time window,  the 
CTD is phosphorylated  at Ser5-residues and capping enzymes are recruited (Pei & Shuman, 
2002). After capping, the kinase P-TEFb binds to Pol II and phosphorylates Spt5 within a 
region called the CTR (C-terminal region) and the CTD on Ser2-residues (Yamada et al, 
2006). This abolishes the repressive nature of the Pol II-Spt4/5-NELF interaction and 
releases the transcription machinery into the phase of productive transcript elongation.  
 
1.3.1 Transcription elongation 
 
At first sight, the phase of transcript elongation appears to be a straight-forward addition of 
nucleotides to the 3’ end of the RNA-chain. This central enzymatic reaction, catalyzed by Pol 
II, is quite well understood, as outlined in section 1.1. However, also this productive phase is 
highly regulated. This is necessary because Pol II encounters diverse obstacles on its way 
along the gene. One category of these impediments to elongation is coming from the DNA 
template itself, including drug-induced or sequence dependent pause and arrest. DNA 
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lesions can hinder Pol II from proceeding with nucleotide addition. A UV light induced 
thymine-thymine cyclobutane pyrimidine dimer (CPD) or a guanine-guanine intrastrand 
cross-link induced by the anticancer drug cisplatin can form such a block. Recent structural 
studies revealed the molecular basis of how the transcription apparatus copes with these 
situations (Brueckner et al, 2007; Damsma et al, 2007). Pol II stalls at these lesions and the 
components of the transcription coupled repair (TCR) machinery are assembled, the lesion-
containing DNA fragment is removed and the gap in the DNA is repaired. Importantly, the 
detailed mechanism of transcriptional stalling at the two lesions differ.  
Pol II often encounters pause-sites that are template-intrinsic. Those are often A-T rich and 
Pol II moves backwards at these sites, which extrudes the RNA 3’ end through the 
polymerase pore beneath the active site (Cramer et al, 2000; Nudler et al, 1997). Elongation 
factor TFIIS assists Pol II in overcoming such an arrest by cleavage of the extruded RNA 
(Fish & Kane, 2002). TFIIS thereby enhances a weak nuclease activity that is intrinsic to  
Pol II (Izban & Luse, 1992; Reines, 1992; Wang & Hawley, 1993). Cleavage is accomplished 
by insertion of TFIIS into the pore, modifying the Pol II active site, thus triggering nuclease 
activity (Kettenberger et al, 2003). 
In the cell, Pol II is not transcribing naked DNA but a chromatinized template. The basic 
building block of chromatin is a nucleosome, consisting of an octamer of four histone proteins 
wrapped in 147 base pairs of DNA. The histone proteins H2A, H2B, H3 and H4 are each 
composed of a globular domain and an unstructured tail domain (Luger et al, 1997). These 
histone tails can be modified in various ways, including acetylation of lysines, methylation of 
lysines and arginines, phosphorylation of serines and threonines, ubiquitination of lysines, 
sumoylation of lysines, and ADP-ribosylation of glutamic acids. These modifications as a 
whole write down the "histone code" which is defining epigenetic regulation that preserves 
genomic information past the genetic code (Jenuwein & Allis, 2001; Strahl & Allis, 2000). 
Nucleosomes initially pose a block to transcription by Pol II and the chromatin has to be 
"prepared” by specific factors for access of the transcription machinery to do its job. Two 
especially important elongation factors that are maintaining chromatin structure – histone 
chaperones Spt6 and FACT – are described in more detail in section 3.1.2. Numerous other 
factors are involved in this process, regulating modifications like histone-acetylation, histone-
methylation, ATP-dependent chromatin remodeling and histone composition (Hartzog et al, 
2002; Sims et al, 2004). These and other important elongation factors are summarized in 
Table 1. 
When elongating polymerase II reaches the 3’ regions of a gene and transcribes the poly(A) 
site, the transcription cycle enters its final phases: cleavage/polyadenylation and termination. 
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Table 1: Elongation factors of RNA polymerase II  
 
Elongation factor Function  
TFIIF involved in PIC formation, alleviates pausing, stimulates rate of Pol II, modulates TFIIS 
Elongins alleviate pausing, stimulate rate of Pol II 
ELL alleviates pausing, stimulates rate of Pol II 
Spt4/5 (DSIF) stimulates elongation, suppresses early transcript termination, stimulates capping 
NELF Pol II checkpoint control 
CSB 
Stimulates elongation, modulates TFIIS, has a role in rescuing RNAP II at DNA lesions and 
transcription-coupled nucleotide excision repair 
FCP1 Stimulates elongation, recycles RNAP II through dephosphorylation of Ser5 CTD, role in capping 
TFIIS Stimulates RNAP II-mediated cleavage of nascent transcript to alleviate arrest 
Spt6 Stimulates elongation, modulates chromatin structure, histone chaperone activity 
HDAg Stimulates elongation, binds RNAP II, displaces NELF, functionally distinct from TFIIF 
19S Proteosome Recruited by H2B monoubiquitination, involved in H3-K4 methylation 
P-TEFb Relieves NELF-mediated pausing, phosphorylates Ser2 on the CTD and DSIF (Spt5) 
Ssu72 Dephosphorylation of Ser5 CTD, role in 3'-end processing events 
SWI/SNF Remodels chromatin in an ATP-dependent fashion 
Isw1 
Regulates Ser5 and Ser2 phosphorylation, H3-K4 and H3-K36 methylation, and the recruitment of 
3'-end processing factors 
Chd1 Genetically and physically interacts with elongation factors, localized within coding regions 
FACT Facilitates elongation through chromatin, modulates chromatin structure, histone chaperone activity 
Set1 Methylates histone H3-K4, localized to promoter and coding regions 
Set2 Methylates histone H3-K6, localized to coding regions 
Paf 
Modulates H2B monoubiquitination and H3-K4 methylation, recruits Set1 and Set2, involved in 
modulating mRNA maturation 
THO Required for transcription of long transcripts, or those with high GC content 
TREX Links elongation to pre-mRNA splicing and export, surveillance, interaction with Spt6 
Iws1/Spn1 Associates with Spt6, localizes to coding regions 
 
The table is taken and modified from (Sims et al, 2004) 
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1.3.2 Transcription termination 
?
All the preceding phases of the transcription cycle were regulated by a large number of 
different proteins in a highly cooperative manner. This is also true for the final stages of 
transcription, cleavage/polyadenylation and termination. Transcription termination is an 
important process in gene regulation, allowing elongation complexes (ECs) to dissociate 
from template DNA. Defects in termination lead to interference of non-terminated EC with the 
initiation events of genes downstream on the DNA, leading to major disturbances of proper 
gene expression (Bateman & Paule, 1988; Henderson et al, 1989). 
Termination is best described in prokaryotes. In these organisms, termination sites can be 
basically classified as intrinsic or factor-dependent. Intrinsic termination is dependent on  
DNA sequences consisting of a palindromic region followed by a run of T residues 
(d'Aubenton Carafa et al, 1990). When transcribed, the RNA forms a stable hairpin structure 
followed by a stretch of U-residues. There are basically three regions of protein-nucleic acids 
interactions within the bacterial RNAP: the double-stranded DNA binding site (DBS), the 
RNA/DNA heteroduplex binding site (HBS), and the single-stranded RNA binding site (RBS) 
(Korzheva et al, 1998). The formation of the hairpin leads to a destabilization of these 
interactions. The poly-U-stretch forms an unstable A-U-hybrid and occupies the HBS, while 
the hairpin binds the RBS and displaces the RNA. Partial melting of the hybrid is a 
prerequisite for hairpin formation. Subsequently, these changes in elongation complex 
structure lead to destabilization and thus disintegration (Gusarov & Nudler, 1999; Yarnell & 
Roberts, 1999). RNAP can terminate independently by this mechanism, but in vivo it is 
stimulated by additional factors, such as NusA (Farnham et al, 1982; Schmidt & Chamberlin, 
1987; Ward & Gottesman, 1981).  
Rho-dependent termination depends on the homo-hexameric RNA-translocase Rho 
(Roberts, 1969). Termination is induced by a sequence in the nascent transcript called RUT 
(Rho-utilization site), to which Rho is binding (Ceruzzi et al, 1985). After binding, cycles of 
ATP-hydrolysis induce a conformational change that leads to a 5’ to 3’ directed translocation 
of Rho along the RNA. Upon contact, Rho disintegrates the elongation complex and induces 
termination (Nudler & Gottesman, 2002). Again, the termination efficiency in vivo can be 
stimulated by additional factors, NusG (Nehrke et al, 1993; Sullivan & Gottesman, 1992) and 
NusA (Zheng & Friedman, 1994).  
An additional factor that can terminate prokaryotic RNAP and couple it to the DNA excision 
repair machinery is the ATP-dependent DNA translocase MFD, that interacts with the 
polymerase and upstream DNA. Disruption of the elongation complex is achieved by a 
forward translocation of the polymerase over a DNA lesion (Park et al, 2002; Roberts & Park, 
2004). 
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Eukaryotic cells make use of different mechanisms to terminate the transcription of their 
polymerases. Ribosomal DNA (rDNA), that is transcribed by Pol I, is arrayed in ?150 copies 
of the rRNA gene coding for a 35S RNA precursor in S. cerevisiae. For each repeat, 
termination is controlled by two major sites. About 90% of all transcripts are terminated at the 
Reb1-dependent terminator, which is located ?93 nucleotides downstream of the rRNA-
coding sequence (Lang & Reeder, 1993; Reeder & Lang, 1997). There, the Reb1-protein 
binds 3’ of a T-rich sequence element that is coding for the 3’-terminal 10-12 nt of the 
transcript. This “roadblock” pauses polymerase. By a mechanism that probably involves 
transcript slippage facilitated by the weak, T-rich hybrid termination occurs (Reeder & Lang, 
1997). In vivo and in vitro data suggests that an additional factor is required for the release 
(Jansa & Grummt, 1999; Tschochner & Milkereit, 1997). Furthermore, the Pol I subunit 
A12.2, which is a homolog of Pol II subunit Rpb9, seems to be involved in termination at this 
site, since a deletion of the gene leads to increased read-through at the Reb1-dependent site 
(Prescott et al, 2004). Recently it was shown, that A12.2 is required for the intrinsic 3’-RNA 
cleavage activity of Pol I (Kuhn et al, 2007). Polymerases that fail to terminate at the Reb1-
dependent site can be stopped at the “fail-safe” terminator that is located ?250 nt 
downstream of the rRNA coding sequence (Reeder et al, 1999). 
The least regulated form of termination in eukaryotic transcription is the mechanism that is 
employed by Pol III, as it seems to be largely factor-independent (Geiduschek & Kassavetis, 
2001). Short runs of T-residues seem to be enough to elicit termination, the effciency of 
termination is influenced by flanking sequence and increases with the length of the T-run 
(Cozzarelli et al, 1983). This involves transcriptional pausing at these sites. It was anticipated 
that the intrinsic cleavage activity of Pol III, mediated by the subunit C11, is needed for 
termination (Chedin et al, 1998). However, recent studies show, that rather the subunits C37 
and C53 are involved in the recognition of terminator elements, but the cleavage activity is 
not involved (Landrieux et al, 2006). 
The termination mechanism that is still least understood, is the one used by Pol II. A special 
feature of termination of protein coding genes that are transcribed into mRNA by RNA 
polymerase II (Pol II), is that this enzyme does not stop transcription at a specific position at 
the end of a gene like Pol I and Pol III. Rather, the site for termination seems to be random, 
sometimes up to 1kb downstream of the poly(A) site where the nascent transcript is cleaved 
and uncoupled from the transcription machinery by factors that are recruited to the Ser2-
phosphorylated CTD of polymerase II. However, it is well established that termination is 
dependent on the presence of a functional poly(A)-signal and coupled to RNA-processing 
events (Buratowski, 2005; Proudfoot, 1989). Furthermore, it is clear that Pol II employs 
different mechanisms for termination of mRNA-transcription and the termination at genes 
coding for snRNAs (small nuclear RNAs), snoRNAs (small nucleolar RNAs) and CUTs 
(cryptic unstable transcripts), which are not polyadenylated. Surprisingly, Rat1 and 
polyadenylation factors localize to these genes, but mutations that disrupt poly(A) site 
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cleavage or Rat1 activity do not impair termination, which seems to be mediated by Nrd1, 
Sen1 (a  DNA-RNA-helicase) and Ssu72 (Kim et al, 2006; Lykke-Andersen & Jensen, 2007). 
Two models try to explain termination of Pol II transcribing protein-coding genes, the 
"torpedo-model" and the "allosteric model". Both are introduced in detail in sections 4.1.1 and 
4.1.2.  
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2 Materials and common methods 
?
2.1 Materials 
?
2.1.1 Bacterial and yeast strains 
?
?
Table 2? E. coli strains 
Strain   Description       Source 
XL-1 Blue  rec1A; endA1; gyrA96; thi-1; hsdR17; supE44;    Stratagene 
  relA1; lac[F’ proAB lacIqZ?M15Tn10(Tetr)] 
BL21-CodonPlus  B; F-; ompT; hsdS(rB, mB); dcm+; Tetr; gal ?(DE3);   Stratagene 
(DE3)RIL  endA; Hte [argU, ileY, leuW, Camr] 
Rosetta B834  E.coli (DE3) hsd metB      Novagen 
E. coli GM2163  F- dam-13::Tn9 (Camr) dcm-6 hsdR2 (rk-mk+) leuB6   Fermentas 
  hisG4 thi-1 araC14 lacY1 galK2 galT22 xylA5 mtl-1 
  rpsL136 (Strr) fhuA31tsx-78 glnV44 mcrA mcrB1 
 
 
 
Table 3: S. cerevisiae strains 
Strain   Description       Source 
S288C MAT?; SUC2; gal2; mal; mel; flo1; flo8-1; hap1; ho; bio1; bio6  Euroscarf 
 
FY119 Spt6?C  MAT?; his4-912; lys2-128; leu2-1; ura3-52; trp1-63   Youdell et al., 
(isogenic to S288C)         (2008) 
 
S288C Spt6-TAP  MAT?; SUC2; gal2; mal; mel; flo1; flo8-1; hap1; ho; bio1;   This study 
bio6; URA3 
 
FY119 Spt6?C TAP MAT?; his4-912; lys2-128; leu2-1; ura3-52; trp1-63   This study 
(isogenic to S288C) 
 
 
 
2.1.2 Plasmids, oligonucleotides and peptides 
?
?
Table 4: Plasmids 
Plasmid   Description      Source 
pET21b(+)  T7; T7-Tag, His-Tag 3’ of MCS; lacI; pBR 322 origin;  Novagen 
  f1 origin; bla coding sequence, Apr 
pET24b(+)  T7; T7-Tag; His-Tag 3’ of MCS; lacI; pBR 322 origin;  Novagen 
  f1 origin; Kanr 
pET28b(+)  T7; T7-Tag; His-Tag 5’ and 3’ of MCS; lacI;    Novagen  
  pBR322 origin; f1 origin; Kanr 
pBS1539 K.I. URA3, Ampr, C-terminal, TEV cleavage site  Euroscarf 
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Table 5: Oligonucleotides 
Name  Sequence       Source 
Sc115  GGAGGAGGACATATGAATCATCCTTACTATTTCC   ThermoFisher 
Sc116  GGAGGAGGAGCGGCCGCACCGCTTTTGAATTTTTCAC  ThermoFisher 
Sc117  GGAGGAGGAGCGGCCGCTCACAAGAGCCTTACCTTGTTTTG ThermoFisher 
Sc118  GGAGGAGGACATATGCATCGTGTTATCAATCATC   ThermoFisher 
Sc119  GGAGGAGGAGCGGCCGCGCCTTGGAAGTACAGGTTCTCTTT ThermoFisher 
 TTCACTAGATGTCATTTC 
Sc128  GGAGGAGGAGCGGCCGCTCATTTGAATTTTTCACTAGATG ThermoFisher 
Sc129  GGAGGAGGAGCGGCCGCTCATGTCATTTCATTCAAGAGCC ThermoFisher 
Sc132  GGAGGAGGACATATGGTTATCAATCATCCTTAC   ThermoFisher 
Sc133  GGAGGAGGACATATGCATCCTTACTATTTCCCTTTC  ThermoFisher 
Sc134  GGAGGAGGAGCGGCCGCTCATTCATTCAAGAGCCTTACCTTG ThermoFisher 
Sc135  GTCTTGATTGTCGATTTAGACCAG    ThermoFisher 
Sc136  CTGGTCTAAATCGACAATCAAGAC    ThermoFisher 
Sc137  GTCTTGATTGTCTTAGACCAGATC    ThermoFisher 
Sc138  GATCTGGTCTAAGACAATCAAGAC    ThermoFisher 
Sp118  GGAGGAGGACATATGGCTCGCGTAATTAAGCACCCG  ThermoFisher 
Sp129  GGAGGAGGAGCGGCCGCTCATTCATCTATTTTTTTAGCAATGGC ThermoFisher 
Mm118  GGAGGAGGACATATGAAGCGAGTGATTGCACACCCG  ThermoFisher 
Mm129  GGAGGAGGAGCGGCCGCTCAGTCTCGAGCAAAGGAAGCCATG ThermoFisher 
Hs118  GGAGGAGGACATATGAAGAGAGTGATCGCACACCC  ThermoFisher 
Hs129  GGAGGAGGAGCGGCCGCTCAGTCCCGGGCAAAGGATGC ThermoFisherC 
Cg141  GGATTATATGAGAAGTAAAG     ThermoFisher 
Cg142  CTTTACTTCTCATATAATCC     ThermoFisher 
Cg143  CATTTGGCTATGACTTGG     ThermoFisher 
Cg144  CCAAGTCATAGCCAAATG     ThermoFisher 
Cg145  CAAGAAATGGAAAAGGAAAATCC    ThermoFisher 
Cg146  GGATTTTCCTTTTCCATTTCTTG     ThermoFisher 
Cg147  CTTGCCATGGGTAAAGTCTTGG     ThermoFisher 
Cg148  CCAAGACTTTACCCATGGCAAG     ThermoFisher 
Cg149  GGAGGAGGAGCGGCCGCCTCGTTCAGTAGTCTAATCATGTTTTG ThermoFisher 
CgAfw GGATTATATGAGAAGTAAAG     ThermoFisher 
CgArv CTTTACTTCTCATATAATCC     ThermoFisher 
CgBfw CATTTGGCTATGACTTGG     ThermoFisher 
CgBrv CCAAGTCATAGCCAAATG     ThermoFisher 
CgCfw CAAGAAATGGAAAAGGAAAATCC    ThermoFisher 
CgCrv GGATTTTCCTTTTCCATTTCTTG     ThermoFisher 
CgDfw CTTGCCATGGGTAAAGTCTTGG     ThermoFisher 
CgDrv CCAAGACTTTACCCATGGCAAG     ThermoFisher 
CgErv  GGAGGAGGAGCGGCCGCCTCGTTCAGTAGTCTAATCATGTTTTG ThermoFisher 
SH2RLfw TTCGTGATCCTACAGTCTAGCCG    ThermoFisher 
SH2RLrv CGGCTAGACTGTAGGATCACGAA    ThermoFisher 
SH2RKfw TTCGTGATCAAACAGTCTAGCCG    ThermoFisher 
SH2RKrv CGGCTAGACTGTTTGATCACGAA    ThermoFisher 
SH2kofw AGAGAACAATGACATCTAGTGAAAAATTCA   ThermoFisher 
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Table 5 (continued) 
SH2korv ATGTCATTGTTCTCTTTGCACGGGCTTCT   ThermoFisher 
Ctermkofw  GGTAAGGCTCTTGAATGAATAGATGCGTATGTAGTGTCCATTG ThermoFisher 
Ctermkorv GGACACTACATACGCATCTATTCATTCAAGAGCCTTACCTTG ThermoFisher 
Spt6flTAPfw CTTCTAAAATCTAACAGTAGTAAGAATAGAATGAACAACTACCGT ThermoFisher 
 TCCATGGAAAAGAGAAG 
Spt6flTAPrv TAATAATAAAATTAATAATAACAATGGACACTACATACGCATCTA ThermoFisher 
  TACGACTCACTATAGGG 
Spt6dSH2TAPfw GAGGAGAGGAAATTGATGATGGCAGAAGCCCGTGCAAAGAGA ThermoFisher 
 ACATCCATGGAAAAGAGAAG 
Rat1flfw   GGAGGAGGAGCTAGCATGGGTGTTCCGTCATTTTTCAGATGGC ThermoFisher 
Rat1flrv  GGAGGAGGAGCGGCCGCACGCCTATTTGCTCTTGAATTGTCATA ThermoFisher  
CCG 
Rai1flfw GGAGGAGGACATATGGGTGTTAGTGCAAATTTG   ThermoFisher 
Rai1flrv   GGAGGAGGAGCGGCCGCTTTCAAAGATTTTCTCCAC  ThermoFisher 
Rtt103flfw GGAGGAGGACATATGCCTTTCTCTTCTGAGCAATTC  ThermoFisher 
Rtt103flrv GGAGGAGGAGCGGCCGCATTTGCAAGCTTACTTAACAAG  ThermoFisher 
Rtt103?CIDfw GGAGGAGGACATATGGAGAGCTCACCAGTGGAAGC  ThermoFisher 
torpedoCBNT BGGCTACCGACGCTAGGTCAAGGCAGTACTAGTAATGACCAGG           Biomers  
 CTCAAGTACTTGAGCTTGGAGTCAGTCGACGATGACTGG 
torpedoCBT CCAGTCATCGTCGACTGACTCCAAGCTCAAGTACTTGAGCCTGG           Biomers  
  TCATTACTAGTACTGCCTTGACCTAGCGTCGG 
torpedoRNA PUAAUCCCAUAUAUAUGCAUAAAGACCAGGC             Biomers 
activityRNA  UCCCAUAUAUAUGCAUAAAGACCAGGC              Biomers 
RNaseHDNA1 GCCUGGUCUUUAUGCAUAUAUAUGGGA              Metabion 
RNaseHDNA2 GCCUGGUCUUUAUGCAU               Metabion 
poly(A)1CBNT BCGACGCTAGGTCAAGGCAGTACTAGTAATGACCAGGCTCAACT           Metabion 
  ACTCAATAAACCCTACACTCCACCATGGGTAGAGTG 
poly(A)1CBT CACTCTACCCATGGTGGAGTGTAGGGTTTATTGAGTAGTTGAGC              Metabion  
 CTGGTCATTACTAGTACTGCCTTGACCTAG 
poly(A)cCBNT BCGACGCTAGGTCAAGGCAGTACTAGTAATGACCAGGCTCAACT           Metabion  
 ACTCCTACCACCCTACACTCCACCATGGGTAGAGTG 
poly(A)cCBT CACTCTACCCATGGTGGAGTGTAGGGTGGTAGGAGTAGTTGAGC            Metabion  
 CTGGTCATTACTAGTACTGCCTTGACCTAG 
poly(A)2CBNT BCGACGCTAGGTCAAGGCAGTACTAGTAATGACCAGGCTCAACTA          Metabion  
 CTCAATAAACCCTACACTCCACCATGGGTAGAGTG 
poly(A)2CBT CACTCTACCCATGGTGGAGTGTAGGGTTTATTGAGTAGTTGAGCC           Metabion  
 TGGTCATTACTAGTACTGCCTTGACCTAG 
poly(A)RNA1 PUCCCAUAUAUAUGCAUAAAUCAAUAAA               Biomers 
poly(A)RNA2 PUACAGCGAGUCUAUGAGCAUCAAUAAA               Biomers 
poly(A)xtalNT CAGCTACTTGAGCT                  Biomers 
poly(A)xtalT AGCTCAAGTAGCTGCTTTABrUTGCATT              Metabion 
poly(A)xtalRNA UGCAUUUCGCAAUAAA                  Biomers 
 
All oligonucleotides are shown in the direction 5’ to 3’; B = Biotin; P = Phosphate; BrU = 
Bromo-dU; in magenta: RNA-oligonucleotides; 
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Table 6: Synthetic peptides 
Name   Sequence       Source 
P1 SPSYpSPTS       Anaspec 
P2  YpSPTSPSYpSPTSPS      Coring 
P3  Fluo-(Linker)-SYpSPTSPSYpSPTSPS    Coring 
 
pS = Phosphoserine; Fluo = Fluorescein; (Linker) = ?-aminocaproic acid 
 
 
2.1.3 Media and supplements 
 
 
Table 7:Growth media 
Media    Description 
LB  1% (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) NaCl (+1.5%(w/v) 
  agar for selective media plates) 
ZY  1% (w/v) tryptone; 0.5% (w/v) yeast extract 
YPD  2% (w/v) peptone; 2% (w/v) glucose; 1.5% (w/v) yeast extract (+1.8% (w/v) 
  agar for selective media plates 
SOB  2% (w/v) tryptone; 0.5% (w/v) yeast extract; 8.55 mM NaCl; 2.5 mM KCl; 
  10 mM MgCl2; 
SOC  see SOB + 20 mM glucose (before use) 
Minimal medium  7.5 mM (NH4)2SO4; 8.5 mM NaCl; 55 mM KH2PO4; 100 mM K2HPO4; 1mM  
  MgSO4; 20 mM glucose, 1 ?g/l trace elements (Cu2+, Mn2+, Zn2+, Mo42-), 
  10 mg/l thiamine; 10 mg/l biotine; 1 mg/l Ca2+; 1 mg/l Fe2+; 100 mg/l amino 
  acids (A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, Y); 100 mg/l 
  selenomethionine 
 
?
Table 8: Supplements 
Supplement  Description     Applied concentration 
Ampicillin  Antibiotic     100 ?g/ml for E.coli culture 
Kanamycin  Antibiotic     30 ?g/ml for E.coli culture 
Chloramphenicol Antibiotic     50 ?g/ml for E.coli culture 
IPTG  Isopropyl-?-D-thiogalactopyranosid   0.5 mM 
 
 
2.1.4 Buffers and solutions 
?
?
Table 9: General buffers, dyes and solutions 
Name    Description     Method 
1x Bradford dye   1:5 dilution of Bradford concentrate (BioRad) Protein concentration 
4x stacking gel buffer  0.5M Tris; 0.4% (w/v) SDS; pH 6.8 at 25°C  SDS-PAGE 
4x separation gel buffer  3 M Tris; 0.4% (w/v) SDS; pH 8.9 at 25°C  SDS-PAGE 
electrophoresis buffer  25 mM Tris; 0.1% (w/v) SDS; 250 mM glycine SDS-PAGE 
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Table 9 (continued) 
5x SDS sample buffer  250 mM Tris/HCl pH 7.0 at 25°C; 50% (v/v)  SDS-PAGE 
  glycerol; 0.5% (w/v) bromophenol blue; 7.5% 
  (w/v) SDS; 12.5% (w/v) ?-mercaptoethanol 
Gel staining solution  50% (v/v) ethanol; 7% (v/v) acetic acid; 0.125% Coomassie staining 
 (w/v) Coomassie Brilliant Blue R-250   
Gel destaining solution  5% (v/v) ethanol; 7.5% (v/v) acetic acid;   Coomassie staining 
TBE  8.9 mM Tris; 8.9 mM boric acid; 2 mM EDTA Agarose gel 
  (pH 8.0, 25°C)     electrophoresis 
TE  10 mM Tris pH 7.4; 1 mM EDTA   nucleic acids 
10 x TBS  500 mM Tris/HCl pH 7.5; 1.5 M NaCl  ChIP 
1 x PBS  2 mM KH2PO4; 4 mM Na2HPO4; 140 mM NaCl; diverse 
  3 mM KCl, pH 7.4 @ 25°C 
6x Loading dye (Fermentas) 1.5 g/l bromophenol blue; 1.5 g/l xylene cyanol; Agarose gel 
  50% (v/v) glycerol    electrophoresis 
2x Urea loadig dye  20% (v/v) 10x TBE; 8 M urea; 0.03% (w/v)  denaturing RNA- 
  bromophenol blue; 0.03% (w/v) xylene cyanol FF PAGE 
Blotting buffer   10% (v/v) methanol in ddH2O   Edman sequencing 
Swelling buffer  200 mM Tris/HCl pH 8.5 at 25°C; 2% (w/v) SDS Edman sequencing 
TFB-1  30 mM KOAc; 50 mM MnCl2; 100 mM RbCl;  chemically 
  10 mM CaCl2; 15% (v/v) glycerol; pH 5.8 at 25°C competent cells 
TFB-2  10 mM MOPS pH 7.0 at 25°C; 10 mM RbCl;  chemically 
  75 mM CaCl2; 15% (v/v) glycerol   competent cells 
20x NPS  0.5 M (NH4)2SO4; 1 M KH2PO4; 1 M Na2HPO4 autoinducing 
        protein expression 
50x 5052  25% (w/v) glycerol; 140 mM glucose; 300 mM autoinducing 
   ?-lactose     protein expression 
100x PI  0.028 mg/ml Leupeptin; 0.137 mg/ml Pepstatin A; protease  
0,017 mg/ml PMSF; 0.33 mg/ml benzamidine;  inhibitor mix 
in 100% EtOH p.a. 
beads blocking buffer  50 mM Tris/HCl pH 8.0 at 25°C; 150 mM NaCl; bead assays 
  2 mM EDTA pH8.0; 0.1% (w/v) triton X-100; 
  5% (w/v) glycerol; 0.5% (w/v) BSA; 200 ?g/ml 
  insulin; 0.1 mg/ml heparin; 0.5 mM DTT 
beads breaking buffer  50 mM Tris/HCl pH 8.0 at 25°C; 150 mM NaCl; bead assays 
  0.1% (w/v) triton X-100; 5% (w/v) glycerol; 
  0.5 mM DTT 
TELit  10 mM Tris/HCl pH 8.0; 1 mM EDTA; 155 mM yeast transformation 
lithium acetate 
LitPEG  40% (w/v) polyethylen glycol 3350 in TELit  yeast transformation 
LitSorb  100 mM D-sorbitol in TELit   yeast transformation 
 
 
 
Table 10: Spt6 SH2 domain purification buffers 
Name    Description 
Spt6 cell resuspension  50 mM Tris/HCl pH 8.0 at 4°C; 1M NaCl; 10 mM Imidazole; 10 mM  
buffer  ?-mercaptoethanol; 10% (v/v) glycerol 
Spt6 cell lysis buffer  50 mM Tris/HCl pH 8.0 at 4°C; 1M NaCl; 10 mM Imidazole; 10 mM  
  ?-mercaptoethanol; PI 
Spt6 IMAC elution  50 mM Tris/HCl pH 8.0 at 4°C; 200 mM NaCl; 10 mM Imidazole; 10 mM  
buffer  ?-mercaptoethanol 
Spt6 anion exchange  50 mM Tris/HCl pH 8.0 at 4°C; 100 mM NaCl; 5 mM DTT 
buffer A 
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Table 10 (continued) 
Spt6 anion exchange  50 mM Tris/HCl pH 8.0 at 4°C; 2 M NaCl; 5 mM DTT 
buffer B 
Spt6 C. glabrata size  50 mM Tris/HCl pH 8.0 at 4°C; 200 mM NaCl; 5 mM DTT 
exclusion buffer 
Spt6 S. cerevisiae/  50 mM Tris/HCl pH 8.0 at 4°C; 100 mM NaCl; 5 mM DTT 
Homo sapiens size 
exclusion buffer 
Spt6 S. pombe size  30 mM bicine pH 9.0 at 4°C; 300 mM NaCl; 5 mM DTT 
exclusion buffer 
SH2 low salt buffer  50 mM Tris pH 8.0 at 20°C, 20 mM NaCl, 5 mM DTT 
 
 
 
Table 11: Rat1, Rai1, Rtt103 purification and reaction buffers 
Name    Description 
Rat1 cell resuspension  50 mM Tris/HCl pH 8.0 at 25°C; 500 mM NaCl; 10 mM imidazole; 10 mM 
buffer  ?-mercaptoethanol; 5% (v/v) glycerol; 
Rat1 cell lysis buffer  same as Rat1 cell resuspension buffer + PI 
Rat1 IMAC buffer  50 mM Tris/HCl pH 8.0 at 4°C; 100 mM NaCl; 10 mM imidazole;10 mM 
  ?-mercaptoethanol 
Rat1 heparin buffer A  50 mM Tris/HCl pH 8.0 at 4°C; 100 mM NaCl; 5 mM DTT 
Rat1 heparin buffer B  50 mM Tris/HCl pH 8.0 at 4°C; 2 M NaCl; 5 mM DTT 
2x Rat1 size exclusion  50 mM Tris/HCl pH 8.0 at 4°C; 200 mM NaCl; 2 mM MgCl2; 2 mM DTT 
buffer (RNAse free) 
Rat1 storage buffer  25 mM Tris/HCl pH 8.0 at 4°C; 100 mM NaCl; 1 mM MgCl2, 1 mM DTT; 
(RNAse free)  10% (v/v) glycerol;  
Rat1/Rai1 cell resus-  50 mM Tris/HCl pH 8.0 at 25°C; 150 mM NaCl; 10 mM imidazole; 10 mM 
pension buffer  ?-mercaptoethanol; 5% (v/v) glycerol 
Rat1/Rai1 cell lysis  same as Rat1/Rai1 cell resuspension buffer + PI 
buffer 
Rat1/Rai1 IMAC  50 mM Tris/HCl pH 8.0 at 25°C; 100 mM NaCl; 10 mM imidazole; 10 mM  
buffer  ?-mercaptoethanol 
2x Rat1/Rai1 size  same as 2x Rat1 size exclusion buffer 
exclusion buffer 
(RNAse free) 
Rat1/Rai1 storage  same as Rat1 storage buffer 
Buffer (RNAse free) 
Rtt103 cell resus-  same as Rat1 cell resuspension buffer 
pension buffer 
Rtt103 cell lysis  same as Rat1 cell lysis buffer 
buffer 
Rtt103 IMAC   50 mM Tris/HCl pH 8.0 at 4°C; 150 mM NaCl; 10 mM imidazole, 10 mM 
buffer  ?-mercaptoethanol 
2x Rat1/Rai1/Rtt103  same as 2x Rat1 size exclusion buffer 
size exclusion buffer 
10 xRat1 reaction   200 mM Tris/HCl pH 8.0 at 30°C; 1.5M NaCl; 20 mM MgCl2; 10 mM DTT 
buffer  
Rat 1 wash buffer  20 mM Tris/HCl pH 8.0 at 30°C; 500 mM NaCl; 2 mM MgCl2; 1 mM DTT 
 
?
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Table 12: Polymerase II purification buffers 
Name    Description 
TEZ0  10% (v/v) 10x TEZ0; 1 mM DTT; PI 
10x TEZ0  500 mM Tris/HCl pH 7.5 at 20°C; 10 mM EDTA; 100 ?M ZnCl2 
3x Pol II  150 mM Tris/HCl pH 7.9 at 4°C; 3 mM EDTA; 30 ?M ZnCl2; 30 % (v/v)  
freezing buffer  glycerol; 3 % (v/v) DMSO; 30 mM DTT, PI 
HSB150    50 mM Tris/HCl pH 7.9 at 4°C; 150 mM KCl; 1 mM EDTA; 10 ?M ZnCl2; 
  10% (v/v) glycerol; 10 mM DTT, PI 
HSB600  50 mM Tris/HCl pH 7.9 at 4°C; 600 mM KCl; 1 mM EDTA; 10 ?M ZnCl2; 
  10% (v/v) glycerol; 10 mM DTT, PI 
Pol II buffer  5 mM HEPES pH 7.25 at 20°C; 40 mM (NH4)2SO4; 10 ?M ZnCl2; 10 mM  
DTT 
TEZ250  10% (v/v) 10x TEZ0, 
TEZ500  10% (v/v) 10x TEZ0; 500 mM (NH4)2SO4; 1 mM DTT; PI 
TEZ500 + glyerol  same as TEZ500 + 50% (v/v) glycerol; PI 
 
 
 
Table 13: Crystallization buffers 
Name    Description 
Spt6 SH2 seeding  50 mM MES pH 6.5 at 20°C; 200-400 mM Mg acetate; 10-20% (w/v)  
buffer   PEG 3350; 5 mM TCEP 
Spt6 SH2-1  100 mM HEPES pH 7.0 at 20°C; 1 M Succinic acid; 1% (w/v) PEG 2000  
  MME; 5 mM TCEP 
Spt6 SH2-2  50 mM bicine pH 8.0 at 20°C; 4.3 M NaCl; 5 mM TCEP 
Spt6 SH2 desalting  30 mM bicine pH 8,0; 300 mM NaCl; 50% (w/v) PEG 2000; 5 mM TCEP 
buffer 
Pol II + poly(A) 50 mM HEPES pH 7,0 at 20°C; 3,5% (w/v) PEG 6000; 200 mM ammonium 
acetate, 5mM TCEP 
 
 
 
Table 14: Chromatin immunoprecipitation buffers 
Name    Description 
FA lysis buffer   50 mM HEPES pH 7.5; 150 mM or 500 mM NaCl; 1 mM EDTA; 1% Triton 
X-100; 0.1% Na-deoxycholate; 0.1% SDS 
 
ChIP wash buffer   10 mM Tris/HCl pH 8.0; 250 mM LiCl; 1 mM EDTA; 0.5% Nonidet P-40;  
0.5% Na-deoxycholate 
 
ChIP elution buffer  50 mM Tris/HCl pH 7.5; 10 mM EDTA; 1% SDS 
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2.2 Common methods 
?
2.2.1 Molecular cloning 
?
Polymerase Chain Reaction (PCR) primers were designed by using an overhang of several 
nucleotides (usually 5’-aggaggagg-3’) at the 5’ end, followed by the restriction side and 20 to 
25 nt complementary to the sequence of the gene of interest (2.1.1, Table 5). PCR reactions 
were carried out with Herculase or Herculase II polymerases (both stratagene) in a volume of 
50 ?l together with the respective buffer, 100 ?M of dNTP mix, 0,5 ?M of each primer and 
variable DMSO concentrations, usually  1% (v/v). About 100 ng genomic DNA or cDNA of 
the target organism was usually used as a template. In cases, where the gene of interest 
was allready cloned, the same amount of the specific vector was used. 
For the introduction of point mutations and loop-deletions, the overlap extension method was 
used. Here, two overlapping PCR-products are produced with primers carrying the desired 
mutation. In a second PCR reaction these products were used as a template to produce the 
gene of interest containing the mutation. 
Thermocycling programs were adjusted to the specific needs of the individual reactions in 
terms of annealing temperature and elongation times and usually contained 30 cycles 
(Biometra T3000 Thermocycler). PCR products were visualized by 1% agarose gel 
electrophoresis and staining with ethidiumbromide. Purification of the DNA was carried out 
with the QIAquick gel extraction protocol (Quiagen). 
 
Enzymatic restriction cleavage. DNA was digested using restriction endonucleases (New 
England Biolabs and Fermentas) as recommended by the producer. Cleaved PCR products 
were purified using the QIAquick PCR purification protocol, cleaved plasmids by the 
QIAquick gel extraction protocol (both Quiagen). 
 
Ligation of digested DNA into linearized vectors was carried out for 1 hour at room 
temperature in a volume of 20 ?l using T4 DNA ligase (Fermentas) and its corresponding 
buffer. Concentrations of DNA components were varied depending on the different reactions. 
Usually a 5- to 10-fold excess of insert, relative to linearized vector was used. 
 
Transformation of E. coli and isolation of plasmid DNA. Chemically competent E. coli XL-
1 blue cells (see 2.1.1, Table 2 and 2.2.2) were transformed with DNA by a heat shock 
protocol.  
3-5 ?l of the ligation reaction or 1 ?l of plasmid DNA were added to a 50 ?l aliquot of 
competent cells and incubated for 5 minutes on ice. Cells were then heated to 42°C for  
30 seconds and put back on ice for 2 minutes. The transformed cells were recovered by 
incubation at 37°C in 700 ?l LB for one hour. After sedimentation (30 sec, 14000 rpm in a 
2 Materials and common methods 20 
microcentrifuge) the cells were resuspended in 100 ?l LB medium and plated on LB-Agar 
plates containing the corresponding antibiotic for selection of transformed cells.  
E. coli cells from a 5 ml overnight culture, grown from a single clone were used for the 
preparation of plasmid DNA using the QIAquick Miniprep Kit protocol (Qiagen). Isolated 
plasmids were verified first by restriction analysis, second by DNA sequencing. 
 
2.2.2 Preparation of competent cells 
?
Chemically competent cells were prepared by inoculation of 200 ml LB with 5 ml of an 
overnight culture of the desired strain. Cells were grown at 37°C to an OD600 of 0.4-0.55 and 
incubated on ice for 10 minutes. All following steps were carried out at 4°C. After 
sedimentation at 1000 g for 10 minutes, the pellet was washed with 50 ml TFB-1 (see 2.1.4, 
Table 9). After a second centrifugation step, the pellet was resuspended in 4 ml of TFB-2 
(see 2.1.4, Table 9), aliquoted and frozen in liquid nitrogen. Competent cells were stored at –
80°C. 
 
Competent yeast cells were prepared by inoculation of YPD medium (see 2.1.3, Table 7) 
with the appropriate strain to an OD600 of 0.2. Cells were grown to OD600 of 0.5-0.7 at 30°C, 
then transferred to Falcon tubes. After sedimentation at 5000 g for 5 min at room 
temperature, cells were washed with 0.5 volumes of sterile water. After a subsequent 
centrifugation step, cells were washed with 0.1 volumes of LitSorb (see 2.1.4, Table 9), then 
resuspended in 360 ?l of LitSorb per 50 ml of the inital culture. 40 ?l (per 50 ml culture) of 
pre-heated (10 minutes at 95°C, then put on ice) salmon sperm DNA was added. Aliquots of 
50 ?l were put on –80°C without freezing in liquid nitrogen. 
 
2.2.3 Protein expression in E. coli and selenomethionine labeling 
?
Proteins in this work were expressed recombinantly in E. coli BL21-Codon plus (DE3)RIL 
cells (see 2.1.1, Table 2), where not stated otherwise. For that, plasmids containing genes 
for the desired protein variants were used for the transformation of the cells (see 2.2.1). 
Depending on the protein to be expressed, different protocols were used: 
 
For IPTG-induced protein expression, an expression culture of the desired volume 
containing LB-medium (see 2.1.3, Table 7) and the antibiotic corresponding to the resistance 
cassette of the vector was inoculated from an overnight-culture of the transformed cells in a 
1:100 diluton. Cell were grown to an OD600 of 0.6-0.9, then put on ice. Protein expression 
was induced by the addition of 0.5 mM IPTG and was carried out at 18°C overnight. 
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Autoinducing protein expression medium was used, when the protein showed low 
solubility and/or low yield in IPTG-induced protein expression. This was carried out as  
described (Studier, 2005). For that, the desired volume of ZY-medium was supplemented 
with NPS, 5052, 1 mM MgSO4 and the appropriate antibiotic for selection of the plasmid 
(2.1.2, Table 4). The expression culture was inoculated from an overnight culture of the 
transformed cells at a dilution of 1:100. Cells were grown to an OD600 of 0.6, then the 
temperature was shifted to 18°C. Protein expression was carried out overnight. 
 
Cells were harvested by centrifugation at 4400 g (SLC-6000 rotor) for 30 minutes at 4°C, 
resuspended in the corresponding resuspension buffer (see 2.1.4, Tables 10 and 11) and 
frozen in liquid nitrogen. Cell pellets were stored at –80°C. 
 
For selenomethionine incorporation, the desired expression plasmid was transformed into 
the methionine auxotroph E. coli strain B834 (DE3) (see 2.1.1, Table 2). Cells were grown in 
LB-medium (see 2.1.3, Table 7) supplemented with the appropriate antibiotic at 37°C to an 
OD600 of 0.5, centrifuged and resuspended in the same amount of minimal medium (see 
2.1.3, Table 7) supplemented with selenomethionine and antibiotics. Cells were grown at 
37°C until the OD600 increased by 0.2, then cultures were shifted to 18°C and protein 
expression was induced by the addition of 0.5 mM IPTG. Protein was expressed overnight. 
 
2.2.4 Measurement of protein concentration 
?
Protein concentrations were usually determined by the Bradford protein assay (Bradford, 
1976). The assay was performed according to the instructions of the manufacturer of the Dye 
reagent (Biorad) . A calibration curve was generated for each new batch of dye reagent using 
bovine serum albumin (Fraktion V, Roth). 
?
2.2.5 Protein purification 
?
Purification of all different recombinantly expressed protein variants included the same basic 
steps with slight variations, due to the fact that all variants contained a hexahistidine-tag. The 
variations in the different protocols for the specific proteins are described in the respective 
chapters (see 3.2.2 and 4.2.2). Steps that were carried out for all of the purifications the 
same way, were: 
 
Cell lysis. Cell pellets were resuspended in 50 ml of the respective cell lysis buffer (see 
2.1.4, Tables 10 and 11) and sonicated for 20 minutes. The resulting cell extract was cleared 
by centrifugation (2x 20 minutes at 24000 g in a SA-300 rotor). The pellet was resuspended 
2 Materials and common methods 22 
in an equal amount of 6 M urea relative to the cell extract and analyzed by SDS-PAGE (see 
2.2.7) for the content of expressed protein in the insoluble fraction. 
 
Affinity chromatography. Cleared extracts were applied twice to 1-2 ml of Nickel-NTA-
Agarose (Qiagen) in a column. The amount of resin used differed according to the 
expression level of the different protein variants. Nickel-NTA-Agarose was washed with  
10 column volumes of ddH2O and equilibrated with 10 column volumes of the corresponding 
cell lysis buffer (see 2.1.4, Tables 10 and 11) prior to usage. After binding of the protein, the 
resin was washed with 10 column volumes of the corresponding cell lysis buffer. 
 
2.2.6 Limited proteolysis 
?
To delineate flexible regions in proteins that might interfere with crystallization, protein 
variants were probed with proteolytic enzymes: for trypsin and chymotrypsin treatment of 
purified protein samples, 100 ?l of a protein solution with the concentration of 1 mg/ml was 
mixed with 1 ?g of the corresponding protease. The reaction was carried out in the gel 
filtration buffers of the respective proteins (2.1.4, Tables 10 and 11), supplemented with  
1 mM CaCl2. The reaction mixture was incubated at 37°C. Aliquots of 10 ?l were taken at 
different timepoints (usually after 1, 3, 5, 10, 30 and 60 minutes) and the reaction was 
stopped immediately by the addition of 5 x SDS sample buffer (see 2.1.4, Table 9) and 
incubation at 95°C for 5 minutes. 
For Subtilisin and Proteinase K treatment 1 ?l of a dilution of the respective protease (1 ?g, 
100 ng, 10 ng, 1 ng) was added to 50 ?l of a protein solution with the concentration of  
1 mg/ml. Samples were incubated for 1 hour on ice, then the reactions were stopped as 
described for trypsin and chymotrysin. 
All samples were analyzed by SDS-PAGE (see 2.2.7). Bands of interest were cut out of the 
gel and prepared for edman sequencing (see 2.2.8) 
 
2.2.7 Electrophoresis 
?
Electrophoretic separation of DNA was carried out in horizontal 1x TBE (2.1.4, Table 9) 
agarose gels containing ethidium bromide (0.7 ?g/ml). Agarose concentrations varied 
between 1% to 2%, depending on the size of the DNA-molecules to seperate. Separation 
was carried out in PerfectBlue Gelsystem electrophoresis chambers from Peqlab. Samples 
were mixed with 6x loading dye (see 2.1.4, Table 9) and DNA was visualized and 
documented using a ultraviolet transiluminator from INTAS Science Imaging Instruments 
(?=366 nm). 
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Electrophoretic separation of RNA was conducted by the use of denaturing 
polyacrylamide gels containing 8% acrylamide, 0.42% bisacrylamide and 6 M urea. TBE was 
used as buffer for the gel, as well as for running buffer. Depending on the need for 
separation, electrophoresis was carried out in 1.0 mm cassettes for the XCELL Shure Lock™ 
gel-system (Invitrogen) for small gels, or Sequigen® GT Sequencing Cell (BioRAD) for large 
gels. Detection of radioactivly labeled RNA molecules was conducted by exposure of the 
gels to mounted storage phosphor screens (GE Healthcare) of the appropriate size. 
Exposure time was usually overnight at 4°C, but could be longer or shorter for individual 
experiments. Read-out of the phosphor screens was done by the use of Typhoon™ or 
Storm™ Scanners (GE Healthcare). Quantitation of signals from radioactive RNAs was 
carried out with the ImageQuant Software (GE Healthcare). 
?
Electrophoretic separation of protein was conducted by SDS-PAGE with 15%-17% 
acrylamide gels (with acrylamide:bisacrylamide = 37.5:1; (Laemmli, 1970) in BioRad gel 
systems. For buffers see section 2.1.4, Table 9. Gels were stained with Coomassie gel 
staining solution for 20 minutes and destained overnight in gel destaining solution. 
 
2.2.8 Edman sequencing 
?
Proteins analyzed by SDS-PAGE (2.2.7) and stained with Coomassie staining solution (see 
2.4.1, Table 9) were carefully excised from the gel and dried in a speed vac. The dried gel 
piece was rehydrated in 50 ?l of swelling buffer (see 2.1.4, Table 9). Afterwards 200 ?l of 
ddH2O was addet to set up a concentration gradient. For transfer, a small piece of 
polyvinylidene difluoride (PVDF) membrane (Schleicher & Schuell), which was pre-wet in 
methanol, was added to the tube. Once the solution turned blue, 24 ?l of methanol (final 
concentration of 8-10%) was added as a catalyst. After 1-2 days of incubation at room 
temperature, when the membrane turned blue, it was washed 5 times with 10% methanol. 
After drying, the membrane was used for N-terminal sequencing of the protein in a PROCISE 
491 sequencer (Applied Biosystems). 
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3 Structure and requirement of the Spt6 SH2 domain 
?
?
3.1 Introduction 
 
3.1.1 Structure and function of SH2 domains 
 
Separation of function in proteins is often achieved by folding these molecules into separate 
domains. In this way, a single polypeptide chain can be seen as an array of modules that 
assign different functions to the protein. These functions can involve protein-protein 
interactions, DNA/RNA-binding, binding to phospholipids, catalysis of chemical reactions and 
many more.  
Such a modular nature is characteristic for proteins involved in cellular signal transduction 
pathways. In receptor tyrosine kinase (RTK) mediated signaling, ligands bind to their specific 
transmembrane receptors which dimerize upon this interaction. This leads to the activation of 
the cytoplasmic kinase domain which then either phosphorylates specific tyrosine-residues 
within the cytoplasmic part of the receptor (autophosphorylation) or on cytoplasmic proteins. 
This ligand-induced tyrosine-phosphorylation creates high-affinity docking sites for 
cytoplasmic signaling proteins. Upon binding, these proteins can be phosphorylated and 
activated, and transduce the signal to other proteins that are part of their specific signaling 
cascade (Fig. 3 A). The phosphorylated tyrosine residues can be recognized by SH2 
domains or PTB-domains (Blaikie et al, 1994) that are thus transmitting the signal of the 
activated receptor to a cytoplasmic signaling protein, which can contain a variety of other 
domains with different specificities (Fig. 3 A): PH-domains as well as FYVE-domains interact 
mainly with phospho-inositides and can target the protein to the cell membrane. SH3 
domains and WW domains bind proteins with proline-rich target motifs, wheras PDZ-domains 
bind specifically to hydrophobic residues in the C-termini of target molecules (reviewed in 
Schlessinger, 2000). The signaling proteins can be mere adaptors that transmit the signal 
from the activated receptor to the next protein in the signaling cascade (e.g. Grb2, Nck), or 
they can possess intrinsic enzymatic activity to modify downstream targets (e.g. Src, PLC?), 
e.g. by another phosphorylation reaction. 
With the use of this arsenal of domain functions, a cascade of protein interactions can be 
constructed, that transmits the signal from the ligand-receptor interaction into the interior of 
the cell. 
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Figure 3: SH2 domains are adaptors in receptor-tyrosine-kinase pathways that bind to phosphorylated 
tyrosines 
(A) Protein domains that play a role in cellular signaling pathways. Upon specific binding of a ligand a cell surface 
receptor is dimerized and activated. The cytoplasmic kinase domain can then autophosphorylate specific tyrosine 
residues. These phosphates serve as docking sites for cytosolic signaling proteins, that bind via SH2 or PTB 
domains. The Figure is adapted and modified from Schlessinger (2000). 
(B) Structure of the Src SH2 domain in complex with its high affinity target peptide pYEEI (Waksman et al, 1993). 
The phosphotyrosine-binding site is marked green, the pY+3-5 binding-site is marked yellow. The Figure is taken 
and modified from (Kuriyan & Cowburn, 1997) 
(C) Schematic representation of the "two-pronged plug” mode of peptide recognition by SH2 domains (reviewed in 
(Kuriyan & Cowburn, 1997). The SH2 domain is shown in blue, the target peptide in orange. The phosphotyrosine  
residue is binding to a specific pocket on the surface of the SH2 domain. Specificity of binding is accomplished by 
interaction of the domain with peptide residues C-terminal of the phospho-tyrosine. A residue at position +3 to +5 
C-terminally from the phospho-tyrosine, which inserts into a second pocket on the domain surface, is especially 
important for this interaction. 
 
SH2 domains are widely used as adaptors in higher eukaryotes. Human cells contain 120 
different SH2 domains distributed over 110 proteins (Liu et al, 2006) (see also Fig. 11 A). 
These domains were originally described in 1986. Insertion mutants in the transforming 
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protein p130gag–fps of Fujinami sarcoma virus, a cytoplasmic tyrosine-kinase, showed impaired 
kinase activity in vivo. However, when the mutant proteins were expressed in E. coli, they 
showed the same kinase activity as the wild-type. The mutations were located in a highly 
conserved region of the cytoplasmic tyrosine kinases, immediately N-terminal of the kinase 
domain. This region was named „Src-homology 2“ (SH2) after the cytoplasmic kinase Src, 
that contains this conserved region (Sadowski et al, 1986). A few years later it was 
discovered, that SH2 domains bind to phospho-tyrosines on activated receptors, which made 
the SH2 domain the first targeting module in signaling to be described (Anderson et al, 1990; 
Kazlauskas et al, 1990; Moran et al, 1990). But these modules are not only used for 
targeting: the SH2 domain of Src can bind intramolecularly to a phospho-tyrosine in the C-
terminal region of the same protein to inhibit its kinase activity (Roussel et al, 1991). Thus, 
SH2 domains also have a function in the regulation of enzyme activity. In subsequent work it 
was shown, that the flanking regions of the phospho-tyrosine are important for the specificity 
of binding (Escobedo et al, 1991; Fantl et al, 1992; Kazlauskas et al, 1992; Ronnstrand et al, 
1992; Yoakim et al, 1992) and extensive peptide-library screening could assign specific 
sequence motifs as targets to various SH2 domains (Songyang et al, 1993). 
In 1992, the first structures of SH2 domains emerged: the crystal structure of the Src-domain 
phosphopeptide complex (Waksman et al, 1992) and the NMR solution structures of the 
uncomplexed SH2 domains of Abl (Overduin et al, 1992) and of phosphatidylinositol-3-OH 
kinase (Booker et al, 1992). The structure of the Src-phosphopeptide complex revealed the 
interaction with the phosphate-group, but not how the domain could identify its specific target 
peptide (reviewed in Waksman & Kuriyan, 2004). Only one year later, the X-ray structure of 
the Src SH2 domain in complex with its high affinity target peptide was published (Waksman 
et al, 1993) revealing the „two-pronged plug“ mode of peptide recognition (Fig. 3 C) . This 
was followed by the elucidation of a large number of SH2 domain structures of numerous 
signaling factors (reviewed in Kurian & Cowburn, 1997). 
The common structure of a SH2 domain contains a central ?-sheet, consisting of strands ?B-
?C-?D (Fig. 3 B). One side of this sheet is flanked by ?-helix ?A (N-terminal helix), the other 
side by helix ?B (C-terminal helix). Often additional short ?-strands add up to the central 
sheet (?A N-terminal of helix ?A and ?G C-terminal of helix ?B). 
In most of the known SH2 ligand structures, the peptide binds in an extended conformation 
orthogonal to the central ?-sheet (Fig. 3 B, reviewed in Kurian & Cowburn, 1997; Yaffe, 
2002). The phospho-tyrosine inserts into a pocket with an invariable arginine at its base, that 
makes contact to the phosphate oxygens together with residues that are part of ?A, ?B and 
loop BC (the loop between ?-strands ?B and ?C). This pocked is marked green in Fig. 3 B. 
The phenyl-ring of the phospho-tyrosine is stabilized by an amino-aromatic interaction with 
an arginine that is jutting out from helix ?A into the binding pocket (Arg ?A2, Fig. 3 B; see 
also Fig. 12 D and E), and in addition by a lysine residue in strand ?D (Lys ?D6) (Eck et al, 
1993; Waksman et al, 1992; Waksman et al, 1993; Yaffe, 2002).  
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Specificity of binding is accomplished by residues in the loops EF and BG, which are highly 
variable in SH2 domains. A single mutation in this region can switch the specificity of the Src 
SH2 domain to that of GRB2 (Marengere et al, 1994). These residues usually form a second 
pocket, where a peptide residue that is 3-5 positions C-terminal of the phospho-tyrosine is 
recognized (yellow in Fig. 3 B, reviewed in Kuryan & Cowburn, 1997). 
There are exeptions from this binding mode. In GRB2, the +3 binding site is filled with a 
tryptophane residue that closes the site for interactions with the peptide. In the GRB2-ligand 
structure, the peptide binds in a bent conformation to the domain (Rahuel et al, 1996). 
Binding the phosphate provides about half of the free energy that is needed for the 
interaction (Bradshaw et al, 1999), the remaining energy is provided by the sum of rather 
weak interactions with the residues C-terminal of the pTyr described above (Yaffe, 2002). 
The large contribution of the phosphate to the binding energy provides that the SH2 domain 
can discriminate between the phosphorylated and unphosphorylated state of the target. 
 
3.1.2 Transcription elongation factor Spt6 
 
The gene encoding Spt6 was originally identified in a genetic screen in yeast as a 
suppressor of transposon insertion in the promoter region of a reporter gene (Winston et al, 
1984). It was later described as an essential, nuclear protein (Clark-Adams & Winston, 1987; 
Swanson et al, 1990) that is involved in the elongation phase of transcription, like Spt4 and 
Spt5. Spt4/Spt5 (DSIF in human cells) were identified in the same genetic screen as Spt6. 
The complex interacts physically with Pol II via Spt5 (Hartzog et al, 1998). Spt4 was 
characterized as a positive elongation factor (Rondon et al, 2003) but in conjunction with 
NELF (negative elongation factor), DSIF is responsible for promoter proximal pausing of  
Pol II (Yamaguchi et al, 1999). Spt6 interacts genetically with Spt4 and Spt5. Spt6 and Spt5 
also interact physically, albeit weakly (Swanson & Winston, 1992). Together with Spt5, Spt6 
colocalizes with Pol II on actively transcribed genes in yeast (Krogan et al, 2002), in human 
cells (Endoh et al, 2004) and on Drosophila polytene chromosomes (Andrulis et al, 2000; 
Kaplan et al, 2000). 
Mechanistically, Spt6 was found to be important for the maintenance of chromatin structure. 
It is interacting with histone H3 and has the ability to deposit nucleosomes onto "naked" DNA 
in a supercoiling assay (Bortvin & Winston, 1996). Furthermore, mutations in Spt6 lead to an 
altered chromatin structure in vivo and can supress a null mutation of the Swi/Snf complex 
that remodels nucleosome positions at promoters (Bortvin & Winston, 1996). Consistently, 
recent findings show that the impairment of Spt6-mediated re-assembly of nucleosomes in 
promoter regions leads to transcription initiation without the need for transcriptional activators 
(Adkins & Tyler, 2006).  
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The finding that mutations in Spt6 lead to transcription initiation from cryptic start sites within 
the coding regions of genes led to the suggestion that Spt6 is involved in the maintenance of  
proper chromatin structure during elongation (Kaplan et al, 2003). As a consequence, 
nucleosomes cannot be deposited back onto DNA after the passage of Pol II in a cell where 
Spt6 is not functional, which leads to higher accessibility of the coding regions of genes.  
Another factor that acts together with Spt6 as a histone chaperone is the heterodimeric 
FACT complex (Spt16/Pob3 in yeast). Whereas intact nucleosomes pose a block to 
transcription by Pol II, the polymerase can transcribe nucleosomes deficient in one H2A/H2B 
dimer (Kireeva et al, 2002). Independent studies support the model that FACT removes the 
H2A/H2B dimer from the nucleosome, thus creating a substrate that can be transcribed by 
Pol II (Belotserkovskaya et al, 2003; Orphanides et al, 1999). Additionally, FACT also seems 
to play a role in the maintenance of correct chromatin structure and the suppression of 
cryptic transcription (Mason & Struhl, 2003). Taken together, Spt6 interacts physically with 
Pol II, FACT and Spt5 in vitro and in vivo (Endoh et al, 2004; Krogan et al, 2002; Swanson & 
Winston, 1992). Besides, an interaction of the homologs of Spt6 and FACT in Drosophila 
with the Paf-complex was reported. There, depletion of Paf1 leads to a significantly 
decreased recruitment of Spt6 and FACT to the Hsp70 heat shock gene (Adelman et al, 
2006) (Fig. 4 A) 
Another protein that interacts with Spt6 is Spn1. The essential gene coding for Spn1 was 
identified in a genetic screen as a suppressor of a mutation in the TATA-binding protein 
(TBP) that shows a defect in the activation of transcription after binding to the TATA box 
(Fischbeck et al, 2002). Spn1 was shown to interact directly with Pol II and Spt6 at the 
promotor of the CYC1 gene, which is regulated post-recruitment of Pol II . Spn1 is a negative 
regulator of transcription of CYC1 by inhibiting recruitment of the chromatin remodeling 
complex Swi/Snf. This inhibition is abolished by the interaction of Spn1 with Spt6, which 
appears at the promotor shortly after induction of CYC1 expression (Zhang et al, 2008). 
However, the functions of Spn1 and Spt6 do not seem to be generally linked, since an Spn1 
mutant that fails to be recruited to the promotor of CYC1 due to a failure of the interaction 
with Pol II does at the same time not show cryptic transcription at the FLO8 gene as is seen 
in a Spt6 mutant strain (Kaplan et al, 2003; Zhang et al, 2008). Spn1 is also known as Iws1 
and it was further shown that it interacts with the RNA-export factor REF1/Aly (Yra1 in yeast) 
(Yoh et al, 2007). In yeast, Yra1 interacts with Sub2 and the THO-complex to form the 
TREX-complex to direct export of mRNP-particles to the cytoplasm (Lei et al, 2001; Strasser 
& Hurt, 2001). Depletion of Iws1 consequently showed retention of RNA in the nucleus in 
HeLa cells as well as RNA processing defects. Intriguingly, displacement of the C-terminal 
SH2 domain of Spt6 from its target - the Pol II C-terminal domain (CTD) phosphorylated at 
Ser2 residues - by competitive in vivo overexpression of the domain alone, showed the same 
phenotype. This suggests that this interaction is important for proper processing of RNA, at 
least for the genes tested, probably via the interaction of Spt6 with Iws1 and REF1/Aly (Yra1) 
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(Yoh et al, 2007). Very recent results from the same lab show another interaction of Iws1 
with the HYPB/Setd2 histone methyltransferase, thus directing H3K36 trimethylation (Yoh et 
al, 2008). Setd2 is interacting with the CTD of Pol II, but in contrast to Spt6 it binds the 
doubly phosphorylated form (Ser2-Ser5) (Kizer et al, 2005; Li et al, 2005; Vojnic et al, 2006) 
(Fig. 4 B).  
 
Figure 4: Spt6 is involved in multiple processes during transcription elongation 
(A) Spt6 is involved in the maintenance of chromatin structure. Histone chaperone FACT removes one H2A/H2B 
dimer from the nucleosome octamer, thus creating a substrate that can be transcribed by Pol II. Together with 
Spt6 it re-establishes proper chromatin structure after the passage of Pol II. 
(B) Spt6 is involved in RNA processing and histone modification. Spt6 binds to Ser2-phosphorylated CTD and 
Iws1, which interacts with REF1/Aly and Set2d. REF1/Aly is involved in RNA-export from the nucleus. Set2d is a 
histone-methylase that interacts with Ser2-/Ser5-phosphorylated CTD. Template DNA, non-template DNA and 
RNA are shown in blue, cyan and red, respectively. Factors in this figure are not drawn to scale. See text for 
details. 
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Thus, the interaction between Spt6 and the CTD of Pol II, mediated by a SH2 domain, seems 
to connect important events like RNA processing and histone modification to transcription 
elongation. 
 
3.1.3 The SH2 domain of Spt6 
 
Recruitment of Spt6 to the transcription machinery and its interactions with it are complex 
(see above). Given the importance of Spt6 for transcription elongation as well as for post-
transcriptional processes, structural information is highly anticipated to understand this factor 
on a molecular basis. The C-terminal part of Spt6, that contains an SH2 domain, was shown 
to interact specifically with the CTD of polymerase II that is phosphorylated at Ser2 residues 
(Yoh et al, 2007). This makes this particular SH2 domain highly interesting for two reasons: 
First, the Spt6 SH2 domain shows a binding specificity that is unusal for SH2 domains. It 
binds to a Ser2-phosphorylated target, whereas SH2 domains of signaling factors usually 
bind to phospho-tyrosines (see section 3.1.1). Although other domains with altered specificity 
have been characterized (Muller et al, 1992; Pendergast et al, 1991), to our knowledge there 
is no structural information on such an interaction. 
Second, the Spt6 SH2 domain is the only SH2 domain encoded in the yeast genome 
(Maclennan & Shaw, 1993). Whereas these modules are widely encoded in the genomes of 
higher eukaryotes, the SH2 domain of Spt6 somehow represents the “minimal equipment” of 
a simple eukaryotic cell regarding SH2 domains. This domain seems to be an ancestor of the 
modern SH2 domains, because Spt6 evolved prior to the divergence of the eukaryotic taxa 
(see also Fig. 11 A). The structure of the Spt6 SH2 domain will consequently give an exciting 
insight into the evolution of these important domains. 
 
3.1.4 Aim of this work 
?
The C-terminal domain of Pol II cannot be observed in Pol II crystal structures, due to its high 
flexibility. As a consequence, high resolution structural information can be obtained only in 
complex with molecules that bind the CTD, as exemplified by the structures of the CTD 
interacting WW-domain (Verdecia et al, 2000), the CID-domain (CTD-interacting domain) of 
Pcf11 and Nrd1 (Meinhart & Cramer, 2004; Vasiljeva et al, 2008) and the Set2 SRI-domain 
(Li et al, 2005; Vojnic et al, 2006). As soon as the interaction of the Spt6 SH2 domain with 
the CTD was published (Yoh et al, 2007), we started to initiate work on the structure solution 
of this domain (described in 3.3.1 – 3.3.4) and the analysis of its interaction with the CTD 
(described in 3.3.7 – 3.3.10). The structure opened way to a deeper analysis of evolutionary 
relationships between SH2 domains, due to its outstanding position in the development of 
these domains (described in 3.3.5 and 3.3.6). We were also interested in the influence of the 
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SH2 domain on overall gene expression in yeast. Since Spt6 is an important regulator of 
transcription elongation, the disturbance of its direct interaction with Pol II should have a 
significant effect. This question was tackled in cooperation with Andreas Mayer (3.3.12). In 
addition, a high resolution occupancy profile of Spt6 on the yeast genome was established in 
a ChIP-on-chip experiment. From the comparison of this data with the occupancy profile of 
Rpb3 (Pol II) (described in 3.3.13), we attempted to look for answers on the recruitment of 
Spt6 to transcribed genes and its overall presence on the genome. 
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3.2 Specific procedures 
?
3.2.1 Vectors 
?
The following vectors have been created with the methods described in 2.2.1: 
 
Table 15: Vectors containing Spt6 genes 
Vector       Source Plasmid (see 2.1.2, Table 4) 
Cg118+129     pET28b(+) 
Hs118+129     pET28b(+) 
Sc118+129     pET28b(+) 
Sp118+129     pET28b(+) 
SH2RL     pET28b(+) 
SH2RK     pET28b(+) 
SH2ko     pET28b(+) 
Ctermko     pET28b(+) 
CgSeMetCD     pET28b(+) 
CgSeMetCDE     pET28b(+) 
 
?
3.2.2 Purification of the Spt6-SH2 domain 
?
Variants of the Spt6 SH2 domain from the organisms Schizosaccharomyces pombe,  
Candida glabrata and Homo sapiens were purified each from 1 l of IPTG induced expression 
culture (2.2.3). S. cerevisiae variants were purified from 1 l of autoinducing expression 
culture (2.2.3). After binding to Ni-NTA-Agarose (2.2.5), proteins were eluted by a step 
gradient of increasing imidazole concentration. For this, 10 ml of Spt6 IMAC elution buffer 
(see 2.1.4, Table 10) + 20 mM, + 30 mM, + 50 mM, + 100 mM and + 300 mM imidazole were 
applied to the column. The fractions were analyzed for recombinant protein by SDS-PAGE 
(see 2.2.7). 
Fractions that contained the recombinant protein and showed a sufficient purity for the next 
step of the purification were pooled. The protein concentration was determined by the 
Bradford assay (2.2.4) and 1 unit of Thrombin protease (from bovine serum, Sigma) per ?g of 
protein was added to remove the N-terminal Hexahistidine-tag. The sample was then 
dialyzed against Spt6 IMAC elution buffer (see 2.1.4, Table 10) at 4°C overnight to reduce 
the imidazole concentration. Subsequently, the sample was applied again to the Ni-NTA-
column. The flowthrough, which contained recombinant protein now lacking the His-tag, was 
collected. The flowthrough from the Ni-NTA-column was applied to a MonoQ 10/100 GL 
anion exchange column (GE Healthcare). The column was equilibrated with Spt6 anion 
exchange buffer A (see 2.4.1, Table 10), bound proteins were eluted with a linear gradient of 
20 column volumes from 100 mM to 1 M NaCl. Peak fractions and flowthrough of this 
chromatography step were checked by SDS-PAGE (2.2.7) for the presence of recombinant 
protein. 
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Fractions containing the corresponding Spt6 SH2 variant were pooled and concentrated 
(Amicon Ultra centrifugal filter devices, cutoff 10k, Millipore). Afterwards samples were 
applied to a Superose 12 10/300 GL column (GE Healthcare), pre-equilibrated with the 
respective Spt6 size exclusion buffer (see 2.1.4, Table 10). Peak fractions were pooled and 
concentrated to 10-20 mg/ml for crystallization. 
The purification protocol was similar for C. glabrata Spt6 SH2 variants containing point 
mutations for selenomethionine labeling.  
 
3.2.3 Design of selenomethionine mutants of the Spt6 SH2 domain of  
C. glabrata 
?
Selection of positions for methionine mutants in the Spt6 SH2 domain was based on two 
criteria. First, the position should contain a conserved hydrophobic amino acid residue, 
preferably a leucine because of its comparable size to a methionine. Second, the probability 
of such a residue to be part of the hydrophobic core of the domain should be high. Taken 
together, these criteria should increase the probability to find sites for mutations, which do 
not disturb the overall structure of the domain and hence its ability to crystallize. A multiple 
sequence alignment of Spt6 SH2 domains from diverse organisms revealed the desired 
conserved residues. These were mapped onto the structure of the SH2 domain of Grb2, 
which was initially used in a structure based alignment with the S. cerevisiae Spt6 SH2 
domain (see Fig. 5) to check the possible position of these residues in the Spt6 SH2 domain 
fold. Figure 5 summarizes the selected mutations. Mutation E could not be mapped onto the 
Grb2 structure because of low sequence conservation in this area of the domain (see Fig. 5 
structure based alignment), but was chosen because of a highly conserved methionine 
residue in the Spt6 molecules of the other organisms. Fig. 5 B shows that mutations A, B and 
D have a high probability to be part of the hydrophobic core, whereas  the probability of 
mutation C is lower. Nevertheless, mutation C was used because of its high conservation. 
 
3.2.4 Crystallization 
?
Initial screens of crystallization conditions using different protein variants from different 
organisms were set up with a Hydra II crystallization robot (Matrix). 500 nl drops were set up 
in Corning 96 well sitting drop crystallization plates with the robot, additionally adding fresh 
reducing agent (Tris(2-carboxyethyl) phosphine hydrochloride, TCEP) at a concentration of  
5 mM. Commercial screens used for initial setups were: Index, Classic screen, Natrix, 
PEG/Ion (all Hampton), pH-clear, anions suite, cations suite, classic suite (all Qiagen), JB 
Screen Classic HTS I S and JB Screen Classic HTS II S (both Jena Biosciences). Plates 
were incubated at 20°C and checked regularly after several days. 
3 Structure and requirement of the Spt6 SH2 domain 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Design of point mutations for seleno-methionine incorporation based on the Grb2-structure 
(A) Multiple sequence alignment (ClustalW) with Spt6 SH2 domains of Candida glabrata (Cg), Saccharomyces 
cerevisiae (Sc), Gibberella zeae (Gz), Neurospora crassa  (Nc), Neosartorya fischeri (Nf); Schizosaccharomyces 
pombe (Sp), Homo sapiens (Hs); conserved hydrophobic residues chosen for mutation are marked orange. 
(B) Structure-based alignment of the yeast Spt6 SH2 domain sequence and the human Grb2 SH2 domain 
sequence. ?-helices are shown as red boxes, ?-strands as blue arrows. Predicted secondary structure elements 
of Spt6 are shown as colourless boxes and arrows. 
(C) structure of the Grb2 SH2 domain (PDB accession Nr.: 1JYR). ?-helices and ?-strands are coloured as in (B). 
Residues of Grb2, that align to the highly conserved residues identified in (A) are highlighted in orange. 
?
Promising initial crystals were refined in 24 well hanging drop plates (Easy Xtal Tool, Qiagen) 
by varying the concentrations of constituents of initial conditions. Diffraction quality crystals of 
the wild type (wt) Spt6 SH2 domain of Candida glabrata were grown by mixing  
1 ?l of purified protein in the respective size exclusion buffer (see 2.1.4, Table 10) with a 
concentration of 15 mg/ml with 1 ?l of Spt6 SH2 seeding buffer (see 2.1.4, Table 13). Plates 
were incubated for 2 hours at 20°C. To trigger growth of single crystals, streak seeding 
(Bergfors, 2003) was performed. Seeds were produced by crushing initial crystals by dilution 
with 10 ?l of the respective reservoir solution and pipeting up and down several times. Seeds 
were transferred to the pre-equilibrated drops using a cat whisker. Usually, seeds that were 
taken up were used for seeding sequentially 6 different drops, creating dilutions which 
increased the probability for growth of suitably sized single crystals. Before freezing, crystals 
were transferred to Spt6 SH2 seeding buffer containing additionally 10%-22% (w/v) PEG 400 
or 5%-17% (w/v) glycerol as cryo-protectants for several minutes. Crystals were then flash-
frozen by plunging into liquid nitrogen. This procedure was resulting in diffraction quality 
crystals as summarized in Fig. 7 on page 42. 
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Selenomethionine double mutant CD (see 3.2.4 and 3.3.2) was crystallized using the 
hanging drop method by mixing 1 ?l of purified protein in the respective size exclusion buffer 
(2.1.4, Table 10) with 1 ?l of buffer Spt6 SH2-1 or -2 (see 2.1.4, Table 13), resulting in crystal 
form 1 or 2, respectively (see Fig. 7 B). Before freezing, crystals were transferred to buffer 
Spt6 SH2-1 containing 13% (w/v) PEG 400 or 15% (w/v) glycerol as cryo-protectant. In case 
of buffer Spt6 SH2-2, crystals were frozen directly from the drops. 
 
3.2.5 Data collection and structure solution 
?
Synchrotron radiation data of selenomethionine double mutant CD crystal forms A and B 
were collected at Berliner Elektronen-speicherring - Gesellschaft für Synchrotronstrahlung 
m.b.H. (BESSY) BL 14.1. Multiwavelength anomalous diffraction (MAD) data were collected 
from a selenomethionine-labeled crystal form A to a resolution of 1.9 Å. For a 
selenomethionine-labeled crystal of form B, single wavelength anomalous diffraction (SAD) 
data was collected to a resolution of 2.4 Å. Data were processed with HKL (Otwinowski, 
1996). Selenium sites in crystal form A were located with HKL2MAP (Pape & Schneider, 
2004) and MAD phases  were calculated with SHARP (Terwilliger, 2002). A model of the 
SH2 domain was built with Coot (Emsley & Cowtan, 2004) and refined with CNS (Brunger et 
al, 1998). For crystal form B, phases were calculated by molecular replacement using 
PHASER (McCoy, 2007) with one molecule of the assymetric unit of crystal A as a search 
model. Model building was done as for crystal A, Refmac5 was used for refinement 
(Murshudov et al, 1997). X-ray and refinement statistics are shown in  
Table 16. In case of the desalted crystals used for peptide soaks (3.2.7 and 3.3.9), XDS was 
used for Data processing (Kabsch, 1993). Structure was solved as for crystal form B, but not 
refined to the end (Table 18). 
 
3.2.6 Co-crystallization of the Spt6 SH2 domain with synthetic CTD-
peptides 
?
The Spt6 SH2 domain from C. glabrata was purified as described in 3.2.2 and dialyzed to a 
lower salt concentration in a buffer with 50 mM Tris/HCl pH 8.0 at 25°C and 20 mM NaCl. 
The sample was concentrated to 10 mg/ml and incubated with 3x the molar amount of 
peptide 1 (P1, see 2.1.2, Table 6) and 2x the molar amount of peptide 2 (P2, see 2.1.2, 
Table 6) at 20°C for 2 hours. After this time, the samples were used to set up commercial 
crystallization screens at the crystallization facility of the Max Planck Institute for 
Biochemistry in Martinsried. The following screens were used: Complex screen I (Qiagen), 
Magic screen I and II, Index screen (Hampton) and PEGs (Qiagen). Crystallization plates 
were incubated at 20°C and documented by an imaging system. 
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3.2.7 Desalting of Spt6 SH2 domain crystals for peptide soaks 
?
Different kinds of PEG (1000 – 8000) were used in different concentrations (10%-50% w/v) to 
stabilize the crystal while replacing the salt. In these initial tests, crystals were transferred to 
10 ?l of buffers containing different amounts of PEG at lower salt concentrations (300 mM 
NaCl) and examined visually by light microscopy. Crystals that were transferred to Spt6 SH2 
desalting buffer (see 2.1.4, Table 13), cracked immediately, but “healed” after ?30 seconds 
(see Fig. 14). These crystals were tested for diffraction quality on an X-ray generator 
(RINT2000 Series CE Marking, Horizontal Type Rotor Flex). 
Since these crystals did not diffract anymore, the desalting protocol was changed to a step 
protocol: Buffer Spt6 SH2 B and Spt6 SH2 desalting buffer were mixed in the following ratios: 
0.9/0.1, 0.8/0.2, 0.6/0.4, 0.4/0.6, 0.2/0.8, 0.15/0.85, 0.1/0.9, 0.05/0.95. Crystals were 
successively transferred to 100 ?l of these solutions and incubated for 1 hour. For each step, 
one crystal was tested for diffraction on the generator. The last step, where crystals still 
diffracted, was used for overnight incubation. Subsequently, crystals were again tested for 
diffraction. In parallel, crystals were transferred imediately into different step conditions 
without incubation in preceding steps and tested for diffraction. 
 
3.2.8 Soaking of Spt6 SH2 crystals with synthetic peptides 
?
Buffer Spt6 SH2 B and Spt6 SH2 desalting buffer (see 2.1.4, Table 13) were mixed in a ratio 
of 0.15/0.85. Synthetic peptides were added at a concentration of 1,1 mM for P1 and 0.8 mM 
for P2 (see 2.1.4, Table 6). Crystals that were grown in buffer Spt6 SH2 B were transferred 
to 20 ?l of these solutions and incubated for 1 hour at 20°C. After this, the crystals were 
directly frozen in liquid nitrogen. Datasets were collected at the SLS Villigen and the structure 
was solved as described in 3.2.4. 
 
3.2.9 Fluorescence anisotropy (FA) 
?
FA measurements were carried out on a FluoroMax-P Spectrofluorimeter (Horiba Jobin 
Yvon). 800 ?l or 1 ml of Peptide P3 (see 2.1.2, Table 6) in SH2 low salt buffer (2.1.4, Table 
10) were used as a reaction solution. A fluorescence emission spectrum was recorded to 
evaluate the strength of the fluorescence signal. The Spt6 SH2 domain of different 
organisms was titrated to the solution and the change in anisotropy of the fluorescence 
signal was recorded via direct measurement of the polarization of emission light. Binding of 
the S. cerevisiae SH2 domain was measured in SH2 low salt buffer in a titration ranging from 
82 nM to 9 ?M. The binding of the C. glabrata SH2 domain was tested in SH2 low salt buffer 
and in SH2 low salt buffer +150 mM NaCl in a titration ranging from 250 nM to 6.8 ?M. The 
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human Spt6 SH2 domain was titrated in a concentration range from 36 nM to 2.6 ?M in SH2 
low salt buffer.  
 
3.2.10 Surface plasmon resonance (SPR) 
SPR experiments were carried out on a BIAcore X system. The Spt6-domains of   
S. cerevisiae  and  H. sapiens were bound to a Sensor-Chip NTA (GE Healthcare) via the  
N-terminal His-Tag (purification analog to 2.2.5 and 3.2.2, omitting the thrombin-cleavage 
step), using SH2 low salt buffer (2.1.4, Table 10) as running buffer. Binding upon injection of 
the respective domain (60 ng/?l) was monitored by an increase in the resonance signal (RU). 
The change in RU upon the domain binding to the chip was ? 2000. After washing with 
buffer, petide P1 or P2 (2.1.2, Table 6) were injected at a concentration of 20 ?M. The 
interaction between the respective domain and peptide was monitored by the change in RU. 
 
3.2.11 TAP-tagging of yeast proteins 
 
A C-terminal TAP-tag was added to S. cerevisiae Spt6 or Spt6?C (deletion of residues 1250-
1451) (Youdell et al, 2008) in yeast strain S288C and the isogenic strain FY119 (see 2.1.1, 
Table 3) as described (Puig et al, 2001). The oligonucleotides „Spt6flTAPfw“, „Spt6flTAPrv“ 
and „Spt6dSH2TAPfw“ (2.1.2, Table 5) were used to amplify the C-terminal TAP-tagging 
cassettes from plasmid pBS1539 (2.1.2, Table 4). The PCR-products were purified from a 
1% agarose gel usind the QIAquick Gel Purification Kit (Qiagen). The strains were 
transformed with the respective purified DNA using Lithium acetate as described (Knop et al, 
1999). Cells that integrated the foreign DNA into their genome by homologous recombination 
were identified on selection plates. Single colonies were cultivated and checked by Western 
blot (Fig. 16). For this, total protein of S. cerevisiae strains (S288C, isogenic to strains used 
in microarray-analysis except for TAP- tags at the C-terminus of the Spt6/Spt6?C protein) 
was resolved by a 8% SDS-PAG and blotted on a PVDF-membrane. The membrane was 
probed with antibodies directed against the TAP-tag (PAP, Sigma) and tubulin (3H3087, 
Santa Cruz Biotechnology) as a loading control. Bound antibodies were detected by 
chemiluminiscence (ECL Plus Western Blotting detection system, GE Healthcare). For 
tubulin, Peroxidase-conjugated AffiniPure Rabbit Anti-Rat IgG (H+L) (Jackson 
ImmunoResearch) was used for detection. 
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3.2.12 Chromatin immunoprecipitation (ChIP) 
 
Chromatin immunoprecipitation experiments were carried out according to an established 
protocol (Aparicio et al, 2005; Jasiak et al, 2008), together with Kristin Leike. 
YPD medium (2.1.3, Table 7) was inoculated to an OD600 of 0.2 from a starter culture of the 
respective strain. The culture was grown at 30°C and 180 rpm until it reached the log-phase 
(OD600 0.7-0.8). Protein cross-linking was achieved by the addition of 37% formaldehyde to 
the culture to a final concentration of 1% and slowly shaking at room temperature for 15 
minutes. Addition of 3M Glycine to a final concentration of 2.5% and incubation for another 
30 minutes stopped the cross-linking reaction. Cells were harvested by centrifugation (4400 
g, 5 min, 4°C) and washed three times with cold 1x TBS (2.1.4, Table 9) and once with FA 
lysis buffer (2.1.4, Table 14) + 2mM PMSF. Cells were frozen in liquid nitrogen and stored at  
-80°C for further use. 
For immunoprecipitation of TAP-tagged proteins, IgG SepharoseTM 6 Fast Flow (GE 
Healthcare) was used (50 ?l of a 50% slurry per IP reaction). Beads were washed with cold 
1x TBS buffer an FA-lysis buffer before use. Chromatin was sheared using a BioruptorTM 
UCD-200 (Diagenode) (25 x 30 seconds with 30 sec breaks at an output of  
200 W). 20 ?l of the resulting chromatin solution was kept as the input sample. Precipitation 
was performed for 3 h at room temperature by incubation of the chromatin solution with 50 ?l 
of the washed beads. After precipitation, beads were washed with FA lysis buffer, FA lysis 
buffer + 500 mM NaCl, ChIP wash buffer (see 2.1.4, Table 14) and TE buffer. Elution of 
precipitated proteins was carried out in ChIP elution buffer (2.1.4, Table 14) at 65°C for 20 
min. Input and IP samples were incubated with Pronase at 42°C for 3h. Reversal of cross-
linking was accomplished by a 9 h incubation at 65°C. The nucleic acids were purified using 
QIAquick PCR Purification Kit (Qiagen) (instead of the standard DNA binding buffer, PB 
buffer from Qiagen (Cat. No. 19066) was used). After purification RNA was removed by 
incubation with RNase A at 37°C for 30 min. DNA was purified once more and the sample 
volume was reduced to the desired concentration using a Speed Vac.  
Amplification and Re-amplification of the immunoprecipitated DNA was carried out with 
GenomePlex® Complete Whole Genome Amplification (WGA) Kit and GenomePlex® WGA 
Reamplification Kit (Sigma). The quality of the resulting samples was checked on a 1% 
Agarose Gel, Ethidium bromide staining and visualization in UV light. A correctly amplified 
sample showed DNA-fragments of various length, with a peak around 300 nt. 
 
3.2.13 ChIP-on-chip 
 
ChIP samples were sent to imaGenes GmbH for labeling, hybridization, array scanning, data 
extraction and a preliminary data analysis using a S. cerevisiae whole genome tiling array 
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(Cat. No. C4214-00-01, http://www.imagenes-bio.de/services/nimblegen/chip). Two 
biologically independent samples of each input and IP DNA were sent. The analysis included 
„dye-swapping“ with the fluorophores Cy3 and Cy5, which improves the signal to noise ratio. 
The bioinformatic analysis of the data was performed by Matthias Siebert and Johannes 
Soeding from the Gene Center Munich, as part of a collaboration.The data quality was high 
and the analysis was carried out as described in Jasiak et al. (2008). Briefly, the logarithm of 
the fluorescence signal of the Chip DNA was divided by the signal from the genomic 
background and this was used in further analysis. A standard background correction was 
performed on all such signals by subtracting their genome-wide average. ChIP-chip 
measurements were repeated with exchanged dyes Cy5 and Cy3 and averaged over 
measurements to subtract out the strong, systematic, dye-related technical noise, which 
effectively eliminates intensity-dependent saturation effects. The experiment was carried out 
as a biologically independent duplicate, resulting in Pearson correlation coefficients of 0.84 
for the Cy5 labeled biological duplicates and 0.82 for the Cy3 labeled biological duplicates.  
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3.3 Results and discussion 
?
?
3.3.1 Delineation of the Spt6 SH2 domain of Saccharomyces cerevisiae 
for crystallization?
Information about sequence conservation (Fig. 9 A) as well as the secondary structure 
prediction (see Fig. 5 B) was used to design variants of the S. cerevisiae Spt6 SH2 domain 
that differed in length at their C- and N-termini. 10 of these variants were cloned, expressed 
and purified (chapters 2.2.1, 2.2.3, 2.2.5 and 3.2.2). The relative solubility was estimated by 
comparing the amount of  protein in the extract (soluble fraction) to the amount in the pellet 
(insoluble fraction) after centrifugation of the cell lysate (2.2.5). The results are summarized 
in Fig. 6. 
 
Figure 6: Solubility of S. cerevisiae Spt6 SH2 domain variants 
The structure based alignment of Fig. 5 B for the Spt6 SH2 domain and the lengths of the different protein 
variants that were expressed and purified is shown. The solubility is indicated by colours. Numbers refer to the 
primers (Sc) that were initially used to clone the respective variants (see section 2.1.2, Table 5) 
 
The solubility of the protein variants gives a good estimation about the boundaries of the 
domain. Unsoluble proteins are considered to be defective in folding because important parts 
of the domain-fold are removed. The length of the N-terminus could be shortened up to 
amino acid 1251 (N-terminus Nr. 118), the C-terminus up to amino acid 1351 (C-terminus 
Nr.129). An internal loop-deletion (dashed line in Fig. 6) rendered this variant insoluble. 
Thus, the domain boundaries were defined by the protein variant 118+129. This variant was 
purified to high purity and homogeneity, and was used for extensive screening of 
crystallization conditions (section 3.2.4). However, the Spt6 SH2 domain from S. cerevisiae 
did not form crystals. 
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3.3.2 Crystallization and structure solution of the Spt6 SH2 domain of 
Candida glabrata 
 
The variant Sc118+129 of the SH2 domain showed an optimal behavior in terms of solubility 
and in limited proteolysis experiments (2.2.6, data not shown) but did not form crystals 
(3.3.1). Due to the high conservation of the domain in various species, the domain borders 
that were delineated in S. cerevisiae could be transferred to the proteins of Candida glabrata, 
Schizosaccharomyces pombe and Homo sapiens (Fig. 9 A). In the new variants two 
additional residues were removed from the C-terminus, based on sequence alignment and 
secondary structure prediction. The coding sequences for these domain variants were 
cloned, expressed and purified (chapters 2.2.1, 2.2.3, 2.2.5 and 3.2.2). These variants 
showed a similar behaviour in the purification compared to the S. cerevisiae protein and were 
purified to high homogeneity. The quality of the protein sample is exemplified for the  
C. glabrata variant in Fig 7 A, but similar results were obtained for the domains from the 
other organisms. 
Initial screenings for formation of crystals gave positive results only for the C. glabrata 
protein. Refinement of these conditions, including streak seeding, lead to an overall 
improvement of crystals and to a native dataset to 2.8 Å resolution (see 3.2.4 and Fig 7 A). 
However, despite several attempts to solve the structure by molecular replacement with 
different search models (not shown), no solution could be obtained. 
Thus we attempted to get de novo phases from anomalous diffraction of Selenium atoms, by 
the incorporation of seleno-methionine (2.2.3). For this we had to insert several point 
mutations into the sequence of the C. glabrata SH2 domain, since the native protein did not 
contain any methionine residue. 5 point mutations were designed (see 3.2.3 and Fig. 5). Four 
of those could be cloned (mutations A, C,D and E) and the resulting proteins were soluble. 
Mutations C, D and E were chosen for further subcloning, resulting in double mutant CD and 
triple mutant CDE, which again showed high solubility. A repeated screening  for inital 
crystallization conditions with the two mutant proteins revealed two novel crystallization 
conditions for mutant CD (buffers Spt6 SH2-1 and -2, chapter 2.1.4, Table 13). Mutant CDE 
was crystallized in similar conditions as the native protein, but a SAD dataset to 3.1 Å 
resolution did not result in solution of the structure because of a weak anomalous signal 
(data not shown). However, crystals from mutant CD were suitable to solve the structure of 
the SH2 domain in multiple wavelength anomalous diffraction experiment (MAD, 3.2.5 , 
Table 16). Subsequently, also the second crystal form of the CD mutant could be solved by 
molecular replacement, using the structure from crystal form 1 as a search model (Table 16). 
All diffraction quality crystals that were obtained are summarized in Fig. 7 B. 
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Figure 7: Quality of the C. glabrata SH2 domain protein sample and the resulting diffraction quality 
crystals 
(A) Chromatogram of a Superose12 size exclusion chromatography of the C. glabrata Spt6 SH2 domain. 
Absorption units at 280 nm and 260 nm are shown in blue and red, respectively. In addition, an overloaded, 
Coomassie stained SDS-PAGE of the pooled peak fractions is shown, to demonstrate the purity of the protein 
sample. 
(B) In columns, the different crystals of the C. glabrata Spt6 SH2 domain, the respective crystallization buffers 
(see also 2.1.4, Table 13), diffraction images and resolution, experiment and results are shown. 
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Table 16: X-ray diffraction and refinement statistics for C. glabrata Spt6 selenomethionine double mutant 
CD crystals  
?
 
3.3.3 Crystallization of SH2 domains from various species 
 
Interestingly, the SH2 domains of S. cerevisiae and C. glabrata only differ in 10 amino acid 
positions, as is shown in the alignment left in Fig. 8. Although most of these positions are 
highly conserved, they make the difference between crystal formation or no crystals. When 
these residues are mapped on the four molecules of the asymmetric unit of the CD mutant 
crystal form 1, all residues except for two (A1291 and V1304) lie on the surface of the 
individual molecules and thus in between the molecules that build up the crystals (Fig. 8, 
right). These „evolutionary point mutations“ render the C. glabrata protein variant suitable for 
crystallization. Thus, making use of naturally occurring variances in proteins by extending 
crystallization trials to different source organisms is an appropriate remedy in the 
crystallization of difficult proteins. 
 
 
 
crystal form 1 
 
  crystal form 2 
Data collection     
Space group P65   P32 
Cell dimensions       
   a, b, c (Å) 54.5, 54.5, 253.4   71.6, 71.6, 87.6 
   ?, ?, ?  (°) 90, 90, 120   90, 90, 120 
 Peak Remote Inflection  
Wavelength (Å) 0.97973 0.90810 0.97987 0.97971 
Resolution (Å) 20-1.9 20-1.9 20-1.9 20-2.4 
Rsym (%) 5.2 (12.9) 5.3 (22.3) 3.9 (12.6) 6.2 (19.0) 
I /  ?I 42.9 (7.3) 34.35 (7.5) 31.24 (6.0) 45.14 (7.7) 
Completeness (%) 99.4 (96.6) 99.9 (100) 99.3 (95.7) 99.5 (95.4) 
Redundancy 4.2 (2.8) 7.7 (6.7) 4.1 (2.8) 3.9 (3.7) 
Refinement     
Resolution (Å) 1.9   2.4 
No. reflections 33162   18513 
Rwork / Rfree (%) 19.6 / 24.1   25.27 / 28.50 
No. atoms     
    Protein 3292   3160 
    Ligand/ion 20   - 
    Water 428   76 
B-factors     
    Protein 26.6   29.8 
    Ligand/ions 23.5   - 
    Water 35.4   27.8 
R.m.s deviations     
    Bond lengths (Å) 0.005   0.007 
    Bond angles (°) 1.2   1.4 
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Figure 8: The crystallizable C. glabrata protein variant differs in only 10 amino acid positions from the  
S. cerevisiae protein 
Alignment of the S. cerevisiae and  C.glabrata SH2 domain sequences (left). Invariant residues are coloured in 
green, conserved residues are indicated in orange (high) and yellow (low), unconserved residues in gray. On the 
right, the 4 molecules of the asymmetric unit of crystal „SeMet mutant CD“ is shown. Invariant residues from the 
alignment are shown as a ribbon model (different greens for every molecule in the asymmetric unit). Conserved 
and unconserved residues are shown as stick models with the same colours as in the alignment. 
 
3.3.4 The structure of the Spt6 SH2 domain reveals a typical SH2 fold 
with unique features 
 
The structure derived from "SeMet mutant CD crystal form 1" in a MAD experiment (Fig. 7) 
reveals the classical core fold of SH2 domains (Kuriyan & Cowburn, 1997) with a central 
three-stranded antiparallel ?-sheet (?B-?D) sandwiched between two ?-helices (?A and ?B, 
Fig. 9 B). In addition to this core fold, the structure contains an ?-helix N-terminal of ?A 
(called ?L here), a small anti-parallel ?-sheet inserted between ?B and ?D (?E-?F ), and an 
extended C-terminal ?-helix (Fig. 9 B, Fig. 12 D and Table 17). Two surface loops, ?B-?C 
and ?D-?B, adopt alternative conformations in two different crystal packings and are thus 
mobile (Fig. 9 C). Interestingly, the seleomethionine residues in mutant CD were not part of 
the hydophobic core as predicted (3.2.3). They are positioned at the beginning and the end 
of loop DE. However they were ordered and did not disturb the overall structure and were 
thus suited for phasing. 
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3.3.5 The Spt6 SH2 domain structure contains features of both sub-
families of SH2 domains 
 
To understand the unique features of the structure, we reviewed available structures from the 
PDB database (Table 17) for the corresponding characteristics. It is possible to group SH2-
domains into two classes, according to specific features of their primary sequences and their 
3D-structures. One group, the "STAT-type" contains the SH2 domains of STAT transcription 
factors, the second group "Src-type" contains most of the other domains that are part of 
proteins involved in cellular signaling pathways (Gao et al, 2004): First, we looked for the 
SH2 core motif sequence, which has the consensus sequence GXF/YBBR (X for any, B for 
hydrophobic amino acids). This motif resides in the ?B-strand (Fig 9 A) and contains the 
highly conserved arginine residue that is binding the phosphate. A specific feature of all 
STAT-type domains is a highly conserved phenylalanine immediately following the arginine  
 
 
Figure 9: Structure of the Spt6 SH2 domain 
(A) Domain architecture of Spt6 (Johnson et al, 2008) and alignment of amino acid sequences of the Spt6 SH2 
domains of C. glabrata (C.g.), S. cerevisiae (S.c.), S. pombe (S.p.), M. musculus (M.m.), and H. sapiens (H.s.). 
Secondary structure elements are indicated above the alignment (cylinders for ?-helices, arrows for ?-strands).  
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Figure 9 (continued) 
Invariant and conserved residues are highlighted in green and yellow, respectively. The red box indicates the 
invariant arginine R1281 that binds the phospho group (see also 3.1.1). Stars indicate positions where methionine 
was introduced for seleno-methionine phasing (sections 3.2.3 and 3.3.2). Residues forming the hydophobic core 
are marked with a triangle.  
(B) Two views of a ribbon model of the Spt6 SH2 domain. Secondary structure elements are labeled as in (A).  
(C) Comparison of the C?-trace of the SH2 domain structure in two different crystal forms (blue, crystal form 1, 
magenta, crystal form 2 of SeMet mutant CD, see Fig. 7 B). Structures were aligned by DALILite (Labarga et al, 
2007), resulting in a RMSD of 1.2 Å for 91 residues. Unstructured parts in crystal form B are indicated by dots. 
 
 
C-terminally (Gao et al, 2004), whereas in Src-type domains this residue is different (Fig. 10, 
Table 17). Spt6 shows no phenylalanine in this position and thus resembles the Src-type in 
this respect. Interestingly, the consensus sequence of the Spt6 SH2 domain core motif as 
seen in Fig 9 A is GXF/BBR, thus varying in the third position from the consensus of all other 
SH2 domains (with the exception of CHK, see table 17). The landmark feature of Src-type 
domains is the small antiparallel ?-sheet ?E-?F, that is inserted between strand ?D and helix 
?B (Gao et al, 2004). Residues from this sheet are involved in interactions with residues of 
the target peptide other than the phospho-aminoacid, and thus important for peptide 
specificity as outlined in section 3.1.1 (Kimber et al, 2000; Waksman et al, 1993). STAT-type 
domains lack this structural feature (Fig. 10). Our review in Table 17 confirmed this with the 
exception of the SH2 domains of Cbl and APS, where a ?E-?F sheet could not be detected. 
The Spt6 SH2 domain has a clearly defined ?E-?F sheet and resembles the Src-type in this 
respect.  
The Spt6 domain has an unusually long C-terminal helix ?B (at least 26 Å long). Only the 
SH2 domain of APS, which is a substrate of the insulin receptor, showed this feature in our 
structure review (Table 17). APS is dimerizing on its substrate and the long C-terminal helix 
is interfering with the canonical peptide binding path (Hu et al, 2003), which is usually in an 
extended conformation, perpendicular to the central ?-sheet (Kuriyan & Cowburn, 1997). 
STAT transcription factors also self-dimerize upon the phosphorylation of a specific residue 
before they can translocate to the nucleus and induce the transcription of specific genes 
(Becker et al, 1998; Chen et al, 1998; Darnell, 1997). The absence of a ?E-?F sheet is a 
unique feature of the STAT-subfamily of SH2 domains, as is the presence of an extended ?-
helical structure, termed ?B’-?B (Gao et al, 2004) (Fig. 10). The extended C-terminal ?-
helices ?B in Spt6 and APS might resemble a primitive or degenerated fused form of this 
?B’-?B structural motif. This suggestion is supported by the fact that APS dimerizes on its 
substrate as STAT transcription factors do. For Spt6, no data on multimerization on target 
binding is currently available.  
The structure of the Spt6 SH2 domain contains a short ?-helix (?L) N-terminally of ?A (Fig. 9 
B). This helix is not a part of the canonical SH2 fold, but is seen in all STAT transcription 
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factors - where it is part of the STAT linker domain that is preceding the SH2 domain N-
terminally – and in a number of Src-type domains (Table 17 and Fig. 10). The absence of 
such a helix as outlined in Table 17 does not necessarily mean its absence in the protein, it 
may just not be a part of the crystal structure. However, the position of ?L in the Spt6 
structure is not artificial, as it is similar in both crystal forms (Fig. 9 C). Its interaction with the 
rest of the domain is mediated by Arg1251, which contacts Asp1330 of loop FB. Additionally 
it packs onto a hydrophobic surface made up by residues of the ?-sheets ?B and ?C. The 
helix ?L adopts the same relative position to the rest of the protein as the C-teriminal helix of 
the STAT linker domain (exemplified by ?11 of STATa of Dictyostelium, yellow in Fig. 10). 
Furthermore, secondary structure prediction of Spt6 further C-terminal of the SH2 domain 
reveals a structural signature consisting of 5 ?-strands. This might resemble the S1-RNA-
binding-domain found in STAT proteins N-terminal of the linker domain (Becker et al, 1998; 
Bycroft et al, 1997; Chen et al, 1998). Taken together, helix ?L as well as the extended 
helical structure ?B are likely to be evolutionary related to STAT transcription factors. 
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Table 17: Review of SH2 domain structural elements 
 
Protein, species a, 
(PDB accesion no.) 
core 
motif b 
?E?F ?B [Å] c ?Ld R155e K203e Z-score 
(Dali server) f 
Src-type 
Spt6, Cg, (-) GDFVIRQ + 26.0 + G D - 
Abl1, Mm, (1OPK) GSFLVRE + 14.3 - R R - 
Aps, Rn (1RPY) GLFVIRQ - 29.0 + R R 8.6 
Blk, Mm, (1BLJ) GSFLIRE + 14.8 - R K 8.0 
PTK6/Brk, Hs, (1RJA) GAFLIRV + 16.7 - R L 8.1 
Cbl, Hs, (2CBL) GSYIFRL - 14.2 + Y A 6.5 
Crk, Hs, (1JU5) GVFLVRD + 16.5 - R I 8.4 
CHK, Hs, (1JWO) GLVLVRE + 17.3 - G R 9.8 
Fes/Fps, Hs, (1WQU) GDFLVRE + 17.9 - R I 7.2 
Fyn, Hs, (1G83) GTFLIRE + 17.4 + R K 9.8 
GADS, Mm, (1R1Q) GFFIIRA + 12.9 + R K 9.3 
Grb10, Hs, (1NRV) GLFLLRD + 14.7 - R N - 
Grb14, Hs, (2AUG) GVFLVRD + 14.7 + R N 9.8 
Grb2, Hs, (1GRI) GAFLIRE + 15.2 - R K 8.6 
Grb7, Hs, (1MW4) GLFLVRE + 10.1 - R L 4.5 
Hck, Hs, (3HCK) GSFMIRD + 15.0 - R K 8.5 
Itk/Tsk, Mm, (1LUK) GAFMVRD + 14.7 - R K 7.7 
P56-Lck, Hs, (1BHH) GSFLIRE + 12.2 - R K 9.2 
Nck1, Hs, (2CI9) GDFLIRD + 16.9 - R K 9.6 
Nck2, Hs, (2CIA) GDFLIRD + 16.5 - R K 10.1 
P85-N, Hs, (2IUG) GTFLVRD + 15.8 + R K 9.3 
PLC?1, Bt, (2PLD) GAFLVRK + 14.5 - R R 6.7 
Syp, Mm, (1AYA) GSFLARP + 17.0 - G K 9.0 
SHP-1, Hs, (1X6C) WTFLVRE + 17.0 - G K 8.1 
Sap, Hs, (1D1Z) GSYLLRD + 12.9 - R R 7.7 
Eat2, Mm, (1I3Z) GNFLIRD + 11.1 - K L 9.6 
SH3BP2, Hs, (2CR4) GLYCIRN + 14.8 - S R 6.9 
Shc1, Hs, (1MIL) GDFLVRE + 15.3 - R L - 
Socs3, Mm, (2BBU) GTFLIRD + 15.0 + G R 4.2 
Syk, Hs, (1CSZ) GKFLIRA + 13.6 - R R 8.0 
Vav1, Hs, (2CRH) GTFLVRQ + 14.2 + R K 7.2 
ZAP70-1, Hs, (1M61) GLFLLRQ + 16.4 - R  P/I 10.4 
ZAP70-2, Hs, (1M61) GKFLLRP + 14.4 + R L 10.4 
STAT-type 
STAT1, Hs, (1BF5) GTFLLRF - 5.7 + 8.8 + P/E K 4.2 
STAT3, Hs, (1BG1) GTFLLRF - 10.8 + 9.8 + P/E K 4.1 
STAT5, Mm, (1Y1U) GTFLLRF - 8.7 + 9.9 + K K 5.5 
STAT, Dd, (1UUR) GTFIIRF - 7.3 + 10.5 + R L 5.7 
Structural data was obtained from the Protein Data Bank (PDB) and inspected for the indicated structural 
elements.  
1Cg=Candida glabrata; Hs=Homo sapiens; Mm=Mus musculus; Rn=Rattus norvegicus; Bt=Bos taurus; 
Dd=Dictyostelium discoideum 
2highly conserved SH2 core motif of consensus sequence GXF/YBBR (X for any, B for hydrophobic amino acids) 
containing the arginine residue binding the phosphate (red) 
3length of helix ?B in Angstroem 
4presence of an ? helix resembling the ?L helix in Spt6 (Fig. 9 B) in position relative to the SH2 fold 
5residue found at the same position as R155 and K203 in the structure of the Src SH2 domain (see also section 
3.1.1) 
6Z-score derived from a DALI-server (Holm & Sander, 1993) search for related protein structures using the Spt6   
 SH2 domain as a query. Higher scores indicate higher similarities (similarities with a Z-score < 2 are insignificant) 
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Figure 10: Unique fold of the Spt6 SH2 domain 
Comparison of the overall structures of the SH2 domains of H. sapiens Src (Waksman et al, 1993), of  
D. discoideum STATa (Soler-Lopez et al, 2004) and of C. glabrata Spt6 (blue). The ?E?F-sheet is coloured in 
green, the Spt6 helix ?L, as well as STATa linker domain helix ?11 are coloured in yellow. The remainder of the 
STAT linker domain is in grey. Below each structure, alignments of the SH2 ?B core motif of five representative 
sequences are shown (hs = H. sapiens;  dm = D. melanogaster; at = A. thaliana; dd = D. discoideum; nc =  
N. crassa; sc = S. cerevisiae; cg = C. glabrata; sp = S. pombe). The highly conserved arginine residue that binds 
the phospho group is highlighted in red, a conserved phenylalanine residue which is a feature of STAT-type 
domains is highlighted in green. A conserved phenylalanine that is invariant in all SH2 domains except for the 
Spt6 domain is in cyan. 
 
 
3.3.6 The SH2 domain of Spt6 is an ancestor of the mammalian SH2 
domains involved in signal transduction 
 
The preceding analysis of the structure of the Spt6 SH2 domain identified features, that re-
lates it to both structural SH2 domain subfamilies, the Src-type and the STAT-type (Gao et 
al, 2004). Both families occur to different extents in the eukaryotic taxa: Human cells contain 
120 SH2 domains –the large majority of them belonging to the Src-type- distributed over 110 
proteins, that are generally involved in phospho-tyrosine recognition during cell signaling 
events (Liu et al, 2006) (Fig. 3 A). This high abundance of SH2-containing proteins in animal 
cells likely reflects the need for fine-tuned intercellular signaling in these complex organisms. 
Dictyostelium discoideum, an organism that can switch between single-cell and multicellular 
lifestyles, contains 12 different SH2 domain-containing polypeptides, 4 of those as part of 
STAT transcription factors (Eichinger et al, 2005; Williams et al, 2005). Two bioinformatic 
studies have found two SH2 domain sequences in plant genomes, which seem to be related 
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to the STAT-type subfamily (Gao et al, 2004; Williams & Zvelebil, 2004). In contrast to that, 
yeast cells only contain one SH2 domain in the genome: that of Spt6 (Maclennan & Shaw, 
1993).  
Spt6, together with its SH2 domain, is found in all eukaryotic taxa. Thus, the protein existed 
prior to the split of plant and animal lines, as well as the STAT type domains (Fig. 11 A). 
Because the Spt6 structure bears features from both subfamilies it is highly likely that the 
Spt6 SH2 domain is the ancestor of the modern SH2 domains. The hallmark feature of the 
Src-type subfamily – the ?E?F-sheet – clearly was already invented with Spt6 (section 3.3.3, 
Fig. 9 B and Fig. 10), so it is currently the first in SH2 domain development showing this trait. 
The relationship between the Spt6 SH2 domain and members of the Src-type subfamily can 
also be shown by a phylogenetic analysis of their protein sequences (Fig. 11 B). There, Spt6 
clusters together with other domains of the Src-type, whereas STAT proteins form their own 
cluster. 
 
 
 
Figure 11: Evolution of SH2 domains 
(A) Unscaled phylogenetic tree of eukaryotic organisms (Eichinger et al, 2005). For every taxon, a representative 
model organism is indicated together with the number of SH2 domain-containing proteins and STAT proteins. 
Colours of the branches of the tree indicate the distribution of SH2 subfamilies and Spt6 in the different taxa 
(Spt6, blue, STAT-type, magenta, Src-type, orange). The dashed, orange line in the Dictyostelium branch reflects 
the fact that it is unclear for some of the twelve SH2 domains to which subfamily they belong.  
(B) The Spt6 SH2 domain (blue) clusters with Src-type domains in a phylogenetic analysis. The cluster of STAT 
sequences is shown in purple. Organisms are indicated as in Fig. 10. The unrooted phylogenetic tree was 
calculated with Proml (Protein maximum likelihood) and drawn by Drawtree, which represent tools of the PHYLIP 
software package version 3.67 (Felsenstein, 1989), figure was provided by Andreas Mayer). 
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The evolutionary relationship to STAT-proteins is less clear. The ?L-helix, as well as the 
extended ?B helix might be a primitive or a degenerated relative of the STAT-linker domain 
and the ?B’?B-motif, respectively. However, the Spt6 SH2 domain is the „minimal 
equipment“ for a eukaryotic cell in terms of SH2 domains, given that the yeast genome 
encodes only one. This strongly suggests a similar situation in a eukaryotic precursor cell at 
the root of the eukaryotic tree of life. 
Spt6 is not found in prokaryotic cells. However, in pathogenic bacteria, a gene-product was 
identified which is involved in the expression of toxin genes (Fuchs et al, 1996). Primary 
sequence analysis of this protein, named Tex (for toxin expression), identified a similar 
domain architecture for Tex and parts of Spt6 (Ponting, 2002): YqgF, HhH and S1 RNA-
binding domains were identified in both proteins (see also Fig. 9 A). Spt6 contains an 
additional N-terminal nucleosome binding domain (Johnson et al, 2008) as well as the  
C-terminal SH2 domain. Thus, the core structure of Spt6 might have evolved from the Tex 
protein (Johnson et al, 2008) and the additional domains might have evolved as an adaption 
to eukaryotic processes, like interactions with nucleosomes and with the CTD of Pol II.  
 
3.3.7 The conserved phospho-binding pocket can explain the unusual 
phospho-serine specificity 
 
The domain surface of the Spt6 SH2 domain shows a conserved patch that includes a small 
pocket (pocket 1, Fig. 12 A) that contains an invariant arginine residue (R1281). This arginine 
is present in all known SH2 domains and interacts directly with the phosphate group of the 
target phosphopeptide in the SH2 domain-phosphopeptide complex (Waksman et al, 1992)  
(Fig. 12 D). In the "SeMet mutant CD" crystal form 1, R1281 binds a succinate ion that was 
present in the crystallization buffer. R1281 side chains from two neighboring domains in the 
crystal each bind a carboxylate of the succinate ion (Fig. 12 B). This observation is 
consistent with a high affinity of pocket 1 for negatively charged chemical groups, and the 
conserved phospho-binding function of R1281. Indeed, mutation of R1281 decreased the 
interaction of the SH2 domain with the phosphorylated CTD in vitro (Yoh et al, 2007). 
We next modeled the possible CTD interaction with the use of the known Src SH2 domain-
phosphopeptide complex structure (Waksman et al, 1993) (Fig. 12 D). The two structures 
were superimposed with their conserved residues in the central ?-sheet of the core domain 
fold. The phospho-binding pockets are highly similar in structure. The positions of C?-atoms 
of the residues that form pocket 1 are essentially identical (Fig. 12 D). The Spt6 residue 
R1281 perfectly aligns with the phospho-tyrosine binding residue R175 of Src and is thus in a 
position to make contacts with the phosphate by specific hydrogen-bonding interactions 
between the two terminal nitrogens and two phospate-oxygens (Fig. 12 E). Although the 
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position of the residues of the phosphate-binding-loop ?B-?C deviates slightly from those of 
Src (dashed blue line in Fig. 12 D), additional contacts of the phosphate group are likely 
conserved, including hydrogen bonds to a backbone amide (E178 in Src, S1284 in Spt6) and 
to the side-chain hydroxyl group of at least one of two residues (S177 and T179 of Src, 
apparently corresponding to S1283 and S1284, respectively, of Spt6). 
Whereas the contacts to the phosphate group are likely conserved, modelling suggests that 
contacts to an aromatic ring of a phospho-tyrosine side chain are apparently not possible in 
the Spt6 domain, consistent with binding to a phospho-serine peptide. The specific 
recognition of the phospho-tyrosine aromatic ring by Src is achieved by amino-aromatic 
interactions, where the ?-electrons of the aromatic ring interact with the amino groups of 
residues R155 and K203 in Src (Fig. 12 E). The aromatic ring of the phospho-tyrosine is 
sandwiched between these two residues (Fig. 12 D). Whereas the two residues 
corresponding to Src residues R155 and K203 are conserved in the majority of SH2 
domains, some SH2 domains lack one of them (Table 17). However, the SH2 domains of 
Spt6 and Cbl are the only SH2 domains within our structural comparisons, in which both 
residues are not conserved. Src residues R155 and K203 are replaced by residues G1263 
and D1305 in Spt6. The negatively charged residue D1305 was only observed  in Spt6 and is 
predicted to repel aromatic ?-electrons, consistent with the selection of serine over tyrosine. 
The alignment also shows that pocket 1 is more shallow in Spt6 than in Src (Fig. 12 F). Thus, 
the Spt6 pocket 1 is suited for phosphate binding and R1281 is better accessible from the 
solvent than in Src, making it possible to interact with a short phosphorylated serine side 
chain, instead of tyrosine. 
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Figure 12: Surface properties of the Spt6 SH2 domain 
(A) Conservation of surface residues. Residues are coloured according to the alignment in Fig. 9 A, with green for 
invariant and orange for conserved residues. The putative peptide-binding pockets 1 and 2 and surface residues 
implicated in peptide binding are indicated.  
(B) 2Fo-Fc electron density map, contoured at 1?, for the arginine residue R1281 of neighboring domains in the 
crystal and a bridging succinate ion.  
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Figure 12 (continued) 
(C) Surface charge distribution of the Spt6 SH2 domain (left) and the Src SH2 domain (Waksman et al, 1993). 
The phosphopeptide bound to the Src domain is shown as a stick model in red, only 4 residues of the original 
structure are shown. The charge distribution is calculated with APBS (Baker et al, 2001). 
(D) Superposition of the Src SH2 domain-phosphopeptide complex structure (Waksman et al, 1993) and the Spt6 
SH2 domain (blue). Structures were aligned using the most conserved residues (G1276-R1281, L1290-K1295, 
Q1302-E1308) of the central ?-sheet strands. The ?-sheets aligned very well, resulting in a RMSD of 0.4 Å for 19 
C? atoms. On the right, a close-up view of the phospho-binding site is shown. Src residues that interact with the 
phosphotyrosine are in orange, and corresponding residues in Spt6 are in blue. The dashed blue line indicates 
the position of loop ?B-?C of Spt6. 
(E) Conservation of the phospho-binding pocket. The modeling of (D) was used to delineate the Spt6 residues 
predicted to be involved in phospho-group binding based on the Src SH2 domain-peptide complex structure. 
Interactions of Src residues with the phospho-tyrosine (Waksman et al, 1992) are in orange, and potential 
corresponding interations of the Spt6 residues with the phospho group are in blue. Phospho-mimetic interactions 
of residues with succinate are in green. Stars indicate the residues depicted in (D).  
(F) Different shape of the phospho-binding pocket. The molecular surfaces of the phospho-binding pockets in 
Spt6 and Src are in blue and orange, respectively, and the phospho-tyrosine residue of the peptide bound to Src 
is in red. 
?
 
 
 
 
3.3.8 A model for CTD binding 
 
We created a model for possible interactions with the CTD (Fig. 13). The model is based on 
the interactions of the human Src-protein with its high affinity target peptide (Waksman et al, 
1993). In this structure, the peptide runs across the binding surface from pocket 1 to pocket 2 
(Fig. 12 C, right), the polaritiy is dictated by the interaction of the phosphotyrosine with 
pocket 1 and an isoleucine C-terminal of the pY with pocket 2. This binding mode is used by 
most SH2 domains (“two-pronged plug“, see Fig. 3 C)  and likely by the SH2 domain of Spt6, 
since a stretch of conserved surface residues extends from pocket 1 to a second pocket 
(pocket 2, Fig. 3 A). 
?
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Figure 13: Model for binding of the Spt6 SH2 domain to the Pol II CTD 
Suggested path for CTD phosphopeptide binding to the SH2 domain (dashed black line) and implications for 
specific binding to the Ser2-phosphorylated CTD. The Spt6 SH2 domain is shown with its surface charge 
distribution as in Fig. 12 C. 
?
In Src, mainly pocket 2 is important for substrate specificity (Kimber et al, 2000; Waksman et 
al, 1993) and accommodates the residue three residues C-terminal of the phospho-tyrosine 
(register +3, Fig. 13). Pocket 2 is negatively charged in Spt6, whereas it is slightly positively 
charged in Src (Fig. 12 C) and is hydrophobic or positively charged in most other SH2 
domains. Amongst ten Src-type and four STAT-type SH2 domains that we picked randomly 
(from Table 17), pocket 2 was negatively charged in only two domains and otherwise 
generally hydrophobic or positively charged (Appendix Fig. A2). The unusual negatively 
charged pocket 2 may be important for specific phosphopeptide binding. Assuming that a S2-
phosphorylated CTD peptide runs along the same path as in the Src-peptide complex, the 
CTD residue Ser5 at register +3 from the phosphoserine could bind into pocket 2. However, 
the presence of 2 phospho-aminoacids (S2 and S5) that could potentially bind into pocket 1, 
makes the situation more complex in terms of selectivity of binding. S5 can also bind into 
pocket 1, which would bring Y1 of the CTD heptad repeats into position (register +3) to 
interact with pocket 2. Selectivity could be accomplished, by sterically rejecting the large, 
aromatic side chain of tyrosine from the shallow, negatively charged pocket (in comparison to 
the small, polar side chain of serine in case of S2-phosphorylated CTD). In case of doubly 
phosphorylated CTD at S2 and S5, the S5-phosphate would be in register +3. The negative 
charge of phospho-Ser5 at the selective position would be repelled by the negatively charged 
pocket 2. (Fig. 13) This model can explain why the Spt6 SH2 domain exclusively binds to 
Ser2-phosphorylated CTD and not to CTD phosphorylated at Ser5 (Yoh et al, 2007).  
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3.3.9 CTD peptide soaks using existing Spt6 SH2 crystals 
 
To test our model of Spt6-CTD interactions we attempted to solve the complex structure. An 
efficient method to solve the structure of protein-ligand complexes is to „soak“ a small 
binding molecule into the crystals of the protein. This can be accomplished because of the 
large solvent content of protein crystals and a relatively good accessibility of protein surfaces 
that are not involved in crystal contacts. 
The „SeMet mutant CD crystal form 1“ (Fig. 7 B) was not suited for this task, since succinate 
molecules were occupying the phosphate-binding pocket (pocket 1), bridging between two 
molecules of the SH2 domain by binding to the highly conserved R1281, thus making crystal 
contacts (Fig. 12 B). Indeed, incubation of these crystals with CTD peptides in a control 
experiment led to the solvatation of the crystals. Likewise, soaking trials with native and 
„SeMet mutant CDE“ crystals (Fig. 7 B) were not successful because incubation with the 
peptides at different concentrations for different times, led to a loss of diffraction. The crystals 
of „SeMet mutant CD crystal form 2“ (Fig. 7 B) showed a good behaviour, stable diffraction, 
and their structure was already solved by molecular replacement, which showed that peptide 
binding pocket 1 of 2 molecules in the asymmetric unit of the crystal was pointed towards 
solvent and free to bind the target peptide. Unfortunately, these crystals were grown in high 
ionic strength (4,3 M NaCl, Table 13 and Fig. 7 B). Since the binding of the SH2 domain with 
the CTD-peptides is mainly based on ionic interactions, these conditions were classified as 
not suitable for soaking experiments. Thus, we tried to prepare these crystals for soaking, by 
gradually exchanging the high salt crystallization buffer to a low salt soaking buffer. This 
screening procedure is described in section 3.2.7. A condition was found were crystals 
cracked immediately upon transfer, but healed after short time (Fig. 14). This condition was 
chosen as a starting point for further screening, since the observed healing suggested that 
the crystal lattice could recover in these conditions and seemed to be intact.  
 
Figure 14: Crystal healing after transfer to low salt buffer 
A crystal that was grown in buffer Spt6 SH2-2 (left, see 2.1.4, Table 13) which was transferred directly into Spt6 
SH2 desalting buffer (middle) is shown. The crystal showed large cracks upon transfer, which healed about 30 
seconds afterwards (right).  
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Finally, the crystals could be directly transferred to a buffer containing ?900 mM NaCl, 
stabilized by ?42.5% PEG 2000 containing phosphorylated CTD peptides for one hour 
without extensively decreasing diffraction quality (3.2.8). Two datasets were obtained with 
this method, one of a crystal soaked with peptide P1 and one soaked with peptide P2 (2.1.2, 
Table 6).  
The structure was solved by molecular replacement as described in 3.2.5 for crystal form 2, 
with the exception that the structure was not refined to the end (see Table 18 for statistics). 
After the first round of refinement, the electron density map was inspected for positive 
difference electron density in the binding-pocket of the SH2 domain, which would indicate 
binding of the soaked peptide. The high Rfree at this point of refinement can be explained by 
the large rearrangements in loop BC and DE (Fig. 9 C). 
Since no density was observed in both datasets that could be assigned to peptide, the 
refinement procedure was cancelled. The failure of the experiment can be explained by the 
still high salt concentration in the soaking condition (?900 mM) which might disrupt 
phosphate binding. Crystals in conditions of lower ionic strength could not be obtained due to 
a loss of diffraction. Another explanation is that the SH2 domain variant in the crystals as well 
as the synthetic peptides used might  not be sufficient to confer binding. This is adressed in 
section 3.3.10. 
Table 18: : X-ray diffraction and refinement statistics for desalted crystal form B, soaked with synthetic 
peptides P1 and P2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
soak P1 
 
soak P2 
Data collection   
Space group P32 P32 
Cell dimensions     
    a, b, c (Å) 70.4, 70.4, 88.8 70.2, 70.2, 89.1 
   ?, ?, ?  (°) 90, 90, 120 90, 90, 120 
   
Wavelength (Å) 1.00841 1.00841 
Resolution (Å) 40-2.7 40-3.0 
Rsym (%) 4.4 (94.7) 4.8 (76.9) 
I /  ?I 35.0 (2.2) 34.5 (2.6) 
Completeness (%) 99.0 (87.1) 99.1 (88.1) 
Redundancy 11.3 (7.2) 11.4 (7.6) 
   
Refinement 
Molecular replacement as described in 
3.2.5 then restrained refinement using 
Refmac5 
Rwork / Rfree (%) 24.8 / 34.9 23.7 / 39.0 
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3.3.10 The SH2 domain is insufficient for binding short CTD phospho-
peptides 
 
We tested whether the Spt6 SH2 domain binds to short, syntehic CTD peptides that were 
phosphorylated at Ser2 residues. We used the SH2 domains of Spt6 from S. cerevisiae 
(residues 1251-1351) and human (residues 1327-1427), together with two different peptides. 
The first one comprising a single CTD heptad repeat and a single phosporylated Ser2 
(peptide P1) and a tandem repeat with two phosphorylated serines (SPSYpSPTS and 
YpSPTSPSYpSPTSPS, respectively. See 2.1.2, Table 6). For fluorescence anisotropy 
experiments, peptide P2 was modified by a fluorescein molecule attached to the N-terminus 
of the peptide by a ?-aminocaproic acid linker. An additional serine residue was added to the 
N-terminus in comparison to peptide P2, to assure enough space for the protein-peptide-
interaction (P3, see 2.1.2, Table 6). We assayed binding by fluorescence anisotropy (3.2.9) 
and by surface plasmon resonance (Biacore, see 3.2.10), but could not detect significant 
binding. Since the published Spt6-CTD interaction (Yoh et al, 2007) used a C-terminal 
fragment of murine Spt6 that did not only include the SH2 domain, but also the adjacent C-
terminal region (residues 1295-1496, whereas the SH2 domain spans residues 1327-1427), 
the SH2 domain alone and/or short CTD fragments are apparently insufficient for an 
interaction between Spt6 and Pol II. Since mutation of the invariant arginine residue 
abolished CTD binding, the SH2 domain is involved in the interaction but apparently requires 
its flanking regions and/or multiple phospho-CTD repeats. Very recent results confirm our 
findings. Yoh and colleagues (2008) show, that a C-terminal fragment of Spt6 containing the 
SH2 domain does not bind syntethic Ser2-, and Ser2-Ser5-phosphorylated tandem CTD-
repeats. In addition, they report that Spt6 binds selectively to the N-terminal and not the C-
terminal half of the CTD in vitro, dependent on phosphorylation by P-TEFb. This region of the 
CTD contains 15 consensus tandem repeats of the CTD motif. This data indicates that a 
higher ordered CTD structure is required for binding of Spt6, consistent with the finding that 
the CTD can adopt different conformations induced by its binding partner (Meinhart & 
Cramer, 2004). 
 
3.3.11 Functional architecture of Spt6 
 
The central region of Spt6 shows homology to the bacterial Tex protein, which is involved in 
toxin gene expression (Fuchs et al, 1996; Johnson et al, 2008). The recent X-ray structure of 
Tex revealed the folds and relative position of domains HtH, YqgF, HhH, and S1 in the 
conserved central region (Johnson et al, 2008). Spt6 additionally contains an acidic N-
terminal region, which might interact with nucleosomes, the C-terminal SH2 domain, and 
short regions flanking the SH2 domain. The previously published model of Spt6 (Johnson et 
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al, 2008) can now be extended with our structure of the SH2 domain (Fig. 15). To create an 
updated model, we aligned Spt6 and Tex protein sequences (Appendix Fig. A1) and mapped 
the 13 resulting sequence insertions in Spt6 onto surface regions within the Tex structure 
(Fig. 15), and added the structure of the SH2 domain. The model illustrates the relative sizes 
and locations of the various regions of the modular Spt6 protein, and is consistent with the 
idea that one side of Spt6 is involved in recruiting Spt6 to the transcribing Pol II via 
interactions with the nascent RNA and the phosphorylated CTD, whereas the other side is 
involved in nucleosome reassembly. 
 
 
Figure 15: Updated structural model of Spt6 
(A) Schematic representation of the Tex domain organization. The relative positions of insertions in eukaryotic 
Spt6 with respect to the bacterial Tex protein were identified by aligning the C.glabrata Spt6 and the  
P. aeruginosa Tex sequences (see Appendix Fig. A1) and are indicated with encircled numbers. The number of 
additional amino acid residues in Spt6 is also indicated. Boundaries of the Tex domains are indicated with 
numbers below the schematic representation.  
(B) ribbon representation of the model for Spt6. Insertions in Spt6 are indicated by dashed lines. The relative 
position of the SH2 domain is arbitrary. Arrows point to potential interaction partners of the different domains. 
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3.3.12 The Spt6 SH2 domain has a widespread function in vivo 
  
Results in this section are the work of Andreas Mayer and are presented here for discussion. 
To investigate the importance of the Spt6 SH2 domain in vivo, we carried out Affymetrix gene 
expression profiling (Affymetrix GeneChip Yeast Genome 2.0) with a yeast strain lacking the 
C-terminal region of Spt6 that includes the SH2 domain (Youdell et al, 2008) (strain spt6?C, 
2.1.1, Table 3). Compared to a wild type strain, 790 out of 5665 genes that were present on 
the array showed significantly altered mRNA levels using a fold-change cut-off value of 
greater +2.0 or smaller than -2.0. Thus the Spt6 SH2 domain is necessary for the regulation 
of a subset of genes (14%) in Saccharomyces cerevisiae. The extent of deregulation of gene 
expression is comparable to strains carrying deletions of other Pol II elongation factor genes, 
including genes encoding subunits of the Paf1 complex (13% for paf1 and 15% for ctr9) 
(Penheiter et al, 2005). Of the mRNAs with significantly altered levels, 465 were up-regulated 
and 325 were down-regulated (Fig. 17 A), suggesting a repressive function of the SH2 
domain at a majority of genes. Western blotting revealed that yeast cells adapt to the 
deletion by increasing the Spt6 protein levels (Fig. 16), which could compensate a failure of 
the mutant protein to localize to the transcription machinery. However, this does not restore 
the wild type phenotype in terms of growth, since the mutant strain shows a slow growth 
phenotype. Elevated Spt6 levels in the mutant can also root in a less efficient degradation of 
the TAP-tagged mutant protein. We were not able to resolve this problem because no 
antibody against the yeast Spt6 protein is available. 
 
 
Figure 16: The cellular concentration of Spt6 
increases when  SH2 containing C-terminus is 
deleted 
Western Blot of Spt6 proteins with a C-terminal 
TAP-tag, resolved in a 8% SDS-PAG. The mutant 
variant of Spt6 shows elevated expression levels 
relative to wild-type Spt6 and tubulin. 
 
 
We next analyzed biological processes that were significantly affected by deletion of the SH2 
domain with the Gene Ontology Enrichment Analysis Software Toolkit (GOEAST) and the 
web-based Gene Ontology (GO) tools (Ashburner et al, 2000; Zheng & Wang, 2008). This 
analysis showed that very diverse biological processes were over-represented, including 
genes involved in the response to toxins, in copper ion transport, and in thiamin metabolic 
processes. 
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A deconvolution of gene expression microarray data is generally difficult as it represents the 
result of primary and secondary effects during gene expression. We nevertheless aimed at 
detecing a possible global, chromatin-related function of the SH2 domain in the 
transcriptome data, with use of correlation analysis. We first investigated whether the 
deregulated genes correlate to genes that were previously described to show cryptic 
transcription initiation in a spt6 mutant that carried an internal deletion of amino acids 931-
949 (corresponding to 930-993 in C. glabrata and comprising the HhH-domain marked purple 
in Fig. 15). From the 960 ORFs that showed cryptic transcription (Cheung et al, 2008), only 
147 were included in our spt6?C differential gene expression profile (Appendix Fig. A3). We 
also investigated whether our set of differentially expressed genes shows any correlation 
with gene length or an unusual number of associated nucleosomes (Lee et al, 2007). 
However, we could not find any significant correlations. These results are consistent with the 
view that Spt6 has multiple functions and is not only required for nucleosome assembly but 
also for mRNA splicing and  
export (Yoh et al, 2007), and that it contains different functional surfaces (Fig. 15) that are 
perturbed in the different mutants. 
To address the problem of secondary effects that influence the microarray data, we 
compared the differentially expressed genes in the spt6?C mutant to a list of transcription 
factors (Hu et al, 2007). 33 genes of transcription factors are contained in our list of genes, 
which is more than 4% of all affected genes in the spt6?C mutant (Appendix Fig. A4). This 
suggests that a number of alternatively expressed genes can probably be related to 
secondary effects induced by the Spt6 mutation. With the tools available, it is currently not 
possible to reveal details of this defective regulation networks. 
To analyze whether the expression of similar genes is affected by deletion or mutation of 
different Pol II elongation factor genes, we compared our gene expression data to available 
data for the yeast strains dst1? (DST1 is the gene encoding TFIIS, (Koschubs et al, 2009), 
spt4?, and rtf1?, (Hu et al, 2007). We expected similarity between these data sets since Spt6 
interacts genetically with TFIIS (Hartzog et al, 1998) and with the Rtf1-containing Paf1 
complex (Costa & Arndt, 2000; Mueller & Jaehning, 2002), and since Spt6 binds the Spt4-
Spt5 complex (Krogan et al, 2002). An unsupervised hierarchical cluster analysis showed 
that the differential expression data from the spt4? and rtf1? strains form a distinct cluster 
within a dendrogram, indicating similarity of their gene expression profiles (Fig. 17 B, lanes 2 
and 3, Methods). However, the spt6?C mutant exhibits a very different expression profile 
(Fig. 17 B, lane 1), suggesting that the function of the Spt6 SH2 domain is clearly distinct 
from the functions of Spt4-Spt5 and the Paf1 complex in vivo. This analysis additionally 
revealed that dst1? showed the most distinct expression profile (Fig. 17 B, lane 4), maybe 
because TFIIS is not only required during elongation, but also during initiation (Guglielmi et 
al, 2007; Kim et al, 2007). Additional correlation studies confirmed these results.  
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Figure 17: The Spt6 SH2 domain is required for normal gene expression in vivo 
(A) Differentially expressed genes as detected by microarray analysis of the spt6?C strain. The fraction of up- and 
down-regulated genes is shown in red and green, respectively. In total, 790 genes showed significantly altered 
mRNA levels between Spt6 wild-type and the spt6?C strain. All gene expression analysis was performed with 
biological duplicates.  
(B) Cluster analysis of differential gene expression profiles of different Pol II elongation factor deletion strains. The 
cluster diagram was calculated for 1350  yeast genes of spt6?C, spt4?, rtf1? and dst1? mutant strains, depicted 
in lanes 1, 2, 3, and 4, respectively. Each row corresponds to a particular gene and each column corresponds to a 
particular elongation factor mutant. Changes in mRNA levels compared with the isogenic wild-type strain are 
depicted in red (increase), green (decrease) or black (no change; see intensity bar). Both rows and columns were 
clustered using a hierarchical cluster algorithm (Saeed et al, 2003). The dendrogram for column clustering is 
shown.  
(C) Pearson’s correlation matrix for gene expression profiles of yeast strains spt6?C, spt4?, rtf1? and dst1?. The 
corresponding correlation coefficients are given. 
The figure was kindly provided by Andreas Mayer. 
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A weak correlation was detected between expression profiles of spt4? and rtf1? strains, but 
no significant correlations were seen between the profiles of the remaining mutant strains 
(Fig. 17 C).  Taken together, deletion or mutation of various elongation factor genes results in 
different changes in the transcriptome, despite the observed genetic and physical interations 
between these factors. 
Taken together, this data shows that the deletion of the Spt6 SH2 domain from the genome 
has a dramatic effect on gene expression. It is currently not resolved if this observation is 
mainly due to the absence of the domain and a resulting defect of Spt6 to recognize the Ser2-
phosphorylated CTD of Pol II, or to raised Spt6-levels in the mutant strain. However, this 
data shows the general importance of Spt6 and especially of its SH2 domain for correct 
transcription of the yeast genome. 
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3.3.13 Spt6 co-localizes with Pol II on the yeast genome 
 
The occupancy profile of C-terminally TAP-tagged Spt6 on the yeast genome showed a high 
correlation to the profiles of Pol II subunits Rpb3 (Pearson correlation coefficient 0.86) and 
Rpb7 (Pearson correlation coefficient 0.87) (Jasiak et al, 2008). Thus, the pearson coefficient 
is only slightly lower than the correlation coefficient of Rpb3 and Rpb7 (0.91), which are both 
part of the same multisubunit complex. This means that Spt6 localizes together with Pol II on  
Figure 18: Genome-wide occupancy profiling of transcription elongation factor Spt6 
A representative 230 kilobase pair sample on chromosome one (genomic positions 0-230.000) of the profiles for 
Rpb3 and Spt6 are depicted. Each green dot represents the signal for a single oligonucleotide probe on the tiling 
array, which has one probe every 32 bp. An example for a region in the genome with different Pol II/Spt6 
occupancy is marked red. 
(A) Difference signal between averaged Rpb3 (B) and Spt6 (C) occupancy profiles. 
(B) Average over three biological replicate traces for Rpb3, one of which with interchanged fluorescent dyes 
(Jasiak et al., 2008) 
(C) Average over two biological replicate traces for Spt6, both with interchanged fluorescent dyes 
(D) Genomic features based on the Saccharomyces genome database annotations 
The figure was kindly provided by Matthias Siebert 
 
3 Structure and requirement of the Spt6 SH2 domain 65 
a genome-wide scale. The significance of these profiles is described in Jasiak et al (2008): 
housekeeping genes as well snoRNA genes show a high occupancy, which is expected 
expected, because these genes are highly expressed. tRNA-genes, that are expressed by 
RNA polymerase III show no increased occupancy. Fig. 18 shows a representative 230 
kilobase sample of the profiles for Spt6 and Rpb3. The profiles are virtually similar, but show 
slight differences in some positions (Fig. 18, marked red). 
We asked, if our data shows recruitment of Spt6 relative to Pol II that parallels Ser2-
phosphorylation of the CTD. We would expect to observe an increase of Spt6 occu-pancy 
towards the 3’ end of the transcribed regions, since it was shown that the SH2 domain binds 
exclusively to the CTD when phosphorylated at Ser2 residues (Yoh et al, 2007), which 
predominate only in 3’ regions of a gene (Komarnitsky et al, 2000). We could not observe 
this general behavior of Spt6 in the occupancy profile.  
To further analyze this question, we asked if the effect of an interaction between the CTD 
and the SH2 domain can be seen at genes of similar length, when the ChIP signals of these 
genes are averaged. For this, based on the Rpb3-data, we filtered out genes with an average 
ChIP signal < 0.2 to eliminate genes that are not transcribed. In addition, overlapping genes 
(both on the same strand and on the opposite strand) were eliminated to get clean signals 
from single genes. For the same reason we excluded neighboring genes that were too close 
to assign clean signals because of a "smearing" of ChIP signals in 5’ and 3’ regions. This 
resulted in 638 genes that showed a distribution in length as shown in Fig. 19 A. We used 
those classes for our analysis, that contained a sufficiently high number of genes (green in 
Fig. 19 A).  
The results of our analysis are shown in Fig. 19 B. The averaged Rpb3 ChIP-signal is high 
around the Start-codon (green, dashed line) and has its maximum shortly after that. This 
behavior can be seen in all classes of gene length and can be explained by polymerases 
paused at promoter proximal sites. In contrast to that, the averaged Spt6 signal shows a 
delay in comparison to the Pol II occupancy, with increasing density toward the 3’ end of 
transcribed regions. This effect decreases with increasing gene length. Thus, Spt6 shows an 
occupancy profile that roughly parallels Ser2-phosphorylation of the CTD, but only when the 
signals of many genes of the same length are averaged. Since it is crosslinking efficiency 
that is directly measured in a ChIP-experiment this effect could be explained by a change in 
crosslinking efficiency of Spt6 relative to Rpb3. Since it can only be seen in the averaged 
data, the effect seems to be very subtle and can rather be explained by a rearrangement 
between Spt6 and Rpb3 (or Pol II) than by a recruitment of Spt6 to the transcription 
machinery by Ser2-phosphorylated CTD. 
Unexpectedly, the Spt6 occupancy has a peak around the Stop codon and shows a 
prolonged signal beyond the end of the coding region in comparison to Pol II (Fig. 19 B). To 
test if this is significant or an artifact of our data processing, we averaged the signals of all 
genes, independent of their length, around the Start codon (+/- 500 bp) and the Stop codon  
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Figure 19 (preceding page): Differences in averaged occupancy profiles of Pol II and Spt6 
(A) Distribution of genes into classes of different length after filtering out untranscribed, overlapping and closely 
spaced genes (see text for details). Length classes that were used for further analysis are marked green. 
(B) Plots of the averaged ChIP-on-chip signals of the different length classes from (A). Classes are indicated 
above the plots. Averaged Rpb3- and Spt6-ChIP signals are shown in red and blue, respectively. The absolute 
values of different datasets cannot be related to each other. 
(C) Plots of averaged ChIP-on-chip signals of the Rpb3-, Rpb7- and Spt6-datasets around regions of the Start 
and the Stop codon. The ChIP-on-chip signal is averaged from all genes. Rpb3-, Rpb7- and Spt6-signals are 
shown in red, green and blue, respectively. Rpb3- and Rpb7-ChIP-on-chip data is from Jasiak et al (2008). 
The plots were kindly provided by Matthias Siebert. 
 
 
 (+/- 500 bp). For this we used the Rpb3 and the Spt6 datasets and in addition the data of the 
Rpb7 ChIP-on-chip experiment (Jasiak et al, 2008). The ChIP-data from Rpb7 is 
independent from the Rpb3-data, but both proteins are Pol II subunits. Indeed, Rpb3 and 
Rpb7 show similar profiles proximal to the Start and the Stop codon, whereas Spt6 again 
shows a maximum around the Stop codon and a longer retention in the 3’ regions of the 
genes relative to Pol II, which is strengthening the significance of our data analysis. 
 
3.4 Conclusions and future perspective 
?
In this work, the structure of the SH2 domain of transcription elongation factor Spt6, including 
a deep analysis of the biological implications of the structure is presented. The results are 
highly informative for different reasons: First, Spt6 is an essential regulator of transcription 
elongation through chromatin and the structure of its SH2 domain is the first structural 
information available for this factor. Second, the Spt6 SH2 domain is the only SH2 domain 
present in the yeast genome, in contrast to the great variety of these modules we have in 
human cells (>100 domains). Thus, the Spt6 domain represents the „minimal equipment“ of a 
lower eukaryotic organism in terms of SH2 domains. By analysis of our structure, we were 
able to put the Spt6 domain in a evolutionary relationship to known structures. This revealed 
that the domain exhibits features of „modern“ SH2 domains that are involved in cell signaling 
pathways. This makes the Spt6 domain an ancestor of this important modules. Thus, our 
data gives an exciting insight into the molecular evolution of SH2 domains.  
Furthermore, the Spt6 SH2 domain is of special interest because it connects Spt6 directly to 
the transcription machinery and thus is of great importance for its function. It shows a 
different specificity in that it binds to Ser2-phosphorylated CTD, wheres all other SH2 
domains on which structural information is available bind to tyrosine-phosphates. 
Unfortunately, we were not able to elucidate functional information of the interaction of the 
SH2 domain and the CTD due to the limitations described. A recent publication showed that 
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the interactions between the Spt6 SH2 domain and the CTD might be more complex 
compared to the interactions of other SH2 domains and their targets, as higher order CTD-
structures seem to be involved (Yoh et al, 2008). Nevertheless, models emerged from our 
analysis that are experimentally testable as soon as we have obtained the right combination 
of SH2 domain variant and CTD-peptide to establish a binding assay. Interestingly, we have 
found a second ?????-motif directly C-terminal to the SH2 domain. Thus we suspect the 
presence of a tandem SH2 domain in the C-terminal region of Spt6. We have already 
initiated work to tackle this question, which led to the crystallization of the whole C. glabrata 
Spt6 C-terminus. Consequently, we will soon learn more about the molecular interactions 
between the transcription machinery and elongation factor Spt6. 
We showed the importance of the Spt6-SH2 domain for the correct transcription of the yeast 
genome. It is at this point still difficult to decide if the differential gene expression we see 
stemms from the absence of the domain or from the resulting change in cellular Spt6 
concentrations, but we initiated work to decipher this problem. Furthermore, a consistent 
interpretation of such results is still difficult as we show by our analysis of the transcription 
factors that are affected in their expression levels in the spt6?C mutant (Appendix Fig. A4). 
This means that a considerable number of the altered expression levels in the dataset are 
likely produced by secondary effects rather than by the mutation itself. In future, 
computational tools are needed, that integrate knowledge about cellular regulation networks 
with the genome-wide expression data to unravel these complex interdependency. It is 
however fascinating to see the dramatic changes in gene expression upon the deletion of a 
100 amino acid module from an elongation factor. This in principle shows the tight and 
minute regulation of transcription at the level of elongation. 
We created a map of Spt6 occupancy on the S. cerevisiae genome and compared it to the 
localization-map of Pol II that was previously published from our lab (Jasiak et al, 2008). The 
result was unexpected, as we saw Spt6 localizing basically to the same positions as Pol II 
throughout the genome. In light of the general importance of Spt6 for various processes like 
chromatin maintenance (Bortvin & Winston, 1996), histone methylation (Yoh et al, 2008) and 
mRNA processing and export (Yoh et al, 2007) it seems reasonable that Pol II keeps 
important factors like Spt6 in close proximity for the efficient transcription of genes. Because 
Pol II- and Spt6-localization was so similar, we could initially not detect recruitment of Spt6 
paralleling the Ser2-phosphorylation of the CTD of Pol II as might be expected from the SH2 
domain - CTD interaction. Only by averaging the signals of many genes a slight effect could 
be detected that seems not to be an artifact of data processing. This effect could be 
explained by a subtle change in the crosslinking behaviour between Pol II and Spt6 due to a 
rearrangement within a higher order structure. However, the analysis of complex genome-
wide data is still developing and our data analysis suggests a way to extract information that 
is hidden in the mere occupancy profiles of proteins. The significance of this procedure still 
has to be evaluated, for example by comparison to the localization profiles of other 
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elongation factors and to gene specific factors. It will be interesting to see, if proteins that 
interact with Ser5-phosphorylated CTD show a similar, but inverted behavior like Spt6 in our 
data. In addition, such data could be useful to define factors that generally localize together 
with Pol II on the genome in a higher ordered structure like a „transcription factory“.  
In summary, a combined, interdisciplinary approach as outlined in this part of the thesis will 
be increasingly powerful to understand proteins and their interactions in a broad context. 
However, the development of more powerful computational methods to analyze the complex 
data derived from genome-wide investigations will be needed to uncover hidden layers of 
information that will add up on the knowledge that will be gained on the interactions of 
cellular components. 
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4 An in vitro system to test the “torpedo model” of 
transcription termination  
?
?
4.1 Introduction 
?
4.1.1 The 5’-3’ exoribonuclease-complex Rat1/Rai and the "torpedo 
model" of transcription termination 
 
The "torpedo model" of transcription termination was first mentioned in 1988 (Connelly & 
Manley, 1988). In their work, Connelly and Manley found that in their transient expression 
assays in human cells, that an intact polyadenylation signal is required for transcription 
termination by Pol II. They proposed a model, where after poly(A)-site-induced cleavage of 
the nascent transcript, downstream RNA is degraded by a 5’-3’ exonuclease which, upon 
reaching the still elongating polymerase gives the signal to terminate. Although they did not 
use the term "torpedo model", it is still used to describe the events that could terminate 
transcription. The concept was further strengthened when it was discovered, that not only the 
poly(A)-signal is mandatory for termination (Connelly & Manley, 1988; Logan et al, 1987), but 
also the factors that accomplish cleavage (or at least some of them) are required for effective 
termination at the CYC1 gene, whereas mutations in polyadenylation-factors did not show 
severe effects (Birse et al, 1998). The "torpedo model" gained strong support, when a 
candidate nuclease was found. Affinity chromatography with Ser2-phosphorylated CTD led to 
the purification of Rtt103. This protein contains a CTD-interaction (CID) domain that is 
related to that of Pcf11 (Meinhart & Cramer, 2004). In addition, the Rat1/Rai1 nuclease 
complex was found to interact with Pol II/Rtt103 (Kim et al, 2004). Rat1/Rai and Rtt103 
crosslink together at the polyadenylation-site and crosslinking of Rtt103 is dependent on 
CTD-phosphorylation by Ctk1. This suggested that these proteins play a role in 3’ end 
processing. 
Rat1 is an essential, nuclear 5’ exoribonuclease of 116 kDa, involved in RNA turnover. It has 
similar enzymatic activity as its cytoplasmic counterpart Xrn1, processively degrading RNA 
from the 5’ end and releasing nucleoside 5’-monophosphates (Stevens & Poole, 1995). Xrn1 
was the first 5’-3’ exoribonuclease characterized in yeast (Larimer et al, 1992; Larimer & 
Stevens, 1990; Stevens, 1980; Stevens & Maupin, 1987). Rat1 is an essential protein, 
whereas cells with a disrupted XRN1 gene are viable (Kenna et al, 1993; Larimer & Stevens, 
1990). Both exonucleases prefer RNAs with a 5’ monophosphate as a substrate, show weak 
activity towards RNA with a 5’-hydroxyl group and single stranded DNA (ssDNA) and no 
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activity for RNAs with a 5’ cap or tri-phosphate (Poole & Stevens, 1995; Stevens & Poole, 
1995). Interestingly, Xrn1 and Rat1 are functionally interchangeable. When the proteins are 
directed to opposite compartments by the deletion or addition of a nuclear localization signal 
(NLS), they can complement defects of their counterpart (Johnson, 1997). In the first 
purifications of endogenous Rat1, an interacting protein of 45 kDa was seen that co-purified 
together with the Rat1-exonuclease activity (Stevens & Poole, 1995). This protein was later 
identified as Rai1 and it was shown that it stabilizes the exonuclease activity of Rat1 (Xue et 
al, 2000). 
Cells with an intact cleavage/polyadenylation machinery, but with a mutated and non-
functional Rat1 (Amberg et al, 1992) or a deletion of its co-factor Rai1, showed dramatic 
termination defects (Kim et al, 2004). In these cells, 3’ transcripts after poly(A)-site directed 
cleavage were greatly stabilized. Similar results were obtained in independent studies on the 
human ?-globin gene . In this gene, the poly(A)-site is associated with an autocatalytic RNA-
structure that undergoes rapid self-cleavage after being transcribed (CoTC for co-
transcriptional cleavage) (Teixeira et al, 2004). This cleavage was shown to create a free 
RNA 5’ end that is a substrate for Xrn2 (the human homolog of Rat1), and that the 
consequent degradation of the downstream RNA induces termination (Teixeira et al, 2004; 
West et al, 2004). Only recently it was shown, that the Rat1/Rai1 activity is also required for 
efficient termination of Pol I transcription (El Hage et al, 2008). Here, the RNase III-like 
endonuclease Rnt1 cleaves the nascent rRNA-transcript to create an entry site for Rat1 
(Kufel et al, 1999). A knockout of the Rnt1-gene showed an increased read-through at the 
„Reb-dependent“ Pol I terminator (see section 1.3.2), showing that co-transcriptional 
cleavage is important for efficient termination at this site (Prescott et al, 2004; Reeder et al, 
1999)  
These results strongly support the “torpedo model” that is depicted in Fig. 20. This model 
somehow resembles Rho-dependent termination in prokaryotes (Nudler & Gottesman, 2002). 
There, Rho an ATP-hydrolyzing RNA-DNA-helicase follows bacterial RNAP along the RNA 
upon a specific signal (without hydrolyzing the RNA) and terminates transcription upon arrival 
at the elongation complex (see also 1.3.2). 
 
4.1.2 "Torpedo model" vs. "allosteric model" 
?
The "torpedo model" is not the only explanation of the events at the 3’ end of genes. First the 
data was explained with the "allosteric model". Here, transcription of the poly(A) sequence is 
predicted to trigger a change in the factors that are associated with polymerase II (Logan et 
al, 1987). This could include the binding of a termination factor or the displacement of an 
anti-termination factor or both, for example by the cleavage/polyadenylation factors. In fact, 
there is data that supports this model over the torpedo model. First, poly(A) site-induced 
cleavage of the transcript, which is necessary for the explanation of the "torpedo model", 
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does not seem to be a prerequisite for termination in general: disruption of poly(A) site 
cleavage by mutants of Pcf11 and Ssu72 did not affect termination (Dichtl et al, 2002; He et 
al, 2003; Sadowski et al, 2003). In an EM study of plasmids injected into Xenopus oocytes 
and in a second one on Drosophila chromosomes it was seen that termination occurs before 
cleavage of the transcript, or that it can even happen without prior cleavage (Osheim et al, 
1999; Osheim et al, 2002). Another study presented data using the RNA IP technique, 
showing that Rat1 and Xrn2 are indeed responsible for co-transcriptional degradation of RNA 
3’ of the poly(A) site, but are not the factors that cause termination (Luo et al, 2006). It was 
rather shown that Rat1 is a part of the recruitment cascade of 3’ processing factors and by 
that involved in termination. 
Figure 20: The “torpedo model” of transcription termination 
After transcription of the poly(A) site, the nascent RNA is cleaved by cleavage/polyadenylation factors that are 
assembled on Ser2-phosphorylated CTD. The cleavage creates a new, uncapped RNA 5’ end, which is a 
substrate for the exoribonuclease-complex Rat1/Rai1 that interacts with the Rtt103-Pol II complex and is also 
assembled based on the Ser2-phosphorylated CTD. Rat1/Rai1 is predicted to degrade the downstream RNA 
processively. Upon contact with the elongating polymerase, transcription termination is induced. Template DNA, 
non-template DNA and RNA are shown in blue, cyan and red, respectively. Factors in this figure are not drawn to 
scale. See text for details. 
 
4 An in vitro system to test the “torpedo model” of transcription termination 73 
Consequently, the cytoplasmic counterpart of Rat1, Xrn1 (see section 4.1.2) can rescue the 
nuclease-activity associated defect of a Rat1 mutation when directed to the nucleus, but 
does not rescue the termination defect (Luo et al, 2006) 
 
4.1.3 Aim of this work 
 
Despite extensive research from different labs, the mechansim of transcription termination of 
protein coding genes is still one of the least understood events during the transcription cycle. 
However, over the years two models were established that try to explain the findings. As 
summarized in sections 4.1.1 and 4.2.2, existing data both support the "torpedo model" and 
the "allosteric model". This suggests that the truth about the events that lead to termination 
lies somewhere in between the two models. To approach this question, it is necessary to 
characterize the factors that are involved in isolation and to gain knowledge about their 
intrinsic properties. The “torpedo model” as such was never tested in a highly pure in vitro 
system, to see if Rat1/Rai1 actually possess the capability to disrupt elongation complexes. It 
is not clear how a nuclease can exert the force on polymerase to disintegrate its interaction 
with DNA and RNA, especially as it was shown that degradation of the RNA alone is not 
sufficient to end elongation (Gu et al, 1996). We were engaging this problem by setting up a 
highly defined in vitro elongation assay (described in 4.3.3). In addition a protocol for the 
production and purification of active, recombinant Rat1 exonuclease complexes was 
established (described in 4.3.1) and their nuclease activity was characterized (described in 
4.3.2). With this in hand we tested transcription termiation as predicted by the the „torpedo 
model“ (described in 4.3.4). The advatage of our assay is, that all the components are easy 
to exchange and to modify, so we were able to test the model using different types of DNA 
and RNA sequences that are involved in the processing of mRNA in 3' regions of genes 
(described in 4.3.5 – 4.3.7). 
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4.2 Specific procedures 
?
4.2.1 Vectors 
?
The following vectors have been created with the methods described in 2.2.1: 
 
Table 19: Vectors containing Rat1, Rai1, Rtt103 genes 
Vector       Source Plasmid (see 2.1.2, Table 4) 
Rat1fl     pET21b(+) 
Rai1fl     pET24b(+) 
Rtt103fl     pET21b(+) 
Rtt103?CID     pET21b(+) 
 
4.2.2 Purification of Rat1, Rat1/Rai1 and Rtt103 
?
Rat1 was purified from a 1 l autoinducing expression culture (see 2.2.3). After binding of 
Rat1, the Nickel-NTA-resin was washed with 20 ml Rat1 IMAC buffer (see 2.1.4, Table 11)  
+ 30 mM imidazole to remove proteins binding unspecifically to the matrix. Elution of Rat1 
was carried out with 30 ml of Rat1 IMAC buffer + 300 mM imidazole. The eluate from the 
Nickel-column was applied to a HiTrap Heparin 5ml column (GE Healthcare), pre-
equilibrated with Rat1 heparin buffer A (see 2.1.4, Table 11). Bound protein was eluted by 
increasing the salt concentration in a linear gradient from 100 mM to 1 M NaCl over 12 
column volumes. Peak fractions from the heparin affinity chromatography were pooled and 
concentrated to 500 ?l, then applied to a Superose 6 10/300 GL column (GE Healthcare), 
pre-equilibrated with  
2x Rat1 size exclusion buffer (see 2.1.4, Table 11). 2x Rat1 size exlusion buffer was RNAse 
free, whenever the enzyme was used for nuclease assays. 10% (v/v) RNAse-free glycerol 
was added to the sample before freezing in liquid nitrogen and storage at –80°C. 
The Rat1/Rai1 complex was co-expressed in E. coli BL21 (DE3) RIL cells by transforming 
the two plasmids with different antibiotic-resistance cassettes at the same time. In the 
complex, only Rat1 has a C-terminal His6-tag. The complex was purified from a 2 l 
autoinducing medium expression culture (2.2.3). 
After binding of Rat1/Rai1 to the Nickel resin and after washing with 10 column volumes of 
the Rat1/Rai1 cell lysis buffer (see 2.1.4, Table 11), the protein was eluted with 40 ml 
Rat1/Rai1 IMAC buffer (see 2.1.4, Table 11) + 300 mM imidazole. The eluate from the IMAC 
was applied to a HiTrap Heparin column (5 ml, GE Healthcare) pre-equilibrated with 
Rat1/Rai1 IMAC elution buffer (see 2.1.4, Table 11). Bound protein was eluted in a linear 
gradient from 0.1 M to 1 M NaCl, buffered by 50 mM Tris/HCl pH 8.0 (Rat1 heparin buffer A 
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and Rat1 heparin buffer B, see 2.1.4, Table 11) over 12 column volumes. Peak fractions from 
the heparin chromatography were pooled, concentrated to 500 ?l and applied to a  
Superose 6 10/300 GL column (GE Healthcare), pre-eqilibrated with 2x Rat1/Rai1 size 
exclusion buffer (2.1.4, Table 11). When Rat1/Rai1 was prepared for use in nuclease assays, 
this buffer was made RNAse free. 10% (v/v) RNAse-free glycerol was added to the sample 
before freezing in liquid nitrogen and storage at –80°C. 
Rtt103 was purified from 1 l of auto-inducing medium expression culture (see 2.2.3). After 
binding to the Nickel-resin, recombinant Rtt103 was eluted with 30 ml of Rtt103 IMAC buffer 
(2.1.4, Table 11) + 300 mM imidazole. The purification protocol is summarized in Figure 21. 
 
4.2.3 Assembly of the Rat1/Rai1/Rtt103 trimeric complex 
?
For the assembly of the trimeric exonuclease complex, the Rat1/Rai1 eluate from the heparin 
column (see 4.2.2) and the Rtt103 eluate from the NiNTA-column (see 4.2.2) were used. 
Protein concentrations of these samples were determined by the Bradford assay (see 2.2.4). 
The molarity of the Rat1/Rai1 sample was calculated (Mw of Rat1/Rai1: 160342). For Rtt103 
the sample-volume that contained twice the molar amount compared to Rat1/Rai1 was 
calculated (Mw of Rtt103: 46459). The calculated volume was multiplied by 3, to compensate 
for the fact that 2/3 of the Rtt103 sample consisted of contaminating proteins (estimated by 
SDS-PAGE, see 2.2.7). The calculated volumes were mixed gently and incubated for 30 
minutes at 20°C. The sample was then concentrated to 500 ?l and applied to a Superose 6 
10/300 GL column (GE Healthcare) pre-equilibrated with 2x Rat1/Rai1/Rtt103 size exclusion 
buffer (2.1.4, Table 11). The assembly protocol is summarized in Figure 21. 
 
4.2.4 RNase and RNase H activity assays 
For RNase assays, a 27 nt RNA („activityRNA“, 2.1.2, Table 5) was labeled at the 3’-end 
using T4 RNA ligase (Fermentas) and [32P]Cp at a concentration of 3 ?Ci/pmol of RNA in 
ligase buffer provided by the manufacturer. Excess radioactive nucleotides were removed 
with MicroSpin™ G-25 Columns (GE Healthcare) and 3’-end-labeled RNA was used as a 
substrate for 5’-end digestion. 3 pmol of labeled RNA were mixed with an equimolar amount 
of pure Rat1/Rai1 or Rat1/Rai1/Rtt103 in 1x Rat1 reaction buffer (2.1.4, Table 11) in a total 
volume of 30 ?l, and incubated at 30°C. After 30, 60 and 180 minutes, 9 ?l of each sample 
were removed and the reaction was stopped by mixing with an equal volume of 2x urea 
loading dye (2.1.4, Table 9) and incubation at 95°C for 5 minutes. The samples were 
analyzed by denaturing PAGE in 8 M urea (2.2.7). Remaining RNA was detected by 
autoradiography and the relative amounts were quantified with ImageQuant software. 
Radioactive gels were exposed to a storage phosphor screen (Molecular Dynamics) for 
several hours and scanning of storage screens was carried out with a STORM 860 imaging 
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system (Molecular Dynamics). All experiments were carried out in triplicates. For RNAseH 
assays, labeled 27 nt RNA was mixed with a four-fold molar excess of fully complementary 
DNA („RNaseHDNA1“, 2.1.2, Table 5) or DNA complementary only to 17 nucleotides in the 
3’ part of the RNA („RNaseHDNA2“, 2.1.2, Table 5) in TE buffer. The nucleic acids were 
annealed by heating to 95°C and slowly cooling to room temperature. The reaction was 
carried out and stopped after one hour as above, and the samples were analyzed as above. 
Control reactions using RNase I (Fermentas) and RnaseH (New England Biolabs) were 
carried out in the buffers provided by the manufacturer. 
 
4.2.5 Purification of RNA polymerase II core enzyme 
?
RNA Pol II core enzyme from Saccharomyces cerevisiae was purified from the deletion strain 
CB010?Rpb4 essentially as described (Edwards et al, 1991). Cells, frozen in 3x Pol II 
freezing buffer (see 2.1.4, Table 12),  were thawed in a water bath, then kept at 4°C. After 
addition of protease inhibitor mix (2.1.4, Table 9) the suspension was transfered to the metal 
chamber of a BeadBeater containing 200 ml soda lime glass beads (? = 0.5 mm). After 
removal of air bubbles by stirring with a glass rod, the chamber was filled with HSB150 
(2.1.4, Table 12) The BeadBeater was running 60-70 minutes in cycles of 30 seconds 
beating followed by a 90 second pause. The chamber with the suspension was kept cold by 
a salt-ice mix which was regularly renewed. The lysate was filtered through a mesh funnel 
which was then washed with HSB150 (2.1.4, Table 12), not exceeding a total volume of 1000 
ml. The lysate was centrifuged twice for 45 min at 13700 g and 4°C. Afterwards it was 
filtererd through cheesecloth and paperfilter, to remove the lipid phase. 
250 ml Heparin Sepharose 6 FF (GE Healthcare) affinity resin was equilibrated with  
3 column volumes of HSB150. After loading of the lysate, the column was washed with  
3 column volumes of HSB150, bound protein was eluted with 2 column volumes HSB600 
(2.1.4, Table 12). Only milliliters 200 to 400 were used for the subsequent purification steps. 
Proteins in the eluate were precipitated by addition of 291 g/l fine-ground ammonium sulfate 
(? 50% saturation) and overnight stirring at 4°C.  The sample was then centrifuged for  
45 minutes at 21860 g and 4°C, the precipitate was dissolved in 40 ml 1x TEZ0 (2.1.4,  
Table 12). Additional buffer was added to set conductivity below the conductivity of TEZ 
containing 400 mM ammonium sulfate (TEZ400). The sample was centrifuged again for  
15 minutes at 34000 g and 4°C, to remove undissolved particles. 
In an immunoaffinity step, Pol II was bound by immobilized antibody 8WG16 (NeoClone, 
Madison, USA) which binds selectively to the unphosphorylated C-terminal domain of Rpb1. 
Two columns with each 5 ml of the respective resin were equilibrated with 3 column volumes 
of TEZ250 (2.1.4, Table 12) lacking DTT and PI, followed by 1 column volume of TEZ250. 
After loading of the sample by gravity flow, the flowthrough of the first column was 
immediately loaded onto the second column. The columns were equilibrated to room-
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temperature for 10 minutes. After washing with 5 column volumes of TEZ500 (2.1.4,  
Table 12), bound proteins were eluted with TEZ500 + glycerol (2.1.4, Table 12). At least 15 
fractions with a volume of 1 ml each were collected and transferred to ice. The protein 
content of these fractions was qualitatively checked by adding 10 ?l of sample to 200 ?l  
1x Bradford dye (2.1.4, Table 9). Peak fractions were pooled and 10 mM DTT was added 
before storage overnight at 4°C.  
The pooled sample was diluted to 50 ml with Pol II buffer (see 2.1.4, Table 12) and 
concentrated with an Amicon Ultra-4 Centrifugal Filter Device (100k cutoff, 1300 x g, 4°C). 
After concentrating to ?5 ml, 10 ml of Pol II buffer were added and concentrated further. 
More sample was added after this step and this cycle was continued until all of the sample 
was added. By doing this, the buffer of the sample could be exchanged to the Pol II buffer, 
which was checked by measuring the conductivity of the flowthrough and comparing it to the 
conductivity of the Pol II buffer. When this value was constant, the sample was concentrated 
to ? 2 mg/ml. The sample was divided into aliquots of 50 to 500 ?g of protein. After adding 
1.13 volumes of saturated ammonium sulfate solution compared to the aliquot volume, 
samples were incubated for 1 hour at 4°C on a rotating wheel and then centrifuged for 30 
minutes at 16000 x g and 4°C to obtain a pellet. Supernatants were partly removed and 
samples were frozen in liquid nitrogen and stored at –80°C 
 
4.2.6 Reconstitution of the 12 subunit RNA polymerase II complex 
?
The recombinantly expressed and purified Pol II subcomplex Rpb 4/7 was provided by 
Elisabeth Lehmann. It was purified essentially as described (Armache et al, 2005b), and 
added in 5 fold molar excess respective to Pol II core enzyme and incubated for 30 minutes 
at 20°C. In cases where the sample was used for transcription bead assays, excess Rpb 4/7 
was not removed by size exclusion chromatography to prevent unnecessary protein loss. 
Separation of 12 su Pol II from unbound Rpb 4/7 was carried out by binding fully assembled 
elongation complexes to magnetic beads (see 4.2.7).  
 
4.2.7 Assembly of RNA polymerase II-nucleic acid complexes 
?
Polymerase II was prepared as described in 4.2.4 and 4.2.5. Nucleic acids were synthetic 
and are listed in chapter 2.1.2, Table 5. 
 
Artificial transcription scaffolds for crystallization of elongation complexes contained the 
template strand poly(A)xtalT, the non-template strand poly(A)xtalNT and the poly(A)xtalRNA 
(2.1.2, Table 5). Nucleic acids were annealed by mixing equimolar amounts of synthetic 
template DNA, nontemplate DNA, and RNA in TE buffer (see 2.1.4, Table 9) at a final 
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concentration of 100 ?M. The mixture was heated to 95°C for 2 min, and cooled down to 
room temperature very slowly. Two molar equivalents of this scaffold and five molar equi-
valents of recombinant Rpb4/7 were incubated with one molar equivalent of Pol II in Pol II 
buffer (2.1.4, Table 12) for 20 minutes at 20°C. Assembled complexes were purified by 
Superose 6 size-exclusion chromatography and concentrated to 3.5 mg/ml. 
 
Fully complementary transcription scaffolds for in vitro bead-based assays were 
assembled as described (Komissarova et al, 2003). For this, equimolar amounts of template 
DNA and RNA were mixed in RNAse-free TE buffer. The oligonucleotides were annealed by 
heating to 95°C for 2 minutes and slowly cooling to room temperature. Pol II (either core or 
12 su Pol II, see 4.2.4 and 4.2.5 respectively)  was incubated with a two-fold molar excess of 
the annealed hybrid for 15 minutes at 20°C while gently shaking. A four-fold molar excess of 
non-template DNA, containing Biotin at the 5’ end, was added and the mixture was incubated 
for 20 minutes at 25°C while shaking. Control-elongation complexes lacking the biotinylated 
non-template strand were assembled identically, omitting the last step 
 
4.2.8 Bead-based termination assays 
 
Magnetic, streptavidin-coated beads (Dynabeads? MyOne? Streptavidin T1, Dynal Biotech, 
distributed by Invitrogen) were prepared by washing twice with beads breaking buffer (2.1.4, 
Table 9) followed by incubation in 500 ?l of beads blocking buffer (2.1.4, Table 9) overnight 
at 4°C. After washing again twice with breaking buffer, beads were resuspended in the 
original volume of breaking buffer. 1-3 pmol fully assembled elongation complexes (4.2.7) 
were added per reaction (= 10 ?l blocked and washed beads) followed by an incubation for  
30 minutes at 25°C, gently shaking. Unbound complexes were removed by washing with  
50 ?l beads breaking buffer, Rat1 wash buffer, and Rat1 reaction buffer (2.1.4, Table 11). 
Beads were resuspended in 19 ?l Rat1 reaction buffer. RNA in the elongation complex was 
labeled at the 3’ end with the use of Pol II activity, by adding 1 ?l of ?[32P]UTP [10 mCi/ml] 
(GE Healthcare), followed by an incubation at 28°C for 20 minutes, slowly shaking. 
Unincorporated nucleotides were washed away by applying twice 30 ?l of Rat1 reaction 
buffer. Beads were resuspended in Rat1 reaction buffer, and nuclease complexes were 
added at a two-fold molar excess respective to the elongation complex concentration used 
for binding to the beads, followed by incubation for 1 hour at 30°C. As a single strand-specific 
control endonuclease, RNase I (100 units, New England Biolabs, #M0243S) was used. After 
the reaction, nucleases were washed away with Rat1 washing buffer and Rat1 reaction 
buffer. Beads were resuspended in 20 ?l of Rat1 reaction buffer.  To test the ability of ECs to 
elongate the transcript after nuclease digestion, beads were resuspended in 19 ?l, and 1 ?l 
of NTP mix was added at a final concentration of 1 mM and incubated at 28°C for  
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30 minutes. The reactions were stopped by adding 20 ?l of 2x urea loading dye (2.1.4, Table 
9) and incubating for 5 minutes at 95°C. Samples were analyzed by 6 M urea PAGE and 
radioactively labeled RNA was detected by exposition of the gels to a storage phosphor 
screen (Molecular Dynamics) overnight at 4°C. Scanning of storage screens was carried out 
with a STORM 860 imaging system (Molecular Dynamics). 
?
4.2.9 Crystallization of 12 subunit Pol II elongation complexes and a 
poly(A) site containing nucleic acid scaffold 
 
Pol II-nucleic acid complexes were purified as described in 4.2.5 and 4.2.6 and assembled 
as described in 4.2.7 An additional amount of the nucleic acid scaffold was added prior to 
crystallization to a final concentration of 2 ?M. Crystals were grown at 22 °C with the hanging 
drop vapor diffusion method by mixing 2 ?l of sample solution with 1 ?l of reservoir solution 
(2.1.4, Table 13). Crystals were harvested after 10-20 days of growth, when they had 
reached their maximum size and were transferred stepwise to mother solution containing 
additionally 0-20 % glycerol over 5 h. After the last step, crystals were slowly cooled to 8°C, 
and flash-frozen by plunging into liquid nitrogen. 
 
4.2.10 Data collection and structure solution 
 
Complete diffraction data to 4.0 Å resolution were collected at the Swiss light source (SLS) 
beamline PX1 (Table 20). The structure was solved by molecular replacement with the model 
of the complete 12-subunit Pol II EC without nucleic acids as a search model (PDB 1Y1W, 
(Kettenberger et al, 2004b). The molecular replacement solution was subjected to rigid body 
refinement with CNS (Brunger et al, 1998). The final structure includes 25 nucleotides of 
DNA and 8 nucleotides of RNA, shows good stereochemistry, and has a free R-factor of 
23.5% (Table 20). The nucleic acids were built into the initial Fo-Fc electron density map 
using the program Coot (Emsley & Cowtan, 2004). A thymine residue in the template strand 
was replaced for 5-bromouracil. Diffraction data were recorded at the wavelength of the 
bromine K absorption edge, and the resulting anomalous difference Fourier maps revealed 
single peaks demarking the positions of the bromine atom. Thus, the register of the nucleic 
acids was unambiguously defined by the identification of the position of bromine in the 
template strand (Fig. 24 E). Atomic positions and B-factors were refined with CNS, the 
progress was monitored with the free R-factor which showed a value of 23.5% at the end of 
refinement. Statisitics for Data-collection and refinement are listed in Table 20 in chapter 
4.3.6. 
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4.3 Results and discussion 
?
4.3.1 Preparation of recombinant Rat1, Rat1/Rai1 and Rat1/Rai1/Rtt103 
 
To investigate the function of the Rat1 nuclease, we established a protocol to obtain the 
protein in recombinant form after overexpression in E. coli (Fig. 21 A and B, 4.2.2). After 
optimization of the procedure, about 0.5 mg of the 116 kDa, 1006-residue Rat1 could be 
obtained from 1 l of bacterial cell culture. We further established a protocol to obtain a 
stoichiometric pure complex of Rat1 with its cellular partner, Rai1 (Fig. 21 A and B, 4.2.2). 
We co-expressed Rat1 and Rai1 from individual plasmids with different antibiotic resistance 
in E. coli cells with the use of autoinducing medium (Studier, 2005) . Affinity purification of 
Rat1, which carried a C-terminal hexahistidine tag, led to co-purification of Rai1 (Fig. 21 A). 
The Rat1/Rai1 complex was very stable, as it could be purified over several columns. To 
purify a recombinant trimeric Rat1/Rai1/Rtt103 complex, we incubated the pure Rat1/Rai1 
complex with partially purified recombinant full-length Rtt103, and subjected the mixture to 
size exclusion chromatography (4.2.3). We obtained a symmetric peak for the trimeric 
complex at a shorter retention than the peak for the dimeric Rat1/Rai1 complex (Fig. 21 B). 
The identities of the three proteins were confirmed by mass spectrometry (not shown). For 
the first time this work provided Rat1, and the complexes Rat1/Rai1 and Rat1/Rai1/Rtt103 in 
pure, bacterially expressed, recombinant form. The results also confirmed that the protein-
protein interactions that were previously inferred from affinity co-purifications of endogenous 
proteins (Kim et al, 2004; Stevens & Poole, 1995) and co-expression of Rat1 and Rai1 in 
yeast (Johnson, 2001; Xue et al, 2000). In addition, this is the first time a direct interaction 
between Rat1/Rai1 and Rtt103 is seen.  
 
4.3.2 Stable Rat1 activity requires Rai1, but not Rtt103 
 
Nuclease activity of the Rat1 homolog Xrn1 was extensively analyzed (Stevens, 1978; 
Stevens, 1980; Stevens & Maupin, 1987) showing its processive 5’-3’ mode of degradation 
and its preference of RNA with a 5’-monophosphate. The characterization of Rat1 basically 
showed comparable results in this respect (Stevens & Poole, 1995). In early work on Xrn1, 
which has comparable properties to Rat1, it was shown that RNA with a 5’-OH is used at 1/3 
to 1/5 compared to RNA with a 5’ phosphate (Stevens & Maupin, 1987).  
To investigate the ribonucleolytic activity of recombinant Rat1, and the influence of Rai1 and 
Rtt103 on this activity, we labeled the 3’-end of a RNA 27-mer of random sequence 
(„activityRNA“, 2.1.2, Table 5) with radioactive phosphate. Although the preferred substrate 
for Rat1 is RNA with a 5’-monophosphate, we used RNA with a 5’-hydroxyl-group. The rea- 
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Figure 21: Preparation of recombinant Rat1, Rat1/Rai1 and Rat1/Rai1/Rtt103 and ribonucleolytic activity 
(A) Expression and purification scheme for Rat1, Rat1/Rai1 and Rat1/Rai1/Rtt103. At the bottom, Coomassie-
stained SDS-PAGEs show the resulting proteins.  
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Figure 21 (continued) 
(B) Size-exclusion chromatography profiles of the nuclease complexes from (A). A plot of the absorption at 280 
nm against the retention time is shown. Profiles are from 3 separate chromatographies.  
(C) Relative ribonucleolytic activity of Rat1/Rai1 and Rat1/Rai1/Rtt103 using RNA with a 5’-hydoxyl group as a 
template. The intensity of signals corresponding to the 27mer RNA were quantified with the ImageQuant software 
resulting in a mean value from three replicates of each experiment. The intensity of the input RNA was set to 
100%, the decrease due to degradation by Rat1 was calculated relative to that value and plotted against the 
duration of the reaction. 
 
son for this is that T4 RNA ligase used in the labeling reaction (4.2.4) produced multimers of 
the RNA molecules, resulting in a heterogeneous substrate that could not be quantified by 
the method we used. Nevertheless, ribonucleolytic activity – albeit lower than the expected 
activity with the natural substrate – could be detected and put into relation for the different 
complexes (Fig. 21 C). Degradation of the labeled RNA after incubation with enzyme 
preparations for different times was monitored by separation of the RNA products in 
denaturing PAGE and autoradiography (Fig. 21 C, 2.2.7). In these assays, recombinant Rat1 
either showed no activity or weak, badly reproducible activity. In contrast, the recombinant 
Rat1/Rai1 complex showed reproducible and stable nuclease activity. This is consistent with 
the published stabilizing effect of Rai1 on Rat1 activity (Xue et al, 2000), where a dramatic 
loss of Rat1 nuclease activity was observed during the first minutes of incubation at 30°C 
when Rai1 was not present. The complex could be stored at –80°C for several months 
without a significant decrease of its activity. The nuclease activity was due to Rat1 since 
buffer from the last purification step did not contain contaminating nuclease activities (Fig. 21 
C). Thus, recombinant Rat1 shows unstable activity that is stabilized by recombinant Rai1, 
consistent with similar observations for the endogenous proteins (Xue et al, 2000). 
We compared the robust nuclease activity of the Rat1/Rai1 complex to that of the trimeric 
Rat1/Rai1/Rtt103. The dimeric and trimeric complexes showed indistinguishable activities 
(Fig. 21 C). This suggests that Rtt103 is not a regulator of Rat1 nuclease activity, consistent 
with the results that Rtt103 is involved in the recruitment of Rat1/Rai1 to the transcription 
machinery via its CTD-interacting domain (CID) (Kim et al, 2004). 
 
4.3.3 An improved in vitro elongation assay 
 
To establish a defined biochemical system for testing the torpedo model in vitro, we 
assembled elongation complexes containing Pol II, DNA with a fully complementary 
transcription bubble, and RNA as described (Komissarova et al, 2003) (Fig. 22 A, top). 
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Figure 22: The Rat1/Rai1 complex does not terminate RNA polymerase II in vitro 
(A) Schematic representation of the bead-based elongation/RNA degradation assay. On top the nucleic acid 
scaffold that was assembled with Pol II into a bead-coupled elongation complex (EC) and used as a substrate for 
Rat1. Template, non-template and RNA strands are coloured in blue, cyan and red, respectively. Below the diff- 
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Figure 22 (continued) 
erent steps in the protocol (4.2.8). Steps a and b represent the control reaction without added nuclease, a’ and b’ 
represent the reaction containing the nuclease.  
(B) Autoradiograph of RNA from bead-based termination assay. As substrates, core Pol II ECs (left panel) and 12 
subunit Pol II ECs (right panel) were used. Samples that were treated as depicted in (A) were separated by a 6 M 
urea PAGE and exposed for several hours to a storage phosphor screen. The steps represented in (A) are 
indicated above the gel, lane numbers below the gel. See text for details. 
 
The presence of a fully complementary transcription bubble is important for a termination 
assay since transcription termination in prokaryotes requires rewinding of the upstream 
bubble (Park & Roberts, 2006). ECs were bound to streptavidin-coated magnetic beads with 
the use of biotin coupled to the 5’-end of the non-template DNA strand (Fig. 22 A). Since 
incorporation of the non-template strand is the last step in the EC assembly protocol, only 
fully assembled ECs were bound to the beads. The RNA engaged in active ECs was labeled 
at the 3’-end by incubation with ?[32P]-UTP, which leads to Pol II-catalyzed incorporation of 
radioactive uridine (Fig. 22 A, step a; Fig. 22 B, lane 1). After washing away unincorporated 
?[32P]UTP, and addition of all four NTPs (Fig. 22 A, step b), these ECs were able to elongate 
the labeled RNA (Fig. 22 B, lane 2). RNA transcripts of various lengths were observed, up to 
the expected 68 nt run-off product. The occurence of transcripts that are shorter than the run-
off RNA was different depending on the scaffolds we used and can probably be related to 
paused and arrested, or unstable ECs. To prevent unspecific binding of ECs to beads, beads 
were blocked prior to use (4.2.8). ECs that were assembled without the biotin-labeled non-
template DNA strand did not bind to these beads, providing a negative control (Fig. 22 B, 
lanes 3 and 4). Thus, in this elongation assay, only complete, bead-coupled elongation-
competent ECs produced signals for RNA products. Compared to a previously described 
bead-based elongation assay (Komissarova et al, 2003), our assay uses magnetic beads 
instead of agarose beads and a bead-blocking protocol. This results in very clear and defined 
RNA signals. 
 
4.3.4 Functional Rat1 complexes do not terminate Pol II in vitro 
 
The bead-based elongation assay (4.3.3), together with the availablity of pure recombinant 
Rat1 complexes (4.3.1), allowed us to test the "torpedo model" in vitro. When Rat1/Rai1 was 
added to our assay (Fig. 22 A, step a’), the RNA was degraded to a length of approximately 
18 nt as judged from a sequencing gel (Fig. 22 B, lane 5). This shows that Rat1/Rai1 could 
use the pure, bead-coupled ECs as substrates, but also that it was unable to totally degrade 
the RNA. The length of the obtained products is readily explained based on the known EC 
structure (Andrecka et al, 2008; Kettenberger et al, 2004b; Vassylyev et al, 2007a). Around 
15 nucleotides of RNA are protected within the Pol II hybrid-binding site and the RNA exit 
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tunnel, and a few additional nucleotides are probably protected due to the probe radius of 
Rat1. Thus, the obtained results are consistent with the model that Rat1/Rai1 degrades RNA 
from the 5’-end until it reaches the Pol II surface, and that it does not degrade the 3’-region of 
the RNA that is protected by Pol II. To examine whether the ECs remained active after partial 
RNA degradation, Rat1/Rai1 was washed away and NTPs were added (Fig. 22 A, step b’). 
The truncated transcripts were readily elongated, and reached a length of up to 55 nt, 
corresponding to the expected run-off product (Fig. 22 B, lane 6). Since the amount of RNA 
in the Rat1-treated samples was lower (lanes 5 and 6) than in the untreated control sample 
(lanes 1 and 2), we used a control nuclease to determine if this observation is due to partial 
termination. However, the same result was obtained when the experiment was repeated with 
the use of the non-specific endonuclease RNase I instead of Rat1/Rai1 (Fig. 22 B, lanes 7-
8), arguing against partial termination. As it was recently shown that transcribing Pol II 
includes the Rpb4/7 subcomplex in vivo (Jasiak et al, 2008; Verma-Gaur et al, 2008), we 
repeated our assay with the complete, 12-subunit enzyme that comprises Rpb4/7. The same 
results were obtained (Fig. 22 B, lanes 9-14). Thus, Rat1/Rai1 degrades RNA that is 
accessible on the EC surface, but does not dissociate Pol II, and leaves the EC intact and 
transcriptionally competent, such that the RNA 3’-end remains in the active site and can be 
re-extended. Since transcription termination is defined as a discontinuation of the ability to 
extend RNA, these results show that Rat1/Rai1 is insufficient to terminate Pol II in a defined 
in vitro system. 
 
4.3.5 A poly(A) site does not trigger termination 
 
At the end of an open reading frame the transcript is cleaved 10-30 nt downstream of a 
specific nucleotide signal, the poly(A) site. This nucleic acid sequence has the consensus  
5’-AAUAAA-3’ in the transcript (Proudfoot & Brownlee, 1976), which is highly consereved in 
almost all polyadenylated mRNAs in higher eukaryotes (Wickens & Stephenson, 1984). 
Interestingly, the poly(A) site sequence represents sequence-motifs that trigger termination in 
the other eukaryotic polymerases evolutionary related to Pol II. In case of Pol I, a T-rich 
sequence in the template strand is mandatory (Lang et al, 1994; Lang & Reeder, 1993) 
whereas for Pol III a short run of A elicit transcription (Geiduschek & Kassavetis, 2001) 
together with other factors. Even in intrinsic terminators in prokaryotes, a stretch of U-
residues is involved (see also section 1.3.2). All of these sequences are composed of T-A 
and A-U basepairs between template strand and transcript, respectively, and are referred to 
as „weak hybrids“ here. Although it is known that the poly(A) site does not induce termination 
in Pol II transcription complexes, we asked the question if this sequence may trigger re-
arrangements of nucleic acids within the Pol II cleft and active site, thereby triggering a 
"termination competent“ form of polymerase II. This might be a prerequisite for induced 
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termination by Rat1/Rai1. We first asked whether Pol II could terminate in our in vitro system 
if the poly(A) site sequence was transcribed. However, the situation in yeast cells is 
somewhat different, as the consensus AAUAAA is not as highly conserved as in higher 
eukaryotic systems. Only in ?50% of all yeast genes this sequence can be found and 
mutations in this sequence do not have a dramatic effect on the 3’ end formation of yeast 
mRNA (Hyman et al, 1991). Yeast poly(A) signals are basically composed of three elements 
that are important for proper cleavage/polyadenylation in yeast, although they are less 
conserved than the mammalian poly(A)-site directing sequence. However, these sequences 
are AT-rich and resemble the "weak hybrid" concept (Graber et al, 1999; Guo & Sherman, 
1996; Osborne & Guarente, 1989; Russo et al, 1993). This, in combination with the fact that 
the process of transcription is conserved, led us to the decision to use the highly conserved 
AAUAAA consensus sequence in our assays rather than the loosely defined yeast site, to 
investigate its influence on the elongation complex. We prepared a nucleic acid scaffold 
containing a poly(A) site 10 nt downstream of the incorporated ?[32P]UTP (Fig. 23 A, poly(A) 
transcription scaffold 1), assembled an EC, and added ATP, CTP, and UTP, but withheld 
GTP from the reaction mixture. This led to transcription of the poly(A)-site plus 16 additional 
base pairs, and EC stalling at a defined position (CCC in the template strand, Fig. 23 A, 
stalling point). RNAs with a length of 41-46 nt were not observed (Fig. 23 B), which means 
that the poly(A)-sequence was transcribed like a control random sequence in our assay (see 
Fig. 23 A, „poly(A) transcription scaffold 1 control“).  
We next tested the model that passage of a poly(A) site would alter EC stability and render 
Pol II prone to Rat1-induced termination. We assembled ECs containing the poly(A) site 
sequence within the DNA-RNA hybrid at positions  –1 to –6 (Fig. 23 A, poly(A) transcription 
scaffold 2). RNA was labeled by incubation with CTP and ?[32P]UTP, which led to 
incorporation of three cytosines and a radioactive uridine (Fig. 23 C, lane 1). Incorporation of 
three additional cytosines ensured that the resulting RNA length was as in the other 
experiments (Figs. 22 , 23 B, 23 D), and mimicked partial polymerase passage of the poly(A) 
site sequence. Addition of NTPs produced the run-off RNA of 53 nt (Fig. 23 C, lane 2). As 
before, RNA was trimmed down by Rat1/Rai1 to around 18 nt, and could be re-extended 
after NTP addition (lanes 3 and 4).  
Very similar results were obtained when RNase I was used instead of Rat1/Rai1 (lanes 5 and 
6). RNAs longer than the run-off transcript were also detected, but were excluded from  
Fig. 23 C because they were present in all the samples of the experiment and likely result 
from transcript slippage as a side reaction. Taken together, Rat1/Rai1 and a transcribed 
poly(A)-site sequence alone are insufficient to trigger termination of Pol II in these assays. 
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Figure 23: Neither a poly(A) site nor a pause sequence trigger termination 
(A) Nucleic acid scaffolds that were assembled with Pol II for the indicated experiments. 
(B) Autoradiograph of RNA extension with a bead-coupled EC including poly(A) transcription scaffold 1. The 
region where signals of RNAs would be expected if elongation had stopped at the poly(A) site sequence is 
indicated. 
(C) Autoradiograph of bead-based assay with an EC containing poly(A)-transcription scaffold 2. Steps a, b, a' and 
b' correspond to steps in Fig. 22 B. 
(D) Autoradiograph of bead-based assay with EC containing the pause site transcriptionscaffold. For a detailed 
description of these experiments refer to text. 
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4.3.6 A hybrid with poly(A) site sequence does not change EC structure 
 
The  results described above suggested that an EC that contains the poly(A) site within the 
DNA-RNA hybrid does not differ significantly in structure from an EC that contains a random 
sequence within the hybrid. To examine this, we solved the X-ray structure of S. cerevisiae 
Pol II EC containing a hybrid that harbors the mammalian poly(A)-site sequence in the active 
center cleft of the enzyme (Fig. 24 and Table 20). The structure could be determined at 4.0 Å 
resolution with the use of established protocols (Brueckner & Cramer, 2008). The unbiased 
difference electron density in the hybrid site did not reveal any significant rearrangement of 
the nucleic acids within the Pol II cleft (Fig. 24 B and C). However, we observed that the 
hybrid was backstepped compared to the designed scaffold, and that the adenine at the RNA 
3’-end was not paired with the DNA template at position +1, but rather disordered (Fig. 24 C). 
Such fraying of the 3’-terminal RNA nucleotide is typical for a paused state of the EC 
(Toulokhonov et al, 2007), and has been directly observed in other Pol II structures that we 
will describe elsewhere (Sydow et al., in preparation). Superposition of our structure with the 
previous complete Pol II EC structure showed a similar position and conformation of the 
DNA-RNA hybrid and downstream DNA (Fig. 24 D). These results are consistent with the 
idea that the poly(A) site sequence is prone to pausing, but do not provide evidence for 
models that postulate that the EC adopts an alternative structure upon poly(A) site passage.  
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Figure 24: Canonical binding of a poly(A) site-containing hybrid within the Pol II EC 
(A) The used nucleic acid scaffold is shown. Filled circles indicate nucleic acids that have interpretable electron 
density, empty circles indicate nucleic acids that were not ordered. The 5-Bromouracil is shown in yellow. The 
template strand is shown in blue, the non-template strand in cyan and the RNA in red throughout this figure. 
(B) Overview of the Pol II EC structure containing the poly(A) site sequence. Pol II is shown as a ribbon model in 
grey. Rpb2 residues 1-828 are omitted for clarity. The Pol II bridge helix (residues 811-843 of Rpb1) is shown in 
green. Nucleic acids are shown in a stick representation, coloured as in (A). 
(C) 2Fo-Fc electron density map contoured at 1? for the nucleic acids in the poly(A) site-containing DNA-RNA 
hybrid. 
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Figure 24 (continued) 
(D) Superposition of the poly(A) site nucleic acids (red) and nucleic acids of random sequence (green, PDB 
accession code: 1Y1W, Kettenberger et al, 2004b)). 
(E) 2Fo-Fc electron density at 1? of the upstream nucleic acids from (C). In raspberry an anomalous difference 
Fourier map at 3.5?, showing the position of the bromine atom. The structure is rotated app. 90° clockwise 
respective to (C). 
 
Table 20: X-ray diffraction and refinement statistics  
 
 
Complete Pol II EC 
containing poly(A)site 
sequence 
 
Data collection  
Space group C222(1) 
Cell dimensions    
   a, b, c (Å) 222.5, 391.6, 284.1 
   ?, ?, ?  (°) 90, 90, 90 
  
Wavelength 0,918905 
Resolution (Å) 50-4.0 
Rsym (%) 10.6 (51.6) 
I / ?I 9.6 (2.7) 
Completeness (%) 99.9 (100) 
Redundancy 4.3 (4.3) 
  
Refinement  
Resolution (Å) 4.0 
Unique reflections 
(anomalous pairs 
 unmerged) 
202,368 (33,630) 
Rwork / Rfree (%) 20,4 / 23,5 
No. atoms  
    Protein 31102 
    Ions 9 
    Nucleic acids 671 
B-factors  
    Protein 137.1 
    Ions 137.8 
    Nucleic acids 196.8 
R.m.s deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 1.5 
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4.3.7 A paused EC is not terminated by Rat1/Rai1 
 
There is evidence that the EC goes through a paused state before termination (Aranda & 
Proudfoot, 1999; Birse et al, 1997; Proudfoot, 1989). This makes sense in light of the 
"torpedo model" as a paused polymerase would create a time window for Rat1/Rai1 to catch 
up. Thus, we also tested whether a paused EC can be terminated in our assay. We 
assembled ECs with a scaffold containing a 3’-uridine in the active site (Fig. 23 A, pause site 
transcription scaffold). Introduction of an additional, radioactively labeled uridine to the RNA 
results in a pause sequence with a UU RNA 3’-end at the Pol II active center (Fig. 23 A). In 
ECs that contain this pause sequence, the RNA 3’-nucleotide adopts a frayed position in the 
pore below the active site (Toulokhonov et al, 2007). We incubated the obtained EC with the 
recombinant Rat1 complexes and checked if they can still elongate the RNA after it had been 
partially degraded (Fig. 23 D). The experiments showed that neither core Pol II (lanes 3 and 
4), nor the complete Pol II (lanes 9 and 10) were terminated. In both cases the incubation 
with RNase I gave similar results (lanes 5, 6, 11 and 12). Thus, a paused EC conformation is 
not sufficient to allow Rat1 to terminate Pol II in our system. 
 
4.3.8 Rat1 contains a putative RNase H-like domain 
 
Rat1 and its cytoplasmatic counterpart Xrn1 contain a eukaryote-specific N-terminal region of 
sequence conservation that was ascribed to the 5PX superfamily of exoribonucleases (Zuo & 
Deutscher, 2001) (Fig. 25 A). This region is required for Xrn1 exonuclease activity, since 
point mutations in D86, E176, E178, D206 and D208 (corresponding to Rat1 residues D102, 
E203, E205, D233, and D235, respectively, Fig. 25 A) and additional residues (dots in  
Fig. 25 A) impair activity (Page et al, 1998; Solinger et al, 1999). Consistently, mutation of 
Rat1 residue D235 abolished exonuclease activity, and resulted in the failure to complement 
the termination defect seen in rat1 mutant cells (Kim et al, 2004). Thus, the N-terminal 
regions of the Xrn1 and Rat1 proteins contain the exonuclease domain. In this region, the 
members of the 5PX superfamiliy were described to show homology in critical catalytic 
residues with several Mg2+-dependent 5’-3’-exonucleases from different organisms, including 
also the phage T4 RNase H (Solinger et al, 1999), a 5’-3’-exonuclease that degrades RNA in 
DNA-RNA hybrids. Thus, we re-examined the Rat1 sequence and found a remote similarity 
of the conserved N-terminal region to the catalytic domain of RNase H enzymes (Fig. 25 B). 
The active site of RNase H enzymes contains four conserved acidic residues, three 
aspartates and a glutamate separated by short sequence stretches and coordinating two  
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Figure 25: Putative RNase H homology in the Rat1 sequence 
(A) Alignment of the N-terminal region of Rat1 and its homologs Dhp1 (S. pombe), Xrn2 (H. sapiens) and Xrn1  
(S. cerevisiae, cytoplasmic). Invariant and conserved residues are indicated in green and orange, respectively. 
Blue circles indicate positions of point mutations that impair exonuclease-activity in Xrn1 (Page et al, 1998; 
Solinger et al, 1999). Red triangles show Rat1 mutations that impair activity as reported in (Kim et al, 2004) and in 
this work (4.3.9). Stars mark potential RNase H active site residues (see also (B)).  
(B) Alignment of RNase H sequences from E. coli (Ec) and H. sapiens (Hs) with S. cerevisiae Rat1. The 
alignment of Ec and Hs sequences is taken from (Nowotny et al, 2007). Secondary structure elements observed 
in the structures of human RNase H1 Nowotny et al, (2007) and E.coli RNase H (Katayanagi et al, 1990; Yang et 
al, 1990) are indicated as rectangles for ?-helices and arrows for ?-strands. Conservation is indicated as in (A).  
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Figure 25 (continued): 
Rat1 secondary structure elements were predicted by PSIPRED (Jones, 1999). Invariant acidic residues that 
constitute the RNase H active site are indicated by stars.  
(C) Autoradiograph of RNA from RNase H assay. The templates used are shown schematically on top. The 
proteins used in the individual reactions are indicated by a (+). See text for details. 
 
catalytic magnesium ions (Katayanagi et al, 1990; Nowotny et al, 2005; Yang et al, 1990). 
We could manually align the sequences of E. coli and human RNase H to the Rat1 N-
terminal region such that the four acidic residues in the RNase H active site correspond to 
conserved Rat1 residues (Fig. 25 B). In these alignments, known and predicted secondary 
structure elements also generally lined up. Consistently, RNase H activity was reported for 
Xrn1 (Stevens & Maupin, 1987). This cytoplasmic counterpart of Rat1 contains the highly 
conserved acidic residues we identified in the Rat1 exonuclease-domain (stars in Fig. 25 A 
and B).  
Since Xrn1 can supply the essential functions of Rat1 when directed to the nucleus by a 
strong localization signal (Johnson, 1997) (although it does not complement a termination 
defect (Luo et al, 2006)), we wondered whether Rat1 complexes also exhibit RNase H 
activity. To test this, we used two different DNA-RNA heteroduplex substrates, a 
radioactively 3’-labeled 27-mer RNA hybridized to a complementary 27-mer DNA strand, or 
the same RNA hybridized to a complementary 17-mer DNA strand, which leaves a 10-
nucleotide 5’-overhang of RNA. The latter substrate resembles the nucleic acids in an EC, 
where Rat1 would degrade single-stranded RNA from the 5’-end and then encounter the 
DNA-RNA hybrid (Fig. 25 C). As a control we used RNase I, which specifically degrades 
single-stranded RNA, and RNase H, which specifically degrades RNA within a DNA-RNA 
hybrid. As expected, RNase I degraded the single-stranded 10 nt overhang (lane 3), and 
RNase H degraded RNA within the hybrid region (lanes 4 and 8). However, neither Rat1, nor 
its complexes Rat1/Rai1 or Rat1/Rai1/Rtt103 led to RNA degradation (lanes 9, 10, 11). It has 
to be considered, that Rat1 shows a low activity concerning single stranded DNA (Stevens & 
Poole, 1995). Since our reaction mixture contains an excess of DNA over RNA molecules, 
the ssDNA can also serve as a substrate and reduce the detectable ribolytic activity. 
However, the 5’-overhang was partially degraded by Rat1/Rai1 and Rat1/Rai1/Rtt103 (lanes 
6 and 7), indicating that the enzyme complexes were active under the assay conditions, and 
providing the positive control. Thus, Rat1 contains a putative RNase H domain in its N-
terminal region, but we did not observe RNase H activity with recombinant Rat1 complexes 
in vitro.  
Nevertheless, the identified RNase H activity of Xrn1, that shows a high sequence 
conservation with Rat1 (Fig. 25 A), together with the similarity of the conserved N-terminal 
region of Rat1 to the catalytic domain of RNase H enzymes we identified (Fig. 25 B) leads us 
to the assumption that Rat1 might exhibit RNase activity in vivo we cannot detect in our 
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highly pure in vitro assay. In such a scenario, Rat1 degrades RNA until it reaches elongating 
Pol II and its associated factors, which may activate a cryptic RNAse H activitiy in Rat1, 
which then may degrade RNA within the DNA-RNA hybrid, destabilizing the EC and leading 
to termination. We refer to this model as the „triggered torpedo model“ since it implies that 
the Rat1 torpedo requires a RNAse H activity that must be activated (triggered). The possible 
RNAse H activity of Rat1 is consistent with a recent study of the role of Rat1 in degrading 
telomeric repeat-containing RNA (Luke et al, 2008) . In this study, overexpression of RNAse 
H rescued telomere elongation defects in cells that lacked functional Rat1. The defects stem 
from an increased concentration of short RNAs that bind to telomeric DNA. These RNAs are 
kept at a low level by functional Rat1. Interestingly, a deletion of Rnase H genes does not 
alter the defective Rat1 phenotype in vivo. The authors suspect the missing activity to be a 
helicase, like the ATP-dependent RNA-helicase Upf1. Another explanation could be that 
Rat1 itself contains RNAse H activity in its functional context in vivo.  
However, to provide evidence for the triggered torpedo model, activation of a possible 
RNAse H activity of Rat1 must be demonstrated. 
 
4.3.9 The Rat1 nuclease active site degrades RNA within the EC 
 
To investigate whether the Rat1 N-terminal region was responsible for the observed RNA 
degradation activity in the context of ECs, we mutated conserved acidic residues and tested 
for RNA degradation. We mutated the highly conserved residue D102, proposed to be part of 
a putative RNase H active site (Fig. 25 A and B). In addition we mutated the conserved 
residue D235 that was shown to be required for nuclease activity in vitro (Kim et al, 2004). 
The Rat1 D102A mutant was slightly impaired in its activity to degrade RNA within the EC 
(Fig. 26, lanes 9, 6, 3).  
 
Figure 26: Effect of Rat1 point mutations on ribonucleolytic activity 
Autoradiograph of RNAs assembled within ECs, that were used as substrates for mutant Rat1 proteins at different 
Mg2+ concentrations. Samples were treated as depicted in Fig. 22 A (steps a’ and b’), separated by 6 M urea 
PAGE and exposed for several hours to a storage phosphor screen.  
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The mutation D235A strongly impaired activity at lower magnesium ion concentrations (Fig. 
26, lanes 8, 5, 2). Higher magnesium ion concentrations could rescue the mutant defect (Fig. 
26, lane 11), apparently by compensating for the decreased magnesium affinity of the active 
site in the mutant. These results are consistent with mutational studies of Xrn1, where 
mutations in corresponding conserved residues also affect exonuclease activity to different 
extents (Page et al, 1998).  
Unexpectedly, degradation of RNA at lower magnesium concentrations sometimes did not 
result in the 18 nt degradation product (Fig 26, lanes 4 and 1). We account this to an overall 
instability of pure elongation complexes at these conditions, that results in degradation of 
RNA that is otherwise protected inside of Pol II. 
 
4.4 Conclusions and future perspective 
 
In this work, the production and purification of the Rat1 exoribonuclease in complex with the 
interacting proteins Rai1 and Rtt103 is shown. The previously reported stabilization of Rat1 
nuclease activity by Rai1 was confirmed and it was shown that Rtt103 is not a regulator of 
Rat1 activity. In addition, the direct interaction of Rat1/Rai1 with the CTD-binding protein 
Rtt103 was shown for the first time. The results from the in vitro termination assay that was 
established in the course of this work show that Rat1/Rai1 is not a dedicated termination 
factor as envisaged by the "torpedo model“. Nevertheless, existing data strongly suggests 
the involvement of Rat1 in the termination process and this work strengthens the concept of 
a "combined allosteric-torpedo model“ that was suggested before (Luo et al, 2006). The 
missing contribution to termination could be a cis-element like a DNA sequence, that could 
change the properties of elongating Pol II. This seems to be reasonable, because the 
concept of a "weak hybrid“ seems to be conserved in the evolution of transcription 
termination mechanisms (see section 1.3.2). In this light, we tested such a „weak hybrid“ that 
occurs in the 3’ regions of protein coding genes, the poly(A) signal. It is known that it does 
not induce termination, but still it might trigger a "termination competent“ form of Pol II that 
could be terminated by Rat1. This was tested in the in vitro assay, but elongation complexes 
remained stable and were not terminated opon Rat1/Rai1 treatment. Also a crystal structure 
of the elongation complex bearing the poly(A) site "weak hybrid“ within its active site showed 
no rearrangements of the nucleic acids within Pol II, which might be expected in a 
"termination competent“ Pol II. Neither did essential pause sites influence the outcome of the 
torpedo reaction. Thus, we conclude that another trans-acting factor might be needed for 
termination. A good candidate for such a factor would be Rtt103. Through binding to the 
Ser2-phosphorylated CTD of Pol II it could transmit a termination signal to the polymerase, 
induced by its interaction with Rat1/Rai1. This could be related to a termination mechanism 
that was reported by Zhang et al (2005). They have shown that the RNA 3'-end processing 
4 An in vitro system to test the “torpedo model” of transcription termination 96 
factor Pcf11 can "dismantle" elongation complexes. They assume that this happens by Pcf11 
forming a bridge between the Pol II CTD and the RNA, that are both bound by this factor. 
This interaction is thought to exert a force onto the elongation complex that disrupts DNA-
RNA hybrid interactions. Unfortunately, we were not able to test this hypothesis in our in vitro 
assay, since we are currently not able to specifically phosphorylate/dephosphorylate 
residues in the CTD of our Pol II preparations. However, since we can produce the highly 
pure and active trimeric complex of Rat1/Rai1/Rtt103, this hypothesis should be tested in the 
future as soon as the experimental limitations have been overcome. Another attractive model 
for Rat1/Rai1-related termination events is what we call the "triggered-torpedo model". We 
found homology of the Rat1 N-terminal region to RNase H domains, but could not see 
RNase H activity (hydrolysis of RNA within DNA-RNA duplexes) in our nuclease preparation 
(see 4.3.8). Basically, an additional factor could modify the activity of Rat1/Rai1 upon 
encountering the elongation complex, "triggering" its inherent RNase H activity. 
Consequently, Rat1 could then attack the RNA within the hybrid of the transcription bubble 
and disrupt elongation compex interactions. As soon as candidate proteins for such a 
"trigger" are defined, this model can be tested by our setup. This immediately shows the 
advantage of our in vitro system: it is easily and quickly adjustable to any desired 
experimental design. First, the coupling of the "substrate“ (elongation complexes) to the 
magnetic beads allows a quick exchange of buffer conditions. Second, the use of sythetic 
oligonucleotides allows the implementation of any nucleic acid sequence that might modulate 
the activity of Pol II and/or Rat1/Rai1. Third, availability of fully recombinant exonuclease 
complexes makes it easy to modify Rat1/Rai1 by point mutations or larger deletions. Fourth, 
an unlimited number of soluble factors can be added to the assay, to establish a minimal 
system for termination of Pol II transcription. A good suggestion for such a future experiment 
would be the addition of the ATP-dependent DNA-RNA-helicase Sen1 when it is available. 
Sen1 is reported to be involved in termination of sn-/snoRNA transcription and also in 
termination at some mRNA-coding genes (Lykke-Andersen & Jensen, 2007; Steinmetz et al, 
2006). Also the addition of nuclear extract, that is fractionated by biochemical methdos, could 
help to identify termination activity in one of the fractions. The assay could then be used to 
monitor this activity and to purify and identify the missing termination factor(s). This 
procedure would be limited by endogenous nucleases that are active in the nuclear extract. 
Those need to be specifically inhibited or removed from the extract in order to carry out such 
an experiment. In addition, the in vitro reaction should be tested with endogenous Rat1/Rai1, 
purified directly from yeast extracts. We cannot exclude that posttranslational modifications, 
that are not present in our preparation, have an influence on the result of the reaction. 
In summary, the in vitro assay described in this work, in combination with the fully 
recombinant and active torpedo-nuclease complexes can be used in future experiments as a 
tool to elucidate the transcription mechanism for protein coding genes. In addition, the assay 
was and will be used further in the research on elongation-related events in vitro. 
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Figure A1: Alignment of Spt6 and Tex protein sequences 
Alignment of the C. glabrata Spt6 (cgSpt6) and P. aeruginosa Tex (paTex) protein sequences by ClustalW. 
Secondary structure elements are indicated in red and green, for ?-helices and ?-strands, respectively 
(information about secondary structure comes from the X-ray structure in the case of Tex and from secondary 
structure prediction (PROFsec) in the case of Spt6. Only the residues with an expected average accuracy > 82% 
were highlighted in the alignment). Tex-domains and the Spt6 SH2 domain are colored as in Figs. 9 A and 15. 
Insertions in Spt6 are numbered as in Fig. 15. 
?
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Figure A2: Surface charge distribution of SH2 domains 
Surface charge was calculated with APBS (Baker et al, 2001) using the same parameters for all the domains. 
Binding pockets are indicated by dashed circles (see also Figs. 3, 12 and 13 ). 
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Figure A3: Venn diagram depicting the overlap of Spt6?C dependent genes with those ORFs showing 
cryptic transcription in the spt6-1004 mutant.  
Of the 960 ORFs known to exhibit cryptic transcription in the Spt6-1004 mutant, the transcript levels of 147 genes 
are significantly altered in the spt6?C mutant. All overlapping genes are listed in the table below. The diagram 
was drawn with the Partek Genomics Suite 6.3 software. The list of the 960 ORFs is from Cheung et al. The 
figure was kindly provided by Andreas Mayer. 
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Figure A4: Venn diagram indicating the overlap of known yeast Pol II transcription factors and spt6?C 
dependent genes.  
33 genes coding for various transcription factors are among the significantly changed genes in the spt6?C 
mutant. The diagram was drawn with the Partek Genomics Suite 6.3 software. The list of the 269 yeast 
transcription factors is taken from Hu et al (2007). The figure was kindly provided by Andreas Mayer. 
?
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